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Cardiovascular disease (CVD) has been identified as the leading cause of mortality in westernised 
society. The triggering factor for the majority of cardiovascular diseases is atherosclerosis, defined as 
an accumulation of fatty materials in the vascular sub-endothelial space. This results in the initiation 
and propagation of inflammatory responses that result in the narrowing of the vascular lumen, as well 
as thickening and hardening of arteries. The initiating stimulus in atherosclerosis is elevated levels of 
low-density lipoprotein (LDL) in circulation, and the cells involved in this process are primarily 
endothelial cells-which interact with blood-, smooth muscle cells-which facilitate the contraction and 
relaxation of large diameter blood vessels-, and macrophages, which are immune cells that are able to 
take up and store lipids. As inflammation progresses, the endothelium becomes dysfunctional and 
expresses adhesion molecules that facilitate the entry of monocytes into the sub-endothelial space, 
where they differentiate into macrophages, take up LDL and become foam cells. These lipid rich foam 
cells are a key component of atherosclerotic plaques, together with dead cells that make up the 
necrotic core. Statins have been established as the gold standard for the treatment of atherosclerosis, 
and have been useful in decreasing morbidity and mortality in CVD patients. They function by 
preventing cholesterol synthesis through inhibition of HMG-CoA, thus lowering amounts of circulating 
cholesterol. In addition to this function, a number of pleiotropic effects have been associated with 
statin treatment including, increasing numbers of circulating endothelial progenitor cells (EPCs), 
reduce inflammation, improve atherosclerotic plaque stability and improve engraftment of MSCs into 
sites of vascular injury.  
To investigate these pleiotropic effects of this ubiquitous drug used in the treatment of the most 
prevalent disease, we developed tissue engineered blood vessel models that incorporated endothelial 
cells (Human umbilical vein endothelial cells (HUVECs)) and smooth muscle cells (Human cardiac artery 
smooth muscle cells (HCASMCs)) to represent the intimal and medial layers of the vasculature and 
could be used individually (Tissue engineered intimal layer-TEIL and tissue engineered medial layer-




models/constructs were subjected to shear stress and used to evaluate the effect atorvastatin has on 
the homing of endothelial progenitor cells, the production of SDF-1 and expression of its receptor 
CXCR4. Further to this, the effect of atorvastatin on initiating cholesterol efflux was also investigated 
with considerations made to examine the role of HUVECs and smooth muscle cells in this process. The 
experiments conducted for this thesis were able to determine that atorvastatin increases the density 
of cells attached onto the surface of a lesioned construct. This was observed for the partial blood vessel 
models (TEIL and TEML) as well as the TEBV. This effect was noted for human mesenchymal stem cells 
(hMSCs) as well as EPCs. Observations in EPCs were consistent under both high (22.16 dyne/cm2) and 
low (2.2 dyne/cm2) shear stress. We were also able to determine that atorvastatin is more functional 
when used in conditions of oxidative stress through examination of different lesioning techniques. 
FeCl3 induced oxidative damage resulted in the recruitment of more cells to the surfaces of the 
lesioned constructs as well as higher levels of SDF-1, compared to the mechanical lesion which 
generated a mild surface abrasion. It was also possible to demonstrate that atorvastatin increases 
secretion of SDF-1 and expression of CXCR4, which are the main cytokine and receptor associated with 
cell homing and migration. This effect was determined to be both time and dose dependent. Through 
the use of different blood vessel models, it was determined that the cells in each layer have differing 
responses to the composite tissue model i.e., observations of cell attachment and SDF-1 production 
on TEBV were an amalgam of TEIL and TEML responses. Through the use of nanofiber inserts to create 
a novel HUVEC-RAW264 co-culture system, we were able to demonstrate that atorvastatin triggers 
consistent cholesterol efflux from cultured foam cells compared to drug free controls, resulting in up 
to a 13% reduction in amounts off internalised cholesterol, a phenomenon that is affected by HUVEC 
integrity i.e., lesioned HUVECs promoted cholesterol efflux, especially in the presence of atorvastatin 
and IFN-γ. Atorvastatin was also able to restrict nitric oxide (NO) production in macrophages and may 
reverse the effects of the inflammatory cytokine IFN-γ. The models used here proved a useful tool for 
investigating the effects of atorvastatin, and could prove useful in evaluating cellular responses to a 
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1 Chapter 1:    





1.1 Cardiovascular Disease 
Cardiovascular disease has been identified as the biggest killer in the developed world with rising 
incidences in the developing world. The term cardiovascular disease (CVD) is used to refer to a wide 
range of conditions that affect the heart and blood vessels. These include coronary heart disease which 
results from the build-up of an atherosclerotic plaque in the coronary arteries, stroke resulting from 
obstructed blood supply to the brain, transient ischaemic attacks which are temporary disruptions to 
blood flow to the brain, peripheral arterial disease which refers to blockage of vessels in the limbs, and 
aortic disease which are conditions that affect the aorta, such as aortic aneurism (Biscetti et al., 2019).  
Atherosclerosis has been identified as a starting point for most cardiovascular disease and is the 
underlying cause of 50% of all deaths in westernised societies (Lusis, 2000; Biscetti et al., 2019). The 
main risk factors that lead to the development of atherosclerosis include smoking, high blood pressure, 
family history of cardiovascular disease, high cholesterol (dyslipidaemia), diabetes, a sedentary 
lifestyle, obesity and age (Libby et al., 2019). There is also some evidence that suggests that 
psychosocial factors such as depression, anxiety, social isolation and chronic life stress also contribute 
to the development of CVD (Rozanski, Blumenthal and Kaplan, 1999; Parvin Zafar, 2015). Because it is 
a disease of the vasculature, it is important to first understand the structure and function of blood 
vessels.    
1.2 Anatomy and Physiology of Blood Vessels 
The walls of arteries and veins are made up of three layers 1) the intima, 2) the media and 3) the 
adventitia (figure 1-1). As the diameter of the vessel decreases, the thickness of the three layers also 
decreases. The arteries, capillaries and veins have differences in the amounts of the tissue components 
present. The constant factors in most arterial anatomy are the endothelial cells (ECs), collagen fibres, 
elastic fibres and smooth muscle cells (SMCs) and the lumen through which blood flows. (Patton and 
Thibodeau, 2018). Together, their thicker walls and smaller diameters give arterial lumens a more 
rounded appearance in cross section than the lumens of veins (Klabunde, 2011). 




number of pores through their cytoplasmic membranes facilitate the diffusion and movement of 
substances and cells into or out of the blood. The collagen fibres in blood vessels are woven together 
to provide extra re-enforcement. The fibres are formed from a number of collagen isoforms that 
aggregate into collagen fibres that are several micrometres in diameter (Patton and Thibodeau, 2018). 
Under physiological conditions, the collagen fibres are not very extensible and are capable of stretching 
only 2% or 3%. Their main role is to keep the lumen of the vessel open as well as contributing to 
maintaining overall tension and strengthening of the vessel wall. The elastic fibres within the vessel 
are mainly made from elastin which is a small insoluble protein polymer. Once secreted into the 
extracellular matrix (ECM), the fibres form a rubber-like network that is highly elastic and capable of 
stretching up to 100% under physiological conditions (Patton and Thibodeau, 2018).  
In large arteries, the elastic fibres are organised in a concentric pattern and allow for recoil after 
distension and this property of elastic fibres plays an important role in the maintenance of passive 
tension in the vessel. This kind of tension is necessary in maintaining normal blood pressure levels 
throughout the cardiac cycle (Patton and Thibodeau, 2018). 
1.1.1 Intimal Layer 
The first layer, the intima (tunica intima) (figure 1) is the innermost, and thinnest, layer of the blood 
vessel and is comprised of an endothelium which is continuous throughout the entire vascular system, 
including the lining of the chambers of the heart. The endothelium in arteries provides a completely 
smooth lining compared with that of veins which also forms semilunar valves that facilitate one-way 
blood flow. The luminal surface of quiescent endothelial cells is anticoagulant and non-thrombogenic, 
such that platelets and leukocytes do not adhere to it and it helps maintain the inactive state of the 
blood coagulation system. Damage to the endothelial lining and exposure of blood to the collagenous 
fibres beneath is one of the primary causes of clot formation. The macromolecules of the basal lamina, 
synthesized by the endothelial cells, are strongly thrombogenic, and activated endothelial cells 
promote thrombus formation. The endothelium is physiologically vital to activities such as regulating 




2018). It regulates blood flow by producing endothelins (ET-1) which cause constriction of the smooth 
muscle within the vessel wall, elevating blood pressure. Production and release of endothelin is 
stimulated by angiotensin II (AII), antidiuretic hormone (ADH), thrombin, cytokines, reactive oxygen 
species, and shearing forces acting on the vascular endothelium. ET-1 release is inhibited 
by prostacyclin and atrial natriuretic peptide as well as by nitric oxide. The unregulated production of 
ET-1 has been linked to both hypertension and cardiovascular disease (Klabunde, 2011). Under 
microscopic view, the entirety of the lumen and the tunica intima of a vein will appear smooth, 
whereas those of an artery will normally appear wavy because of the partial constriction of the smooth 
muscle in the tunica media.  
Endothelial cells also play a vital role in regulating vascular homeostasis by modulating permeability, 
maintaining vascular tone and responding to a variety of stimuli through the production of bioactive 
substances. The intimal surface of healthy endothelium is both anticoagulant and antithrombotic: 
endothelial cells secrete a variety of molecules that are necessary for the regulation of blood 
coagulation and platelet functions. Vessel damage or exposure to certain cytokines or pro-
inflammatory stimuli shifts the balance towards a pro-coagulant/pro-thrombotic phenotype of the 
endothelial cells. Haemostasis processes are classified as either primary, which mainly involve 
platelets, or secondary, predominantly related to fibrin formation or blood coagulation, although the 





1.1.2 Medial Layer 
The second layer is the media (tunica media) (figure 1-1) which is the middle layer comprised of a layer 
of circularly arranged smooth muscle tissue together with a layer of elastic connective tissue (elastin 
sheets) and supported by a framework of collagenous fibres that also binds the tunica media to the 
intima and adventitia (Patton and Thibodeau, 2018). The smooth muscle cells in the media layer 
permits the change of blood vessel diameter. Contraction and relaxation of the circular muscles 
decrease and increase the diameter of the vessel lumen, respectively. This layer is innervated by 
autonomic nerves and supplied with blood by small vessels knows as vasa vasorum as the walls of the 
larger vessels are too thick to allow the diffusion of nutrients (Zhao, Vanhoutte and Leung, 2015; Patton 
and Thibodeau, 2018). This layer is thicker in arteries compared to veins and is absent in capillaries. 
Separating the tunica media from the outer tunica externa in larger arteries is the external elastic 
membrane or lamina. This structure is not usually seen in smaller arteries, nor is it seen in veins (Patton 
and Thibodeau, 2018). SMCs in the vessel wall produce a complex ECM that will ultimately define the 
mechanical properties of the adult vascular system. These properties include: 1) a highly resilient wall 
Figure 1-1: Vascular anatomy (Chen, Liang and Thouas, 2013). This image shows the different layers that comprise a blood 
vessel, with the intima in contact with the blood and the adventitia on the outermost surface. The elastic lamina provides 
the vessel with the elasticity needed to withstand blood flow under pressure. The collagen and proteoglycans are synthesised 




where a large proportion of the energy input during systolic inflation will be recovered by elastic recoil 
during diastole, 2) low hysteresis (the energy lost during an inflation-deflation cycle), and 3) nonlinear 
elasticity characterized by stiffening with increasing pressure to protect the wall from rupture 
(Wagenseil and Mecham, 2009; Basatemur et al., 2019).  
1.1.3 Adventitial Layer 
The third layer is the adventitia (tunica adventitia) (figure 1-1) and is the outermost layer of a blood 
vessel which is found in the larger blood vessels. This layer is made of tough, fibrous connective tissue 
and its main role is to hold the vessel open and to prevent the tearing of the vessel during body 
movements (Patton and Thibodeau, 2018). The adventitia also contains nerve endings, perivascular 
adipose tissue (PVAT) and connective elements (fibroblasts and collagen fibres) that assure adherence 
to the surrounding organs. Components of the adventitia are also involved in vascular development 
and remodelling, immune surveillance and inflammatory cell trafficking, and signal exchanges between 
the blood vessel and its residential tissue (Wagenseil and Mecham, 2009; Patton and Thibodeau, 2018). 
This layer is thicker in veins than arteries where it is slightly thinner than the media and also contains 
groups of smooth muscle fibres. (Patton and Thibodeau, 2018).  
1.3 Pathophysiology of Cardiovascular Disease 
Atherosclerosis is characterised by the accumulation of fatty and fibrous material within the intimal 
layer of arteries (Herrington et al., 2016; Libby et al., 2019). This accumulation of fatty material is 
initiated by elevated levels of cholesterol in the blood which in turn lead to endothelial activation and 
inflammation. Consequently, atherosclerosis can be defined as a chronic inflammatory disease (Libby 
et al., 2019; Qiu et al., 2020), with endothelial cells, leukocytes and smooth muscle cells being the 
major players in the development of disease (Parvin Zafar, 2015; Qiu et al., 2020). 
1.1.4 Role of Low-Density Lipoprotein (LDL) 
Studies into the pathogenesis of atherosclerosis have identified LDL particles as the cause of 
atherosclerosis (Libby et al., 2019), with their accumulation into the sub-endothelial space leading to 




space is facilitated through endothelial LDL receptors, specifically scavenger receptor B1 (SR-B1) 
interacting with the guanine nucleotide exchange factor dedicator for cytokinesis (DOCK4), with 
expression of both being elevated in atherosclerotic arteries compared to normal arteries (Borén et 
al., 2020). The LDL particles in the sub-endothelial space are prone to oxidation through enzymatic and 
non-enzymatic mechanisms, leading to the formation of oxidised LDL (oxLDL) (Lillis et al., 2015; Borén 
et al., 2020).  
1.1.4.1 Endothelial dysfunction 
The endothelial cells are the primary component of the intimal layer and are involved in maintaining 
vascular integrity through regulating both endogenous and exogenous stresses (Qiu et al., 2020), 
through the modulation of vasomotion, haemostasis, angiogenesis and vascular growth, as well as the 
trafficking of circulating cells through up-regulation of adhesion molecule expression. These adhesion 
molecules facilitate leukocyte migration into specific organs under typical physiological conditions and 
accelerating migration to sites of inflammation (Desideri and Ferri, 2005). Endothelial activation has 
no distinct definition but, can refer to the repeated exposure of the endothelium to elements such as 
reactive oxygen species (ROS), LDL and oxLDL, that are harmful or toxic to the endothelium, with 
prolonged exposure leading to an imbalance between endothelial repair and injury. This eventually 
results in endothelial dysfunction, a key stage in the development if atherosclerosis (Mannarino and 
Pirro, 2008; Qiu et al., 2020) A dysfunctional endothelium is characterised by the retention of plasma 
lipoproteins, induction of immune cell infiltration, overproduction of chemokines and an increase in 
endothelial cell death, creating an inflammatory microenvironment (Varghese, Patel and Yadav, 2017; 
Qiu et al., 2020). Another contributor to endothelial dysfunction is oxidative stress, which is defined as 
an imbalance between the synthesis of ROS and their elimination by the antioxidant defence system 
(Costa et al., 2016). ROS originate from Nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, uncoupled endothelial nitric oxide synthase (eNOS), mitochondrial enzymes, lipoxygenases 
and myeloperoxidases (Kattoor et al., 2017). ROS are involved in various processes, such as the 




and progression of heart failure (Costa et al., 2016; Kattoor et al., 2017). Endothelial dysfunction causes 
endothelial cells to produce adhesion molecules such as Intercellular adhesion molecule-1 and 2 
(ICAM-1 and ICAM-2)), Vascular cell adhesion protein-1 (VCAM-1), and platelet endothelial cell 
adhesion molecule-1 (PECAM-1) (Michael A. and Guillermo, 2016).  These molecules belong to a family 
of immunoglobulin-like molecules and they engage with leukocyte counter-receptors to mediate firm 
adhesion and/or trans-endothelial migration. ICAM-1 and VCAM-1 respond to cytokine or endotoxin 
challenge with a time- and dose-dependent increase in EC expression that is transcription-dependent, 
while ICAM-2 and PECAM-1 are constitutively expressed and are not up-regulated in response to 
cytokine challenge (Granger and Senchenkova, 2010; Golia et al., 2014).  
Other adhesion molecules include members of the selectin family i.e., E- and P-selectin. P-selectin is 
normally stored as a preformed reservoir in EC granules, also known as Weibel–Palade bodies, from 
which it can be rapidly mobilized to the cell surface by histamine, ROS, and leukotrienes (Granger and 
Senchenkova, 2010). A slower, more prolonged and transcription-dependent expression of P-selectin 
can be demonstrated within 4 hours after exposure to cytokines such as tumour necrosis factor-alpha 
(TNF-α). E-selectin is entirely under transcriptional regulation and requires up to 3 hours to achieve 
peak expression (Granger and Senchenkova, 2010; Barbier et al., 2020). The expression of adhesion 
molecules, together with the secretion of chemoattractant mediators such as complement factors, 
interleukin (IL)-8, and monocyte chemoattractant protein-1 (MCP-1), leads to mononuclear cell 
recruitment into the vascular wall. Monocytes differentiate into macrophages (Bentzon et al., 2014; 
Silva, Videira and Sackstein, 2018), which become foam cells via oxidised LDL uptake, and then release 
a variety of pro-inflammatory cytokines such as soluble CD40 ligand, IL-1, IL-3, IL-8, and IL-18, and 
TNF-α (Golia et al., 2014; Silva, Videira and Sackstein, 2018). A summary detailing the factors 






1.1.4.2 Macrophages and foam cells in atherosclerosis  
Because of their capacity to take up oxLDL, and LDL to a lesser extent, macrophages have a key role to 
play in the pathogenesis of atherosclerosis (Lillis et al., 2015). This oxidised form of LDL is more readily 
taken up by macrophages than the native form, with macrophages possessing receptors that are 
specific for oxLDL such as scavenger receptor A1/II (SR-A1/II), SR-B1, and CD36, which have also been 
identified on smooth muscle (Li and Mehta, 2005; Lillis et al., 2015). Macrophages that have taken up 
oxLDL are referred to as foam cells due to the formation of lipid droplets as a result of excessive lipid 
accumulation that exceeds the haemostatic capacity of macrophages (Guerrini and Gennaro, 2019). 
Once in the sub-endothelial space, monocytes differentiate into macrophage and dendritic cell like 
phenotypes (H. Xu et al., 2019). Those resident in vascular tissue are involved in the early stages of 
Figure 1-2: Adhesion molecules and chemokines associated with endothelial dysfunction (Khan, Adil and Olson, 2017). This 
image details the homing of MSCs to activated endothelium denoting the adhesion molecules that would aid in the 





plaque formation, actively ingesting excess cholesterol present in the subendothelial space and 
becoming foam cells (H. Xu et al., 2019). The oxLDL also activates scavenger receptor/toll like receptor 
(TLR) cooperative signalling pathways that contribute to the induction of pro-inflammatory 
downstream signalling cascades (Lara-Guzmán et al., 2018). These pro-inflammatory signals contribute 
to endothelial dysfunction, which in turn promotes the expression of adhesion molecules that aid in 
the trapping and infiltration of circulating monocytes, perpetuating the cycle of inflammation and 
contributing to plaque progression (Guerrini and Gennaro, 2019). Macrophages that have accumulated 
in the atherosclerotic plaque also display a reduced capacity to migrate, adding to their failure to 
resolve inflammation and contributing to plaque progression (Guerrini and Gennaro, 2019).  
One of the key pro-inflammatory mediators is interferon-gamma (IFN-γ), which is involved in the 
initiation and modulation of numerous pro-atherogenic processes, one of which is promotion of foam 
cell formation (Voloshyna, Littlefield and Reiss, 2014). This cytokine plays a key role in endothelium 
mediated recruitment of monocytes and T-cells to the atherosclerotic plaque. Macrophage derived 
foam cells that have accumulated in the sub-endothelial space secrete a variety of factors such as 
platelet derived growth factor (PDGF) and matrix metalloproteases (MMPs) which contribute to the 
migration and proliferation of SMCs  (Voloshyna, Littlefield and Reiss, 2014; Biros, Reznik and Moran, 
2021). Figure 1-3 details the process of macrophage infiltration into the sub-endothelial space where 











SMCs which are resident in the media, migrate to the intima where they proliferate and produce 
extracellular matrix. Smooth muscle cells are also prompted to take up oxLDL, thus becoming foam 
cells (Kattoor et al., 2017). Certain constituents of the extracellular matrix, especially proteoglycans, 
bind lipoproteins, thus prolonging their residence in the intima, and render them more susceptible to 
oxidative modification and glycation (Di Pietro, Formoso and Pandolfi, 2016; Kattoor et al., 2017). As 
the lesion progresses, calcification may then occur, and in addition to proliferation, cell death (including 
apoptosis) commonly occurs in the established atherosclerotic lesion. The extracellular lipid that 
accumulates in the intima can coalesce and form the classic, lipid-rich “necrotic” core of the 
Figure 1-3: Mechanisms of foam cell formation (Moore, Sheedy and Fisher, 2013; Linton et al., 2019). These images detail 
the process of monocyte recruitment, differentiation into macrophages and the process of foam cell formation within the 
macrophage. The activated endothelium promotes the adhesion and transmigration of circulating lymphocytes where they 





atherosclerotic plaque (Libby and Theroux, 2005; Geovanini and Libby, 2018). 
1.1.5 Role of Shear Stress 
Hemodynamic shear stress refers to the force that acts on the endothelial cell surface as a result of 
blood flow, and plays a vital role in determining endothelial cell phenotype and function as well as 
embryonic cardiovascular development (Malek, Alper and Izumo, 1999). Normal stretch of the vessel 
due to the effects of blood pressure are transferred to all vessel wall layers. In contrast, the effects of 
shear stress are principally applied only to the vascular endothelium (Cunningham and Gotlieb, 2005).  
The endothelium responds to shear stress through various physiological and pathological mechanisms 
depending on the kind and the magnitude of shear stresses (Lehoux and Jones, 2016). More 
specifically, the exposure of vascular endothelium to typical arterial shear forces stimulates endothelial 
cells to release agents with antithrombotic properties, such as prostacyclin, nitric oxide (NO), and 
thrombomodulin. Therefore, normal shear stresses act to maintain an endothelial phenotype that 
inhibits atherogenesis, thrombosis, adhesion of leukocytes, smooth muscle proliferation and 
endothelial apoptosis (Papaioannou and Stefanadis, 2005; Davies, 2009). 
A disruption of the biomechanical forces, such as shear stress, that maintain endothelial cell integrity 
can also result in the activation of the endothelium, which then results in initiation of the inflammation 
response. Changes in the magnitude of shear stress can activate cellular proliferation mechanisms as 
well as initiating vascular remodelling processes (Davies, 2009). A high grade of shear stress increases 
wall thickness and expands the vessel’s diameter so that shear stress values return to their normal 
values. Contrastingly, lower shear stresses result in a reduction of vessel diameter which can then lead 
to intima-media hyperplasia. Low shear stress that displays varying direction (oscillating shear stress) 
has been associated with the development of atherosclerotic impairment in (Papaioannou and 
Stefanadis, 2005; Lehoux and Jones, 2016).  
In arterial circulation, shear stress has an important role in determining where most vascular pathology 
originates and it is also implicated in the development of endothelial phenotypic changes that are 




Regions of the arterial tree with uniform geometry are exposed to a unidirectional and constant flow, 
which aids in generating physiologic shear stress, while vessel arches and bifurcations are exposed to 
an oscillatory and disturbed flow, which determines a low shear stress. Atherosclerotic lesions develop 
mainly in areas of low shear stress, while those exposed to a physiologic shear stress are protected 
(Cecchi et al., 2011; Nigro, Abe and Berk, 2011). A developing atherosclerotic lesion can alter the shear 
stress profile on the endothelium. A narrowed lumen that results from an atherosclerotic plaque can 
create flow separation in the region immediately downstream and the altered flow has similar 
properties to plaque free regions that are susceptible to shear induced changes, indicating that lesion 
induced changes to blood flow may facilitate the growth of the lesion over time. Studies on endothelial 
cells show that the altered flow pattern promotes pro-inflammatory gene and protein expression that 
is conductive to atherosclerosis susceptibility, plaque growth and instability and an increased risk of 
thrombus (Davies, 2009).  
1.4 Therapies for Cardiovascular Disease (CVD) 
In a number of instances, the treatment or management options for atherosclerosis, and 
cardiovascular disease in general, involves a change in lifestyle (e.g., lowering dietary cholesterol and 
exercise) (Toulassi et al., 2021) but in more serious cases, drugs are prescribed which can either slow 
or completely stop the progression of atherosclerosis. Some of these include statins and fibrates that 
are used to reduce circulating levels of LDL (Solanki, Bhatt and Johnston, 2018).  
1.1.6 Surgical Interventions  
In more severe cases, surgical avenues are used to alleviate the symptoms. Procedures include 
angioplasty which is the widening of narrowed arteries using a balloon, endarterectomy which involves 
the removal of fatty deposits in the vessel to improve circulation and thrombolytic therapy that is to 
remove clots at the site of formation and bypass surgery (Leong et al., 2017). The most common type 
of heart surgery is coronary artery bypass grafting and this involves the grafting of a healthy artery or 
vein from the body, which then bypasses the obstructed portion of the coronary artery, creating a new 




advancements in percutaneous coronary intervention, which involves the widening of occluded vessels 
with stents. One example of stents used is the drug eluting stent (DES) which has come to replace the 
use of bare metal stents (BMS) (Leong et al., 2017; Park et al., 2020). DES work by releasing one or 
more bioactive agents that act on tissues adjacent to the stent. The bioactive component can be either 
linked to the stent surface or embedded and released from within polymer materials, or surrounded 
by and released by a carrier (Fattori and Piva, 2003; Lee and Hernandez, 2018). Compared to bare 
metal stents, DES have fewer incidences of in-stent chronic total occlusion as a result of increased 
thrombus formation (Fattori and Piva, 2003; Bangalore et al., 2018).  These surgical interventions serve 
to cater for more severe presentations of CVD and patients will still need pharmaceutical intervention 
of some kind to aid with inflammation reducing irregularities in lipid metabolism, which are the key 
drivers of atherosclerosis.   
1.1.7 Drug Therapies 
There is a broad variety of alternative therapies available for the treatment and management of 
cardiovascular disease but, as a number of them have no proven benefits to the patient’s health, drug 
therapies and scientifically tested alternatives remain the best option to effectively curb the 
progression of cardiovascular disease.  
1.1.7.1 Cholesterol Regulation 
For atherosclerosis in particular which involves excessive inflammation that is propagated by lipid 
modifications, drugs that regulate cholesterol levels are the go-to therapy currently in use. Statins fall 
under this category and are recommended for most patients because they are the only cholesterol-
lowering drug class that has been directly associated with reducing the risk of a heart attack or stroke. 
There are other cholesterol lowering drugs available, such as (1) bile acid binders, which are also 
referred to as resins, (2) Nicotinic acid and (3) Fibric acids (Pahan, 2006; Kuo, Huang and Hsieh, 2020).  
Bile acids are synthesised in the liver from cholesterol and facilitate the absorption of fatty acids and 
lipid soluble vitamins. Bile acid binders, or resins, function by binding bile acids in the intestines 




clearance. Increased faecal excretion of bile acids results in increased bile acid synthesis which  leads 
to increased expression of LDL receptors in the liver and subsequent reduction in circulating levels of 
LDL (Hansen, Sonne and Knop, 2014; Ross et al., 2015).  
Nicotinic acid, or niacin, has benefits primarily in increasing high density lipoprotein cholesterol (HDL-
C), and has also been shown to decrease concentrations of LDL. The mechanisms of action of this drug 
have not been fully elucidated, as such it’s use in the treatment of cardiovascular disease remains 
limited, although its use in conjunction with statins results in reduced morbidity and mortality and 
promoting regression of coronary atherosclerosis (Shah et al., 2013; Zeman et al., 2015).  
Fibric acid or fibrins do not directly affect cholesterol biosynthesis but rather lower plasma levels of 
fatty acid and triacylglycerol and can also increase HDL levels and educe LDL particle size (Pahan, 2006; 
Boden, Sidhu and Toth, 2014). These drugs, however, are not in common use due to evidence linking 
some variants, such as clofibrate and ciprofibrate cause peroxisome proliferation which causes 
hepatomegaly and tumour formation in rodent livers (Pahan, 2006).  
Statins have proven to be the most effective, and with fewer deleterious effects, at lowering cholesterol 
and remain then primary drug of choice for patients with cardiovascular disease.  
1.1.7.2 Statins: Pharmacology and Systemic Effects 
Statins are categorically classified as HMG CoA reductase inhibitors and their purpose is to prevent the 
formation of cholesterol and are most effective at lowering LDL cholesterol. They do this by interfering 
with the conversion of HMG-CoA to the cholesterol precursor mevalonate. They also help lower 
triglycerides and raise HDL cholesterol (Pahan, 2006; Pinal-Fernandez, Casal-Dominguez and Mammen, 
2018).  HMG CoA reductase is the rate-limiting enzyme for cholesterol synthesis. Normally in 
mammalian cells this enzyme is suppressed by cholesterol derived from the internalization and 
degradation of LDL via the LDL receptor. Competitive inhibitors of the reductase induce the expression 
of LDL receptors in the liver, which in turn increases the catabolism of plasma LDL and lowers the 
plasma concentration of cholesterol, an important determinant of atherosclerosis (Stancu and Sima, 




appreciated for their good tolerance. Angiographic studies have demonstrated that these compounds 
reduce the progression and may induce the regression of atherosclerosis.  There are a variety of statins 
available for clinical use such as atorvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, 
pravastatin, rosuvastatin and simvastatin (Davies et al., 2016).  Atorvastatin and rosuvastatin have been 
shown to have the greatest potency and they also have the longest half-lives (20 h) versus about 12 h 
for simvastatin. All the others have a context half-life of 4 hours (Sirtori, 2014; Chiang et al., 2015). The 
statins are commonly grouped in two types. Type 1 compounds are natural or fungal-derived statins 
(lovastatin, simvastatin, pravastatin). Type 2 statins are synthetic statins and are known to form more 
interactions with HMG-CoA reductase because of their structural characteristics. Lovastatin, 
simvastatin, atorvastatin, and fluvastatin are lipophilic, whereas pravastatin and rosuvastatin are more 
hydrophilic (Davies et al., 2016). The lipophilic properties of the statins are accompanied, except for 
pitavastatin, by low systemic bioavailability because of an extensive first-pass metabolism by the liver. 
The functional difference between natural and synthetic statins relies on their ability to interact and 
inhibit the HMG-CoA reductase and on their lipophilicity (Gazzerro et al., 2012; Davies et al., 2016).  
Angiographic studies have demonstrated that these compounds reduce the progression and may 
induce the regression of atherosclerosis (Stancu and Sima, 2001). Statins have been shown to have 
pleiotropic effects as the products of the inhibited enzyme are necessary for a variety of physiological 
processes. Statins modulate a series of processes leading to reduction of the accumulation of esterified 
cholesterol into macrophages, increase of endothelial NO synthase, reduction of the inflammatory 
process, increased stability of the atherosclerotic plaques, restoration of platelets activity and of the 
coagulation process as well as the inhibition of tumour cell growth and enhancement of rises in 
cytosolic Ca2+ concentration (Stancu and Sima, 2001; Sandhu, Mamas and Butler, 2017). This elevation 
of cytosolic Ca2+ concentration has been demonstrated for human umbilical vein endothelial cells 
(HUVECs) upon Incubation of the cells with cerivastatin or fluvastatin. Heinke et. al., (2004) 
demonstrated that a 24hour incubation of HUVECs with either cerivastatin or fluvastatin significantly 




Cerivastatin. This increase of resting Ca2+ concentration in the presence of cerivastatin also occurred 
when the nitric oxide synthase was inhibited (Heinke et al., 2004). The elevation of Ca2+ concentrations 
has also been observed after introduction of high concentrations of simvastatin to rat L6 myoblasts, 
and a similar effect was observed in cardiomyocytes (Baker and Tarnopolsky, 2001; Heinke et al., 2004; 
Pinal-Fernandez, Casal-Dominguez and Mammen, 2018).  
Statins can also reduce the expression and function of molecules on the leukocytes surface. 
Atorvastatin reduces the number of intimal macrophages, monocyte-chemoattractant protein-1 (MCP-
1) and the activation of nuclear factor NFkB in hypercholesteraemic rabbits. The effect this has is to 
limit the inflammation process which is a key physiological marker of atherosclerosis. They have also 
demonstrated the ability to inhibit trans-endothelial migration and chemotaxis of neutrophils, which 
possibly explains the anti-inflammatory effect of these compounds. Another anti-inflammatory effect 
of statins on monocytes and macrophages is the decrease of the expression of intercellular adhesion 
molecule -1 and the secretion of interleukin-6 (IL-6), induced by lipopolysaccharides (Stancu and Sima, 
2001; Gazzerro et al., 2012). Additionally, all statins, except for pravastatin, reduce aortic smooth 
muscle cell (SMC) proliferation. Preclinical observations and in vitro studies suggest that apoptosis can 
modulate the arterial wall in restenotic or proliferative lesions, where SMCs are dominant. It was 
reported that statins can induce apoptosis of vascular SMCs in culture. This was demonstrated by 
examining lesioned carotid arteries from rabbits that received fluvastatin or atorvastatin, 5 days prior 
to lesion induction. The rabbits presented an increased number of apoptotic SMCs (Stancu and Sima, 
2001). 
Statins have been shown to have positive effects regarding preventing the progression of 
atherosclerosis and have been prescribed to those at risk of developing coronary artery disease to 
lower the likelihood of this happening. Given the pleiotropic effects induced by statins, there is 
potentially a broader selection of molecular and cellular effects that have yet to be determined. Figure 






1.1.8 Alternative Therapies 
There are also a variety of alternative therapies that rely on natural products/extracts to counteract 
the processes initiated by the risk factors that cause the development of cardiovascular disease. A 
number of these therapies have unsubstantiated cardiovascular effects and most research on these 
products is either inconclusive, conflicting, or shows no benefit for their use (Rabito and Kaye, 2013). 
Some of these include; (1) Marine-derived omega-3 polyunsaturated fatty acids which are used to 
prevent the adverse consequences of cardiovascular disease. Reportedly, these function by lowering 
triglyceride levels, preventing arrhythmias, decreasing platelet aggregation, or lowering blood pressure 
(Rabito and Kaye, 2013). (2) Garlic, which is used mainly as a dietary supplement for treatment of 
hyperlipidaemia, heart disease, and hypertension but there is no conclusive evidence verifies these 
beneficial effects. (3) Ginseng has also been used as a treatment for cardiovascular disease with the 
purported effects being cardio-protection, antihypertensive effects, and attenuation of myocardial 
hypertrophy and heart failure. (4) Antioxidants, which include anthocyanins, beta-carotene, catechins, 
coenzyme Q10, flavonoids, lipoic acid, lutein, lycopene, selenium, and vitamins C and E, have shown 
Figure 1-4: Pleiotropic effects of statins. (Gupta et al., 2018) This figure denoted the suspected pleiotropic 
effects of statins in cardiovascular disease, separate from their cholesterol lowering function. Text contained 




promising results in laboratory and observational studies. Unfortunately, systematic reviews of the 
literature and large, randomized, controlled trials have overall found no advantageous effects of 
antioxidant supplements for primary or secondary prevention and, it has been found that vitamin A, 
beta-carotene, and vitamin E may actually increase mortality (Rabito and Kaye, 2013).  
1.1.9 Cell Therapy 
Another technique that shows promise for the treatment of cardiovascular disease is regenerative 
medicine. This technique is used in a number of situations where a vessel needs to be replaced or 
where there is damage to the muscles of the heart. This process involves the conditioning of cells into 
becoming a desired tissue type with the same or similar physical properties as the native tissue. These 
can then be transplanted into the patient with a reduced likelihood of tissue rejection as well as 
eliminating the need of a donor or the derivation of autologous donor tissue. 
Cell therapies have gained popularity over the years and have been effectively used to repair damaged 
organs and tissues. In the case of cardiovascular disease, transplanted adult bone marrow has been 
shown to improve left ventricle ejection fraction, reduce infarct size and ameliorates remodelling in 
patients with ischaemic heart disease (Afzal et al., 2015; Fisher et al., 2016). Other studies have 
demonstrated scar tissue reduction and cardio-protection after mesenchymal stem cell (MSC) 
transplantation. MSCs are broadly distributed throughout the body outside bone marrow and reside 
in adipose tissue, gut, lung, liver, placenta, amniotic fluid, dental pulp, periodontal ligament and in the 
heart. The cells most commonly used in clinical trials to date originate from bone marrow i.e., MSCs 
and mesenchymal precursor cells (MPCs), adipose tissue, and umbilical cord. There are also cells that 
bear the same characteristics of MSCs found in peripheral blood (Karantalis and Hare, 2015). The main 
mechanisms of action that are responsible for the observed cardio-protective effect of MSCs are (1) 
reduction of fibrosis, (2) stimulation of angiogenesis, and (3) restoration of contractile function through 
engraftment, differentiation, and stimulation of endogenous cardiac stem cells to proliferate and 
differentiate. These effects occur in concert and together lead to the replacement of scarred or 




Liesveld, Sharma and Aljitawi, 2020).  
Numerous efforts to further enhance the therapeutic potential of MSCs by genetically modifying or 
pre-treating MSCs with various drugs and cytokines are being undertaken. One attempt involved 
combining MSCs and simvastatin. It did not affect the reduction in perfusion defect, scar size, or end-
diastolic volume, it did, however, potentiate increases in ejection fraction and systolic wall thickening, 
as well as improved MSC retention and survival (Karantalis and Hare, 2015; Bagno et al., 2018).  
The discovery and categorisation of endothelial progenitor cells as a circulating precursor to vascular 
endothelial cells has led to the consideration of using these cells in the treatment of cardiovascular 
diseases in terms of improving the repair of damaged vasculature (Urbich and Dimmeler, 2004).  
1.5 Endothelial Progenitor Cells 
1.1.10 Characterisation and Behaviour 
The progenitor cells that are able to differentiate into functional endothelial cells and sustain 
vasculogenesis are broadly called endothelial progenitor cells. Human endothelial progenitor cells 
(EPCs) have been defined as circulating cells that express a variety of cell surface markers similar to 
those expressed by vascular endothelial cells, adhere to endothelium at sites of hypoxia/ischemia, and 
participate in neovascularisation. The first reported existence of a bone marrow– derived circulating 
progenitor for the endothelial lineage called the endothelial progenitor cell (EPC) in 1997 by Ashara et. 
al initiated a robust area of investigation in experimental animals and human subjects (Yoder, 2012; 
Marchetti, 2015). 
Three different populations of putative human EPCs, with a variety of names in the literature i.e. EPC, 
Colony-forming Unit Epithelial cell (CFU-EC), Circulating angiogenic cell (CAC), Circulating endothelial 
precursors (CEP), Endothelial colony forming cell (ECFC), Low proliferative potential-ECFC (LPP-ECFC), 
High proliferative potential-ECFC (HPP-ECFC), Early Outgrowth EPC (CFU-EC, CFU-Hill, CAC), Late 
Outgrowth EPC (ECFC), have been defined using four cell culture and cell sorting protocols;  
(1) Circulating Angiogenic Cells (CACs): These are obtained from the low-density mononuclear cell 




plates and incubated with a mixture of cytokines. After 4-7 days in culture, the non-adherent cells are 
removed and the remaining cells are examined for their ability to take up acetylated low-density 
lipoprotein (AcLDL) and to bind to Ulex europaeus agglutinin1 (lectin), both considered to be hallmarks 
of EC function. CACs are further characterized by their morphology, adhesion to fibronectin, and cell 
surface protein expression. The isolated cells display pro-angiogenic activity in vitro, by secretion of 
angiogenic cytokines, and also in vivo, but lack the capacity to inosculate into a new blood vessel 
(Medina et al., 2010; Marchetti, 2015)  
(2)  Colony-Forming Unit-Hill (CFU-Hill) and CFU-Endothelial Cells (CFU-EC): CFU-Hill are also obtained 
from the MNC fraction of peripheral blood. MNCs are cultured in the same way as CACs for two days, 
after which the cells of interest, located in the non-adherent cell population, are removed and re-
plated once more on fibronectin-coated plates. After three days, positive colonies are identified as 
having a central core of “round” cells, with more elongated “sprouting” cells at the periphery 
(Marchetti, 2015). Immuno-histochemical staining will confirm whether cells generated in this assay 
express the endothelial markers von Willebrand factor, Vascular endothelial growth factor receptor-2 
(VEGFR2) and CD31. The isolated cells, however, lack the capability to form new vessels in vivo 
(Marchetti, 2015; Ravishankar, Zeballos and Balachandran, 2017).  
(3) Late outgrowth endothelial cells (OECs) or endothelial colony forming cells (ECFCs): These cells are 
obtained by plating human peripheral blood or cord blood-derived MNC on dishes coated with rat 
collagen type I and in media containing endothelial growth factors. Non-adherent cells are discarded 
daily and fresh medium is added. Within one to three weeks, cells possessing clonal ability appear with 
endothelial cobblestone morphology and varying proliferative potentials. Among the ECFC population 
it is possible to identify a distinctive population of high proliferative potential endothelial colony 
forming cells (HPP-ECFCs), which give rise to low proliferative potential endothelial colony-forming cells 
(LPP-ECFCs), generating endothelial clusters and finally mature non-dividing endothelial cells 
(Kachamakova-Trojanowska et al., 2015; Marchetti, 2015).  




These cells have the ability to form colonies after 100 population doublings and are found in cord 
blood. The colonies contain cells that can differentiate into endothelial capillary-like tubes in vitro. 
Adult peripheral blood contains LPP-ECFCs with the ability to proliferate for 20 - 30 population 
doublings. ECFC-derived cells express many EC antigens, including CD31, CD105, CD144, CD146, Von 
Willebrand factor (VWF), VEGFR-2, and Ulex Europaeus Agglutinin I (UEA-1) (Zhang, Malik and Rehman, 
2014a; Marchetti, 2015).  
As yet, there is still no uniformity in terms of the nomenclature used to define EPC subtypes, for 
example early outgrowth EPCs can also be, and frequently are, referred to as CACs (Medina et al., 
2017). Consequently, identification, and classification is based on expression of these surface antigens.  
For general purposes, cells can be defined as EPCs if they are positive for VE-Cadherin, CD31/PECAM-
1, CD34, CD45, CD45.1, CD45.2, CD117/c-kit, CD133, CXCR4, ETV2/ER71, MCAM/CD146, Tie-2, VEGF 
R2/KDR/Flk-1 and VEGF R3/Flt-4. These markers are, however, shared amongst a number of 
hematopoietic and vascular endothelial subsets. The EPCs be discriminated by an extensive gene 
expression analysis or use of a variety of functional assays that are not often applied (Yoder, 2012; 
Medina et al., 2017; Chopra et al., 2018a). 
EPCs can be isolated from circulating mononuclear cells, bone marrow, and cord blood. When these 
cells are injected into animal models with ischemia, they are rapidly incorporated into sites of 
neovascularization. Given that atherosclerosis involves damage and dysfunction of endothelial cells, 
the existence of EPCs has led to the hypothesis that circulating endothelial progenitor cells might 
contribute to ongoing endothelial repair which may reduce the rise of occurrence of acute 
cardiovascular events (Hill et al., 2003). Asahara et. al initially identified and isolated a supposed EPC 
in adult human peripheral blood. Since then, distinctly different cell populations have been isolated 
and called EPCs. These cell populations have subsequently been shown to improve vascular function 
through two principal mechanisms (1) direct incorporation into injured endothelium with formation of 
a functional blood vessel and/or (2) local secretion of pro-angiogenic factors with a paracrine effect to 




have also been identified as biomarkers for cardiovascular disease and have been proposed as a potent 
cell-based therapy for their capacity to stimulate vascular repair in physiological and pathological 
conditions  (Fadini, Losordo and Dimmeler, 2012; Chopra et al., 2018b).  
1.1.11 Role in Vascular Neogenesis 
Asahara et. al established, in their 1997 publication, that purified CD34+ hematopoietic progenitor cells 
from adults can differentiate ex vivo to an endothelial phenotype. These EPCs showed expression of 
various endothelial markers and are incorporated into neo-vessels at sites of ischemia (Lee et al., 2014; 
Peters, 2018). Since the initial discovery of EPCs and their association with vascular repair, numerous 
studies have been carried out and have demonstrate that EPCs were indeed pro-angiogenic in a variety 
of ischemia models. In models of myocardial infarctions an arterial injury EPCs have been shown to 
localize preferentially to sites of vascular lesions, after which they divide, proliferate and become 
incorporated into the endothelial layer of existing vessels, and promote the outgrowth of new vascular 
networks. These cells also have an effect on surrounding cells by producing angiogenic growth factors 
(Kunz et al., 2006; Zhang, Malik and Rehman, 2014b).  
The two types of EPC that have garnered the most attention, in regards to vascular repair, are Early 
(CFU-EC, CFU-Hill, CAC) and Late (ECFC)-Outgrowth Endothelial Progenitor Cells. Currently EPCs are 
defined as either early or late outgrowth based on their biological properties and their time of 
appearance during in vitro culture (Cheng et al., 2013). The early outgrowth cells are short lived, with 
a life span of less than two weeks, and do not differentiate into endothelial cells in vivo. They can, 
however, restore endothelial function and enhance angiogenesis after ischaemia through paracrine 
effects. The late outgrowth EPCs have a high proliferative potential, are able to differentiate into 
vascular endothelial cells and form networks in vivo and in vitro (Cheng et al., 2013). The angiogenic 
function and morphology is maintained in patients with cardiovascular disease risk factors and patients 
at end stage renal failure. It has also been demonstrated that their proliferation and tube forming 
ability are increased with laminar shear stress which suggests a role in autologous vascular repair (Zhao 




colony forming units (CFU-EC), can be used to determine the severity of cardiovascular disease. The 
number of these cells in circulation is inversely related to an individual’s cardiovascular risk profile 
(Kunz et al., 2006).  
The extent and type of vascular intima repair or regeneration seems to be dependent on the extent 
and type of injury and the age of the host (Kachamakova-Trojanowska et al., 2015). EPCs can mediate 
vascular repair and attenuate atherosclerosis progression even in the continued presence of vascular 
injury. Although the mechanisms involved are still not clear, EPCs seem to contribute to the restoration 
of the endothelial monolayer. In addition, autologous EPCs that overexpress endothelial nitric oxide 
synthase (eNOS) improve endothelial integrity when transplanted into mice after carotid artery balloon 
injury. Increased NO bioavailability significantly strengthens the vasoprotective properties of the 
reconstituted endothelium, leading to inhibition of neo-intimal hyperplasia (Renna et al., 2017).  
1.1.11.1 EPC Homing 
For EPCs to contribute to vascular repair, they must first be mobilised to the injury site where they can 
differentiate into mature endothelial cells. The homing of EPCs to neovascular area requires a 
coordinated sequence of multistep events that conclude with differentiation into endothelial cells. The 
homing of leukocytes to denuded endothelium is well documented and the homing of EPCs has been 
shown to share some commonalities. Both involve a multistep cascade of adhesive and signalling 
events including chemotaxis, selectin-mediated tethering and rolling, and integrin-mediated firm 
adhesion and diapedesis (Li et al., 2015; Williams and Silva, 2015). These processes are mediated 
mainly via growth factors which include, but are not limited to, stromal-derived factor (SDF-1), VEGF, 
granulocyte-colony-stimulating factor (G-CSF), stem cell factor, soluble intercellular adhesion molecule, 
granulocyte-monocyte-colony-stimulating factor, hepatocyte growth factor, interleukin-6 (IL-6), IL-10, 
oestrogen, and eNOS (Maeng et al., 2009; Li et al., 2015).   
SDF-1, a member of the chemokine CXC subfamily, was identified as an important factor for the 
trafficking of EPCs to ischemic tissues; it has also been recognized as a prominent target for increasing 




in EPCs, as well as platelets, have also been shown to mediate augmentation of the homing and 
neovascularization capacity of EPCs in vitro and in vivo, while CXCR2 also increased the homing of 
circulating EPCs to the sites of artery injury, possibly by enhancing adhesion of EPCs to extracellular 
matrix co-immobilized with chemokines. Maeng et. al demonstrated that insulin-like growth factor-2 
(IGF2) strongly stimulates the events required for EPC homing. IGF2 expressed under hypoxic 
conditions promoted both the recruitment and incorporation of EPCs specifically through an IGF2R-
dependent signalling pathway, but had no significant effects on the expression of known molecules 
related to EPC recruitment such as CXCR4/CXCR2, VEGFR2, integrins, and their ligands. Vascular 
smooth muscle cells (VSMCs) exposed to the blood flow might also secrete arrest chemokines, thus 
facilitating the capture of circulating progenitor cells (Hristov et al., 2007; Maeng et al., 2009).  
The homing of circulating EPCs to sites of arterial injury is a complex process primarily directed by 
signalling via key CC- and CXC-chemokines and their respective receptors (e.g., CCR2, CCR5, CXCR2 and 
CXCR4) as well as via β-integrins and P-selectin. It has been revealed that blocking CXCR4 significantly 
reduced the adhesion of EPCs after arterial wire-injury in vivo. Additionally, SDF-1 mediated migration 
of isolated EPCs, enhanced their matrix arrest when acting as a soluble chemokine, and was further 
secreted by activated platelets and SMCs after arterial wire-injury (Hristov et al., 2007; Mayorga et al., 
2018). The SDF-1 (CXCL12)/CXCR4 axis is of interest as it is vital for angiogenesis, vasculogenesis as well 
as vascular repair (Ratajczak et al., 2006; Mayorga et al., 2018), and studies have highlighted it’s 
importance in recruiting stem cells to sites of vascular injury (Sainz and Sata, 2007; Xu et al., 2017; 
Liesveld, Sharma and Aljitawi, 2020).  
Adhesion molecules of the selectin and integrin family are also essential for EPC arrest to endothelial 
cells or extracellular matrix compounds both in vitro and in vivo. EPCs have also been found to exhibit 
surface expression of the P-selectin glycoprotein ligand-1 (PSGL-1) and were recruited on activated 
endothelial cells in a P- and E-selectin-dependent manner. Chemokines such as CCL2 have also been 
shown to trigger integrin activation to mediate arrest of rolling leukocytes (Liu et al., 2016; Barbier et 




Platelets have also been shown to have some influence in regards to guiding EPC homing. In the 
pathogenesis of atherosclerosis, activated platelets play a crucial role in terms of propagating the 
inflammatory response. Soon after endothelial denudation, platelets interact with the extracellular 
matrix and become activated. Activated platelets produce SDF-1 and the CXCL7 precursor β-
thromboglobulin, and also induce secretion of diverse chemokines, such as CCL2 and CXCL8. Thus, the 
platelet-coated extracellular matrix represents an attractive adhesive surface promoting arrest of 
circulating CD34+ progenitor cells in vitro as well as in vivo (Hristov et al., 2007).    
 
1.1.12 Effect of Statins on EPC Activities 
Beyond their effects on lowering cholesterol, statins have additional pleiotropic effects that are still 
under investigation. Some of these reported effects include modulation of immune responses, 
enhancement of anti-inflammatory processes, and their alterations of signalling pathways that involve 
cholesterol intermediates. There are a multitude of diseases in which statins induce a clinical benefit 
attributed to these pleiotropic effects. These include multiple sclerosis (MS), inflammatory bowel 
diseases (IBDs), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), chronic obstructive 
pulmonary disease (COPD), cancer, strokes, Parkinson’s and Alzheimer’s diseases, bacterial and HIV 
infections (Ramji and Davies, 2015; Gorabi et al., 2020).  
In relation to EPC behaviour, statins have been shown to have a role in enhancing revascularisation 
after ischaemic events. According to Chiang et al., (2015), administration of the most potent statins, 
atorvastatin and rosuvastatin, had the effect of promoting EPC-mediated small vessel formation which 
enhanced the recovery of capillary density in ischaemic hind limb mice (Chiang et al., 2015). Following 
statin administration, several genes are activated that stimulate ischaemic neovasculogenesis by 
promoting the homing of EPCs to the ischaemic site. According to Kunz et. al (2006), EPC levels have 
been found to be lower in older patients and patients undergoing haemodialysis but increase with 
statin therapy (Kunz et al., 2006).  




demonstrated by Oikonomou et. al (2015) who evaluated the effect of varying doses of atorvastatin. 
The doses used were 10mg/day and 40mg/day and they demonstrated that there was a marked 
increase in numbers of EPC after drug administration, with the 40mg/day dosage showing higher 
numbers of EPCs compared to the baseline and the 10mg/day dosage (Oikonomou et al., 2015).  
The current data available on the interactions between statins and EPCs has repeatedly shown that 
statins can increase the numbers of EPCs in circulation and this in turn contributes positively to 
endothelial repair and neovascularisation in patients with cardiovascular disease (Chiang et al., 2015; 
Gorabi et al., 2020). A likely mechanism behind enhanced recruitment of EPCs could lie in the homing 
signals of the SDF-1/CXCR4 axis, which have been shown to have significance for angiogenesis and 
vascular repair (Mayorga et al., 2018), expecially given that statins have been associated with having 
an effect on this axis (Gao, Yu and Tang, 2019; Yu and Feng, 2008). Figure 1-5 details the mechanisms 
associated with EPC migration and differentiation.  
 
 
Given the vast amount of interest in the role of EPCs and the established correlation of statins and 
these cells, there is value to be gained in determining the exact mechanisms in play between them and 
the effect they have on vascular repair. The primary mode of assessment of this interaction have been 
Figure 1-5: Mechanisms associated with EPC recruitment and differentiation (Meiliana and Wijaya, 2009). This image details 
the factors known to affect EPC behaviour, with statins included as promoters of mobilisation of this cell type and SDF-





the use of animal models (Zhang et al., 2014; Mayorga et al., 2018) or the use of clinical studies to 
evaluate these interactions (Shimoni et al., 2016; Hennekens, Schuttenberg and Pfeffer, 2019; 
Wiśniewski et al., 2020), which highlights a need for alternative methods of evaluating statin-EPC 
interactions that are easy to access and allow control of variables.  
 
1.6 Development of a 3D Tissue Engineered Blood Vessel (TEBV) 
1.1.13 Tissue Engineering Concepts and Components 
Tissue engineering involves the development of tissue and organ substitutes by controlling biological, 
biophysical and/or biomechanical parameters in the laboratory. This allows for accurate and real-time 
studies on a variety of tissues and organs and related diseases without the need to use human 
volunteers or relying on animal models that do not provide the full picture in terms of understanding 
human structures and processes in health and disease states (Castells-sala et al., 2015). A key 
component of tissue engineering is using nature as a model for the development of extracellular matrix 
analogues (scaffolds), either from natural or synthetic origin as well as bioreactors and bio-devices to 
mimic natural physiological conditions of particular tissues (P. Zhao et al., 2018). These scaffolds embed 
cells in a three-dimensional environment that display signals critical for the determination of cellular 
fate, in terms of proliferation, differentiation and migration, among others. The type of cell to be used 
is also of great importance as this can determine the efficacy of the engineered tissue in terms of 
replicating native conditions and can also determine usability of the engineered tissue un clinical 
settings (Castells-sala et al., 2015; P. Zhao et al., 2018). Figure 1-3 shows the inter relation and 




Figure 1-6: Combinations of cell source, scaffold material and signals for generating engineered tissues (Nemeno-Guanzon 
et al., 2012). Tissue engineering triad of cells or source, signals (provided chemically by growth factors/cytokines or physically 
by a bioreactor), and the scaffold which acts as a template for tissue formation allowing the cells to migrate, adhere, and 
produce tissue. These components make up the Triple S (Source, Scaffold, and Signal) of tissue engineering. Any combination 
of these triad components has been considered in various studies in cell therapy which accounts for SS (Scaffold/Signal, 
Scaffold/Source, and Signal/Source). Finally, these three components (Source, Scaffold, and Signal or SSS) have also been 
considered altogether in some research projects. 
 
Ideally, engineered tissues would be three dimensional (3D) representations of physiological and 
pathophysiological systems that would show the interactions between cell-cell and cell-ECM and can 
determine whether a given cell undergoes proliferation, differentiation, apoptosis or invasion. 
However, studies on cellular biology have commonly been performed on two dimensional (2D) 
cultures, where cells are grown under non-physiological conditions. Specifically, they are unnaturally 
polarized having one side attached to a rigid and flat substrate and the other one exposed to culture 
media, which reduces cell-cell and cell-ECM interactions (Castells-sala et al., 2015). The generation of 




detailed understanding of the functioning of the studied system.  
1.1.13.1 Cell Source 
This is a crucial step in the tissue engineering process and becomes especially vital when intended for 
clinical applications. The cells selected should fulfil a specific requirement, namely the cells should be 
able to integrate successfully into the specific tissue and secrete various growth factors and cytokines 
that activate the endogenous tissue regeneration program. The first approach in cell-based techniques 
is the use of native progenitor cells (Castells-sala et al., 2015). For the evaluation of cardiovascular 
disease, the cells needed to replicate vascular tissue will be primary Human Cardiac Artery Smooth 
Muscle Cells (HCASMCs) for the medial layer and Human Umbilical Vein Endothelial Cells (HUVECs) for 
the intimal layer. These cells have been used successfully by Musa et al., (2016) to establish a protocol 
to determine the pro and anti-aggregatory properties of the intimal layer of blood vessels using real-
time measurements of cytosolic Ca2+ signalling to assess platelet activation (Musa, Harper and Yang, 
2016). Other works that are aimed at generating functional TEBVs focus on usability for engraftment. 
An example of this is the work done by L'Heureux et. al., (2006) who used fibroblasts extracted from 
skin biopsies from patients with advanced cardiovascular disease. While not using cells natively found 
in a blood vessel, they were able to demonstrate that the TEBV created was anti-thrombogenic and 
mechanically stable for 8 months in vivo. Histological analysis showed complete tissue integration and 
formation of vasa vasorum (L’Heureux et al., 2006). More recent approaches for vascular tissue 
engineering utilise embryonic stem cells which can be differentiated into endothelial and smooth 
muscle cells (Hielscher et al., 2018), as well as induced pluripotent stem cells (iPSCs) which are somatic 
cells reprogrammed into a stem cells (Hielscher et al., 2018; Song et al., 2018). For example, Nakagami 
et al., (2006), utilised murine embryonic stem cell–derived embryoid bodies on matrigel and found 
that differentiated embryonic stem cells (ESCs) seeded on matrigel additionally secreted the growth 
factors VEGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), transforming 
growth factor (TGF-β) and angiopoietin (Ang-1) (Nakagami et al., 2006; Babczyk et al., 2014). These 




Based on the cell type, the engineered product can be used to determine ideal conditions for 
generating a specific tissue or can be used directly in vivo to replace damaged tissue or can be used to 
evaluate the various mechanisms that are involved in various disease states.  
1.1.13.2 Scaffold Materials 
The main role of scaffolds is to provide an appropriate backbone on which cells can be successfully 
cultured and eventually develop into the desired tissue types. The scaffolds utilised for tissue 
engineering need to mimic the cellular micro-environment which is mainly generated by the 
extracellular matrix. Scaffolds, therefore, should incorporate the appropriate biophysical, 
biomechanical and biochemical cues that guide cell proliferation, differentiation, maintenance and 
function (P. Zhao et al., 2018). An ideal biomaterial to be used as a scaffold designed for clinical 
applications should fulfil a set of requirements. First of all, biocompatibility and biodegradability are 
required. The material needs to allow scaffold replacement by proteins synthesized and secreted by 
native or implanted cells. Additionally, the material must be clinically compliant to minimize 
inflammatory and immunological response (Castells-sala et al., 2015). Scaffolds can either be natural 
or synthetic. The biggest advantage of natural scaffolds is that they are readily accessible and provide 
a wide range of cues that participate in the process of morphogenesis and function acquisition of 
different cell types. However, its composition strongly depends on the specific animal origin and the 
isolation and purification procedures, compromising assay reproducibility. On the other hand, 
synthetic scaffolds can be custom tailored to mimic specific ECM properties, providing controllable 
cellular environments (Castells-sala et al., 2015).  
Some examples of scaffold used in tissue engineering include Bio-ceramic scaffolds, mainly 
hydroxyapatite (HA) which have been used to re-create bone tissue. This material shares many of the 
mineral components of native bone and its biocompatibility and bioactivity successfully promotes new 
bone formation in vivo (Castells-sala et al., 2015). For cartilage repair, a number of natural scaffolds 
have been utilised i.e., collagen, fibrin, hyaluronan, agarose, alginate or gelatin. In addition to natural 




reproducibility. For instance, polyurethane, Poly- (Ethylene Glycol) (PEG), elastin-based polymers and 
self-assembling peptides, such as KLD-12 and RAD16-I are being widely used (Castells-sala et al., 2015). 
For cardiovascular repair, the preferred natural materials that can be used as scaffolds include 
gelatines, collagens, laminin, silk, vitronectin and fibrin. Another is chitosan which has been widely 
used as soft and injectable material and it has been proved that its application in ischemic myocardium 
could improve myocardial infarction microenvironment (Castells-sala et al., 2015; Lee and Kim, 2018).  
Acellular tissue matrices have also been used for the regeneration of skin and genitourinary tissues, 
including urethra and bladder, with no evidence of immunogenic rejection (Sobti et al., 2018). They 
are fabricated by removing cellular components from tissues by mechanical and chemical manipulation 
to produce collagen-rich matrices which supports the cell growth. These acellular matrices are 
considered an ideal scaffolding system due to their structural and mechanical similarity to native 
tissues (Babita Mahanta, 2014; Li and Cui, 2014; Song et al., 2018).  
1.1.13.3 Static and Dynamic Culture Conditions 
Traditionally, cell cultures used for tissue engineering have been grown on a 2D surface under static 
conditions where the cells are incubated with supplemented culture media and nutrients are 
transferred through simple diffusion which is sufficient to maintain cell viability. The obvious limitation 
with this is that tissues are not two-dimensional structures and involve the interplay of a variety of 
factors. For a tissue engineered model to be effective, it must bear as close a resemblance as possible 
to the native tissue in question. This aim has been greatly aided by the development and use of 
bioreactors. A bioreactor is a device that reproduces the physiological environment, including 
biochemical and mechanical functions, that are specific to the tissue that is to be regenerated. 
Bioreactors can also be used to apply mechanical strength during maturation of the tissue and for 
studying and understanding the mechanical factors influencing tissue regeneration (Polak, 2010). They 
have been successfully used for supplying nutrients, oxygen, removing catabolites, monitoring pH and 
applying mechanical stresses to stimulate the formation of extracellular matrix (Polak, 2010; Selden 




and in the context of vascular grafts, axial stretching or torsion loads are of importance in generating 
tissues that are able to withstand physiological stresses (Selden and Fuller, 2018; Stefani et al., 2018). 
Examples of vascular tissue engineering approaches incorporating dynamic flow and shear stress have 
been increasing over the years. An example of this is the creation of porous tubular scaffolds by Tresoldi 
et. al., where they used a gel comprised of alginate and gelatin, functionalised with fibronectin, 
delivered onto a porous scaffold to create a tubular structure in a modified bioreactor that was able to 
provide longitudinal rotation and ensure full coverage of then porous scaffold with the functionalised 
gel (Tresoldi et al., 2019), with the aim of optimising endothelial seeding into a tubular structure 
capable of withstanding physiological shear.  
1.1.14 Comparison of Animal Models vs. Tissue Engineered Models 
Animal models have proven useful over the course of decades of scientific research. A number of 
different animal models have been developed to support preclinical and clinical research (Oppi, 
Lüscher and Stein, 2019). However, many of the conventional animal models are not suitable models 
for studying human disease as the disease pathologies are likely to be different as will the specific 
cellular responses. The limitations are more pronounced when it comes predicting the effectiveness of 
treatment strategies in human beings (Rahbari et al., 2017). With the increasing importance of 
evidence-based interventions in clinical practise, reliable and accurately representative models of 
human tissues and systems need to take precedence over the traditional animal model. An example of 
this is observations on the effect of ketamine, a common anaesthetic used in animal studies. It was 
found that ketamine inhibited platelet aggregation through suppression of IP3 formation and inhibiting 
the activity of thromboxane synthase (Nakagawa et al., 2002; Lisek, Zylinska and Boczek, 2020). 
Ketamine has also been found to interfere with endothelial nitric oxide production and smooth muscle 
Ca2+ signalling (Akata, Izumi and Nakashima, 2001; Kurebayashi and Ogawa, 2001). Using in 
vitro culture models eliminates some but not all of the problems associated with clinical research using 
human subjects and animal models of disease. In many cases, culture models help to overcome 




and responses to treatments (Mobasheri and Lewis, 2013).  
1.1.15 Applications and Relevance of TEBV  
The development of a tissue engineered blood vessel (TEBV) that incorporates a medial and intimal 
layer will provide an ideal and unique opportunity to study a variety of factors that are involved in 
maintaining vascular homeostasis as well factors that contribute to pathogenesis and vascular repair 
processes. The use of cells and components that are part of the native tissue would provide a detailed 
representation of the cell-cell interactions, changes in surface receptor expression in various 
physiological states and allows for the controlled introduction of other factors such as drugs, platelets 
and other cell types. With the incorporation of a perfusion system, flow conditions and their effects 
can also be assessed under various physiological states.  
1.7 Development of a Perfusion System 
As mentioned previously, shear stress is a necessary element in the maintenance of vascular 
homeostasis and variations from normal physiological values contributes to pathological processes, in 
this case vascular remodelling due to cardiovascular disease.  
1.1.16 Shear Stress and its Effects 
As mentioned in earlier, under normal conditions, shear stresses maintain their direction and their 
magnitude within a range of values that impedes atherogenesis, thrombosis, adhesion of leukocytes, 
smooth muscle proliferation and endothelial apoptosis (Papaioannou and Stefanadis, 2005). The 
haemodynamic conditions inside blood vessels lead to the development of superficial stresses near 
the vessel walls, which can be divided into two categories: (1) circumferential stress due to pulse 
pressure variation inside the vessel; (2) shear stress which is applied on the vessel walls by the flow of 
blood. Shear-induced mechanotransduction, which refers to the conversion of mechanical stresses to 
biochemical responses, is particularly important in arteries, in which blood flow regulates vascular tone 
and structure. This regulation occurs via mechanically stimulated release of potent, shear-responsive, 
endothelial-derived factors such as nitro-vasodilators, prostaglandins, lipoxygenases, hyperpolarizing 




Normal arterial shear stress is usually greater than 15 dyne/cm2 and induces endothelial quiescence 
and an atheroprotective gene expression profile whereas shear stresses lower than 4 dyne/cm2 
stimulates an atherogenic phenotype (Malek, Alper and Izumo, 1999).  
1.1.17 Benefits and Limitations of Perfusion System 
The biggest advantage of using a perfusion system is that it allows for the generation of the necessary 
biomechanical forces that are reflective of physiological and pathological conditions. As has been 
already mentioned, shear stress is vital in maintaining vascular tone and conditioning cells to have the 
expected native morphology. It will be possible to visualise in real time the interactions between the 
TEBV and the cells and substances that will be perfused over it. The main limitation with this system is 
maintenance of sterile conditions and conserving cell culture conditions as they would be in an 
incubator.  
1.1.18 Types of Perfusion 
Perfusion, overall, refers to the delivery of blood or other fluid to tissues and organs. In the field of 
tissue engineering, the ability to maintain suitable oxygen tensions and nutrient diffusion throughout 
the scaffold is critical for cell viability and function. One of the ways that this has been addressed is 
through the use of channelled scaffolds (Lovett et al., 2009). Channelled scaffolds have been formed 
by incorporating phosphate-based glass fibres into collagen scaffolds or by using a laser cutting system 
to bore holes into a scaffold. Another technique that can be used to enhance vascularisation is directing 
scaffold vascularization through micro-patterning or molecular gradients. This offers scaffold cues that 
can effectively dictate the migration and alignment of cells within the construct (Lovett et al., 2009). 
Work with scaffold patterning has included the formation of grooved, porous poly-caprolactone 
scaffolds. These scaffolds were produced by mixing the poly-caprolactone (PCL) with Poly D, L-lactic-
co-glycolic acid (PLGA) micro/nanoparticles and casting the polymer onto a grooved surface before 
leaching out the micro/Nano spheres. This process produces surfaces that are conducive for vascular 
cell alignment and also increase medium diffusion. By stacking these layers, it may be possible to build 




directed by forming gradients within the scaffold (Lovett et al., 2009).  
Aside from modifications to the scaffold to facilitate diffusion of oxygen, carbon dioxide and nutrients, 
bioreactor systems are often used to perfuse culture medium through a porous scaffold to try to 
maintain cell viability in the middle and homogeneity throughout the construct. One way this can be 
achieved is through the use of rotating bioreactors. The horizontally rotating bioreactors, or slow-
turning lateral vessels, were designed as a rotating cylinder of culture medium, with a gas-permeable 
membrane for oxygen and carbon dioxide exchange, and fittings for sampling or medium exchange. 
The speed of the rotation could be controlled to match the settling velocity of the tissue constructs, 
keeping them suspended within the vessel. This approach has been used for engineering of bone, 
cartilage, and cardiac tissue (Lovett et al., 2009). 
Microfabrication techniques have gained popularity as they offer fine control over the formation of a 
microvascular network. Through the fabrication of a negative mould, a complex capillary pattern may 
be formed and serve as a template for moulding materials. These capillary networks may be perfused 
and incorporate an endothelial layer, providing a mimic of natural vasculature as well as oxygen and 
nutrient delivery and waste removal. Standard techniques use plasma etching or lithographic 
techniques to produce desired features with micron-scale precision, with replica moulds of 
polydimethylsiloxane (PDMS) cast from the negative feature moulds. These moulds may then be 
bonded with one another before seeding with endothelial cells to form cylindrical capillary channels. 
Direct-write assembly has been used to form 3D microfluidic devices for vascular tissue engineering 
(Lovett et al., 2009).  
Microfluidic channels are especially attractive since they can be easily multiplexed with integrated fluid 
handling operations for efficient and high throughput cellular analysis, imaged for in situ monitoring of 
cellular events, and can recapitulate a physiological cellular microenvironment with controllable distribution 
of biochemical molecules and shear stresses at the cellular resolution (Toh et al., 2007). The main limitation 
with these systems is they are commonly used in 2D settings, with the cells being perfused being cultured 




model have proven to be more physiologically relevant and showed improvements in several 
studies of biological mechanisms like: cell number monitoring, viability, morphology, proliferation, 
differentiation, response to stimuli, migration and invasion of tumour cells into surrounding tissues, 
angiogenesis stimulation and immune system evasion, drug metabolism, gene expression and 
protein synthesis, general cell function and in vivo relevance (Anton et al., 2015). 
In addition to perfusion, the exertion of shear stress and laminar flow, especially  in vascular tissue 
engineering, is an important aspect in generating the necessary stimuli for cell function. Anisi et. 
al., (2014) utilised computational fluid dynamics to optimise conditions in their bioreactor/flow 
chamber. They utilised endothelial cells cultured on a collagen matrix and exposed to unidirectional 
pulsatile flow, generated by a peristaltic pump. They managed to attain endothelial elongation and 
alignment along the direction of flow with minimal detachment of cells (Anisi et al., 2014). Parallel 
plate flow chambers, microfluidic chambers and cone-plate chambers are other common means of 
generating shear stress (Wang et al., 2016). Under steady, pulsatile laminar flow wall shear stress, 
endothelial cells elongate and align parallel to the flow direction through cytoskeletal remodelling, 
while under oscillatory flow, these cells are randomly oriented, adopt a polygonal shape and behave 
in a manner that is typical of endothelial dysfunction (Wang et al., 2016; Kouzbari et al., 2019). This 
demonstrates the importance of flow type and directionality in improving endothelial function and 
generating stimuli that are reflective of physiological as well as pathological conditions.   
1.8 Project Rationale 
There is an increasing need for the development and use of more biomimetic models, that can 
replicate structural and environmental cues, to study disease pathology and associated/potential 
therapies, and which can alleviate the reliance on animal models. As pertains to cardiovascular 
disease, lipid irregularities in atherosclerosis have long been known to be a driving force towards 
disease progression. Statins have been the primary prescription to lower levels of cholesterol, thus 
halting or reversing disease progression. Their association with improving patient health following 




in vascular healing, have led to investigations aimed at defining a new role for statins in managing 
atherosclerosis and related cardiovascular diseases. Tissue engineering provides a unique 
opportunity to create vascular models, which would alleviate the need for animal models, provide 
physiological relevance - as tissues would be made using human cells and be subjected to various 
stimuli in a controlled manner- and can be used to more accurately study human biological 
processes.   
1.9 Project Aims  
The primary aim of this thesis was to evaluate the pleiotropic effects of statins using 3D blood vessel 
models, with a special focus on EPC homing under shear stress. As such, the following objectives were 
developed and implemented per experimental chapter: 
• Chapter 3 - To isolate and characterize endothelial progenitor cells (EPCs) and evaluate their 
responses to atorvastatin individually and in co-culture with endothelial cells (HUVECs). To do 
this, EPCs were obtained from commercial sources and healthy volunteers. EPC were 
characterized based on morphological factors such as colony formation and tube formation, 
as well expression of key surface markers.  
• Chapter 4 - following optimization of isolation and characterization protocols for EPCs, their 
migratory responses to varying concentrations of atorvastatin were evaluated using a scratch 
wound model. Responses were compared to MSCs from different species. 
• Chapter 5 - To evaluate EPC responses to tissue engineered constructs;  
o Create tissue engineered intimal and medial layers and a composite blood vessel 
model enabling the study of individual cell types, their contribution and sensitivity to 
a lesion and atorvastatin. 
o Adapt a commercially available parallel plate flow chamber to accommodate 3D 
tissues; compare shear stress with that of oscillating rocker 
o Evaluate effect of atorvastatin incubation time on homing 





























2 Chapter 2:    






APPLICATION MATERIALS SUPPLIER 
Cell culture: Items used for 
Cell maintenance and 
differentiation 
DMEM Scientific Lab Supplies 
Medium 200 GIBCO, Life Technologies 
Medium 231 GIBCO, Life Technologies 
Low serum growth supplement (LSGS) GIBCO, Life Technologies 
Smooth muscle growth supplement (SMGS) GIBCO, Life Technologies 
Penicillin/Streptomycin (AA) Scientific Lab Supplies 
L-glutamine (LG) Scientific Lab Supplies 
Trypsin Scientific Lab Supplies 
Foetal bovine serum (FBS) Scientific Lab Supplies 
Human cardiac artery smooth muscle cells 
(HCASMC) 
GIBCO, Life Technologies 
Human umbilical vein endothelial cells 
(HUVEC) 
GIBCO, Life Technologies 
Rat bone marrow stem cells (rMSC) Freshly isolated 
Human bone marrow stem cells (hMSC) Isolated from bone marrow 
mononuclear cells, Lonza 
Endothelial progenitor cells Biochain (Amsbio) and 
isolated from Healthy 
volunteers 
RAW 264.7 (RAW264) ATCC 
Cell scrapers Scientific Lab Supplies 
Atorvastatin Calcium Trihydrate (5g)  Active Pharma Supplies Ltd. 




assay and cytotoxicity assay Technologies Inc 
LDL (100mg)  2bscientific 
IFN-γ  Peprotech 
Lipopolysaccharide (LPS) Sigma (Merck) 
Ascorbic acid Sigma (Merck) 
Beta glycerophosphide  Sigma (Merck) 
Dexamethasone  Sigma (Merck) 
Non-essential amino acids (NEAA)  Sigma (Merck) 
Insulin-transferrin-selenium (ITS)  GIBCO, Life Technologies 
L-proline   Sigma (Merck) 
Sodium pyruvate  Sigma (Merck) 
TGF-β3  GIBCO, Life Technologies 
3-Isobutyl-1-methylxanthine (IBMX)  Sigma (Merck) 
Insulin   GIBCO, Life Technologies 
Indomethacin  Sigma (Merck) 
EPC isolation 
Ficoll-paque Sigma (Merck) 
Luer lock syringes (60ml)  Scientific Lab Supplies 
Acid citrate dextrose (ACD) 
(85 mM sodium citrate, 78 mM citric acid 
and 111 mM d-glucose) 
All from Sigma (Merck) 
Imaging 
Olympus Confocal microscope (Fluoview 
FV1200) 
Olympus 
Leica inverted fluorescence microscope 
(MSV269) 
Leica 




EVOS brightfield microscope EVOS 
Perfusion 
Watson-Marlow 505 series peristaltic pump Watson-Marlow 
PDMS Scientific lab supplies 
Parallel plate flow chamber (ProFlow 
Chamber) 
Warner Instruments, USA 
Fluorescein isothiocyanate isomer I Sigma 
Silicon grease RS 
3D Models 
Rat tail collagen I Scientific Lab Supplies 
(Corning) 
Whatman filter paper Scientific Lab Supplies 
Scalpel blades Scientific Lab Supplies 
Polytetrafluoroethylene (PTFE) Scientific Lab Supplies 
Fibronectin from bovine plasma  Sigma (Merck) 
Cell staining  
5-(and-6) carboxyfluorescein diacetate, 
succinimidyl ester, mixed isomers (CFSE)  
GIBCO, Life Technologies 
Mouse anti-human PECAM-1 (CD31),  Santa Cruz Biotechnology 
goat anti-mouse IgG FITC  Santa Cruz Biotechnology 
Alexafluor-568 Goat anti-mouse IgG  Gibco Life Technologies. 
Hoechst-33258 ThermoFisher Scientific 
E-selectin Alexa fluor 488-conjugated 
primary antibody 
R&D Systems 
Nile Red Sigma (Merck) 
Oil Red-O Sigma (Merck) 
Anti-mouse CD36 antibody abcam 




Flk-1-NL463 conjugated antibody  Santa Cruz 
Mouse anti-human CD45 antibody Santa Cruz 
Mouse anti-human CD34 antibody Santa Cruz 
Rabbit anti-human CXCR4 antibody Abcam 
Donkey anti-rabbit IgG  R&D Systems 
Poly-L, D-lactic acid (96% l/4% d) (PLA)  Purac BV (Gorinchem, the 
Netherlands). 
Electrospinning 
Chloroform  Sigma (Merck) 
N-N-dimethyl formamide (DMF) Sigma (Merck) 
Acetate sheets  Ryman’s 
3M spray on adhesive Amazon/Ryman’s 
ABTS  Sigma 
Cytokine profiling 
SDF-1 mini ABTS ELISA kit  Peprotech 
Tween-20 Sigma (Merck) 
Copper sulphate (CuSO4.5H2o)  Scientific Lab Supplies 
Miscellaneous 
 
EDTA Sigma (Merck) 
Isopropanol (isopropyl alcohol/propan-2-ol) Sigma (Merck) 
Bovine serum albumin (BSA) Sigma (Merck) 
Phosphate buffered saline (PBS) Scientific Lab Supplies 
UV cabinet  BioRad 
Slide-a-lyzer dialysis cassettes ThermoFisher Scientific 
dialysis cassette floats ThermoFisher Scientific 
99.9% Ethanol Scientific Lab Supplies 
Plate reader Biotec 




Phosphoric acid Sigma (Merck) 
Sulphonamide Sigma (Merck) 
Naphthalene-diamine-hydrochloride Sigma (Merck) 
Sodium nitrile Sigma (Merck) 
Iron III chloride (FeCl3) Sigma (Merck) 
See-saw rocker Cole-Parmer 







2.1.1 Cell culture 
2.1.1.1 HCASMC 
Human cardiac artery smooth muscle cells (HCASMCs) were used in the assembly of the tissue 
engineered blood vessel (TEBV). These cells were cultured in medium 231 and supplemented with 
smooth muscle growth supplement (SMGS) as per the supplier specifications. The cells used in the 
assembly of the TEBV were between P3 and P5. 
2.1.1.2 HUVEC 
Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in medium 200 supplemented with 
low serum growth supplement (LSGS) as per the supplier recommendations. The cells used were 
between P2 and P5. 
2.1.1.3 RAW 264 
RAW 264 cells were cultured in DMEM supplemented with 10%FBS, 1%LG and 1% AA. Cells were sued 
between P3 and P14.  
2.1.1.4 rMSC 
Rat mesenchymal stem cells (rMSC) were derived from rat bone marrow by Hamza A. Owida (Owida 
et al., 2017), and were cultured using Alpha MEM (without L-glutamine) and supplemented with FBS, 
L-glutamine and AA. The supplements were mixed as follows based on total media volume; 10% FBS, 
1% L-glutamine and 1% AA. Cells used were between passage 3 and 6 (P3 and P6).  
2.1.1.5 hMSC 
Cell were obtained from Anthony Deegan and were previously differentiated into monocytes (Deegan, 
2013). Cells were cultured in DMEM (4.5g/L glucose) supplemented with 10% FBS, 1% AA and 1% LG. 
Cells used were between passage 3 and 6 (P3 and P6). 
2.1.1.5.1 Tri-lineage differentiation 




and cultured for 21 days. Cells were differentiated along osteogenic, chondrogenic and Adipogenic 
lineages (Chong et al., 2012; Heidari et al., 2013). Osteogenic media was comprised of ascorbic acid 
(5μM), beta glycerophosphide (10mM), dexamethasone (0.1μM), FBS (10%), NEAA (1%) and L-
glutamine (1%); Chondrogenic media was comprised of insulin-transferrin-selenium (ITS) (1%), 
dexamethasone (0.1μM), ascorbic acid (50μM), L-proline (40μg/ml), sodium pyruvate (1%), TGF-β3 
(10ng/ml), FBS (1%), NEAA (1%) and L-glutamine (1%). Adipogenic media was comprised of 
dexamethasone (0.5μM), 3-Isobutyl-1-methylxanthine (IBMX) (0.5mM), Insulin (10μg/ml), 
indomethacin (100μM), FBS (10%), NEAA (1%) and L-glutamine (1%). Control samples were fed with 
the standard media composition described previously. All media was changed every 2 days. After 21 
days, samples were fixed with 4% PFA for 20 minutes then stored in PBS. To assess differentiation, 
samples were stained with alizarin red, alcian blue and oil red-O for osteogenic, chondrogenic and 
Adipogenic differentiation respectively.  
2.1.1.5.1.1 Histological staining  
2.1.1.5.1.1.1 Alizarin red 
To identify mineral/calcium deposits, a 2% alizarin red solution, prepared in distilled water, was added 
to fixed cells for 15 minutes at room temperature. The stain was then removed and the cells washed 
twice with dH2O. Following this, cells were imaged with EVOS microscope. 
2.1.1.5.1.1.2 Alcian Blue  
To identify glycosaminoglycans secreted by chondrocytes, a 0.1% solution of alcian blue was prepared 
by filtering 1% (v/v) alcian blue mixed with 0.1M HCl. Cells were stained for 15 minutes, followed by 
two dH2O washes. Cells were imaged using EVOS microscope.  
2.1.1.5.1.1.3 Oil Red-O 
To identify cellular lipid content, a 0.5% solution of oil red-O in isopropanol was diluted 3:2 with 
deionised dH2O and added to fixed cells for 15 minutes. The stain was removed and cells washed twice 





2.1.1.6 Commercially sourced EPCs 
Purchased cell were revived and cultured according to supplier protocol. Frozen cells were first thawed 
in a 37°C water bath, followed by transfer inti a 15 ml falcon tube. The vial containing the cells was 
rinsed with 1 ml of fresh growth medium, which was also added to the falcon tube. Cells were 
centrifuged for 6 minutes at 400g. Supernatant was removed and the resultant cell pellet was 
transferred to a T-25 flask topped up with 8 ml of EPC medium.  
2.1.1.7 EPC isolation from whole blood and culture 
EPCs were isolated by collecting 60mL of whole blood from healthy volunteers. To prevent coagulation, 
the blood was split into 2 falcon tubes with 5mL of ACD (85 mM sodium citrate, 78 mM citric acid and 
111 mM d-glucose) in each. The blood-anticoagulant mix is then split into 15ml falcon tubes and 
centrifuged at 2800 rpm for 8 minutes. After Centrifugation, the sequence of layers occurs as follows 
(seen from top to bottom) (figure 2-1): Plasma, enriched cell fraction (interphase consisting of 
lymphocytes / Peripheral bone marrow cells (PBMCs)), Erythrocytes and granulocytes. The plasma 
fraction is carefully discarded, to avoid agitating the layers, leaving approximately 0.5-1mL above the 
interface.  
 
The enriched cell fraction is pooled into one tube and diluted 1:1 with PBS. To further separate the cell 
i.e., eliminate residual plasma and RBCs, the pooled fraction is carefully layered over 8mL of Ficoll-
paque, ensuring no mixing of the layers, and centrifuged again for 20 minutes at 400g. After 
Figure 2-1: Blood separation. Here we see the expected separation of blood components (A). The plasma fraction is 





centrifugation, any residual red blood cells are below the separation medium and the enriched cell 
fraction should be immediately above it with diluted plasma and platelets above this. Discard the 
plasma layer and leave about 0.5mL above the enriched cell fraction. The cell rich fraction was again 
diluted with PBS (topped up to 10mL), then centrifuged again at 400g for 10 minutes. After 
centrifugation, supernatant is discarded, and the resultant pellet is resuspended in 2mL of complete 
EPC media, comprised of Medium 200, 10% FBS and 1% AA. The cell suspension is then split into 2 
wells of a 12 well plate that has been coated with fibronectin (at a concentration 0f 2.5 μg/cm2). Some 
cells were cultured on collagen (2mg/ml) coated plates as a comparative substrate. After seeding, the 
well-plate is transferred to an incubator (37°C; 5% CO2). The cells are now at culture day zero (D0). On 
the following day (D1), the contents of the wells are agitated and transferred to new wells (figure 2-2).  
 
This agitation and transfer of non-adherent cells to new wells was carried out for another 3 days to 
ensure maximum collection of non-adhered cells. Media is changed daily for the first 7 days then every 
2-3 days for the duration of culture.   
2.1.1.8 RAW 264 
Isolated from mice, RAW264.7 cells were cultured in DMEM supplemented with 10%FBS, 1%LG and 
1% AA. Cells were used between P3 and P14.  
2.1.1.9 Cell fixation 
To preserve cells/tissue samples, they were fixed with 4% PFA; 20 minutes for monolayer culture and 
1 hour for TE constructs. This was followed by removal of the fixative and addition of PBS for storage 
at 4°C. 
 
D0 D1 D2 D3 
Figure 2-2: Sequence of cell transfer. To ensure trapping as many adherent cells as possible, after initial seeding in the first 
well, the next day, media is removed and sedimented cells are mixed with fresh media, which is agitated to gather all non-
adhered cells, and transferred to another well. This was repeated daily for 3 days at which point the majority of adherent 




2.1.1.10 EPC characterisation 
2.1.1.10.1 Morphology 
Isolated EPCs were cultured in Medium 200 supplemented with 1%AA and 10% FBS. Cells were 
cultured for up to 20 days as they are not proliferative and attain senescence after this time frame. 
Cells used for experimentation were aged between 8 and 20 days. Images were taken every 3 days for 
duration of culture and sued to evaluate morphology changes, colony and tube formation.  
2.1.1.10.2 Key biomarker expression 
Immunostaining was carried out to identify specific markers of EPC identification. Antibodies used 
were CD31, CD34, CD45, Flk-1 and CXCR4. Samples were first incubated with 5% BSA for 1 hour, 
followed by addition of the primary antibodies, used at a concentration of 1:200. Samples were 
incubated for 2 hours at 37°C, 5% CO2. Following this, samples were washed twice with 0.05% Tween 
20, then twice with PBS before the addition of secondary antibody at 1:400 dilution. Secondary 
antibody was incubated for 1 hour at 37°C, 5% CO2. This was followed by 2 washes with 0.05% Tween 
20, and another 2 washes with PBS. DAPI was used at a concentration of 10 ng/ml. Negative controls 
were done by adding the secondary antibody to PBS only wells. Images were taken using the confocal 
microscope.  
2.1.1.11 Statin dose 
The statin used was Atorvastatin Calcium Trihydrate (Active Pharma Supplies). The drug was weighed 
and dissolved in methanol to make a 20mg/ml stock solution. A fresh stock solution was made per day 
of experimentation. The working concentrations used across all experiments were 0.6μg/ml, 1.2μg/ml, 
3μg/ml, 6μg/ml, 10 µg/ml, 30 µg/ml, 60 µg/ml, 80 µg/ml, 100 µg/ml, 120 µg/ml, 140 µg/ml, 160 
µg/ml, 180 µg/ml, 200 µg/ml, 400 µg/ml and 800 µg/ml. Dilutions were made by adding stock solution 
to supplemented culture media.  
2.1.1.12 Cell viability assays 
To evaluate if there was any effect on cell proliferation with the addition of atorvastatin, CCK-8 was 




well plate and incubated overnight. This was followed by taking a baseline reading by adding 10 μl of 
CCK-8 to 100 μl of fresh media and incubating the samples for 3 hours at 37°C/5% CO2. The media with 
the reagent was collected and read using a plate reader (Biotec). After determining the baseline, 
atorvastatin was used at 0.6, 1.2, 3, 6, 30, 60, 80, 100, 120 and 140 μg/ml. The cells were then 
incubated with the drug for 24 hours. The dosed media was then removed and replaced with fresh 
media containing CCK-8 diluted 1:10 with media. Samples were then incubated for 3 hours at 37°C/5% 
CO2, followed by reading with the plate reader at 450nm. Absorbance values were used to plot 
comparative graphs to gauge the effect of atorvastatin on cell metabolism.  
2.1.1.13 Electrospinning 
Aligned PLA nanofibers were prepared through previously established protocol (Yang, Wimpenny and 
Ahearne, 2011), with some modification, to generate the scaffold. 2% PLA solution was prepared by 
dissolving PLA in a mixture of chloroform and DMF (in a 7:3 ratio) to generate nanofibers through 
electrospinning. 250µl (0.250ml) of the solution was delivered at a rate of 0.025 ml/min from a syringe 
pump through an 18-gauge (18G) needle which was attached to the positive electrode. The generated 
fibres were deposited on the collector which was connected to the negative electrode. The distance 
between the needle tip and the collector was set at 15cm. The electrodes were supplied with a power 
supply charged at ±6 kV (Spellman HV, Pulborough, 26 United Kingdom). Once the desired volume of 
polymer was deposited on the collector, the fibres were gathered using a 16cm2 acetate frame coated 
with adhesive. The frame facilitates easier collection of the aligned fibres, maintaining fibre orientation 
and providing stability. Prior to use in cell culture, the fibres were sterilised under UV light for 90 
seconds three times. The fibres are then incubated with fibronectin, at a concentration of 10mg/ml, 
for one hour before cell seeding. 
2.1.2 Scratch wound migration assay 
To evaluate effect of atorvastatin on wound closure, a scratch wound was created with a 1-10µl pipette 
tip scraped over the centre of the confluent HUVEC layer from the top to the bottom of the well. After 




media. Atorvastatin doses used were 0µg/ml, 30µg/ml, 60 µg/ml, 80 µg/ml, 100 µg/ml, 120 µg/ml and 
140 µg/ml. After creation of the scratch, the rMSCs, hMSCs and EPCs, labelled with CFSE, were added 
at a density of 5x103 cells per well. Samples were incubated at 37°C, 5% CO2. Images were taken at 1 
hour and 24 hours for comparison. Scratches were placed on the bottom of the culture wells to ensure 
imaging of the same location at both time points. Dyes used for cell identification/tracking are detailed 
below.  
2.1.2.1 Live-cell tracking 
2.1.2.1.1 Hoechst-33258 
This nuclear stain was used at a concentration of 2 µl in 10 ml of PBS, diluted from the 10 mg/ml stock 
solution. The diluted solution was then added to the HUVECs seeded in a well plate and incubated at 
37°C for 15 minutes. After this, the cells were washed with PBS and topped up with fresh supplemented 
media. For HUVECs in suspension, following the dye incubation period, cells were centrifuged and 
supernatant replaced with fresh media and the pellet resuspended.  
2.1.2.1.2 CFSE 
This membrane stain was used at a concentration of 5μM. The cells to be stained (rMSCs, hMSCs and 
EPCs) were passaged and counted and re-suspended in 1m of fresh supplemented media. The stain 
was then added and the cells incubated for 15 minutes at 37°C. The cell suspension was centrifuged 





2.1.3 3D vascular models 
2.1.3.1 Collagen gel formation 
2.1.3.1.1  Low concentration 
The collagen gel was prepared at a concentration of 3 mg/ml. The other reagents used to make the 
hydrogel were 10x DMEM, 1M sodium hydroxide (NaOH) and sterile filtered deionised water (dH2O). 
Depending on the desired final volume, the reagents are added one by one and to prevent premature 
gelation, the reagents were mixed in an ice bath with the collagen added last. Sample calculation is 
detailed below. Once the collagen is added, the solution is mixed by pipetting up and down several 
times until homogenous. Care is taken in the mixing to prevent formation of bubbles in the solution.  
(a) Collagen vol. = (Desired concentration ÷  stock concentration) x total volume.  
(b) DMEM vol. = Final volume ÷ 10 
(c) NaOH vol. = Volume of collagen x 0.023 
dH2O/cell suspension vol. = total volume – (a + b + c) 
2.1.3.1.2 Plastic compression 
To increase collagen concentration and stiffness, the collagen gels underwent plastic compression 
following a procedure modified from Brown et al., (2005). 1500μL of collagen solution, made as 
previously described, was poured into customised metal moulds placed in 9.6 cm² petri dishes under 
sterile conditions. A sterile cover slip (24 x 24mm) was placed at the bottom of the mould to create a 
sealed space and to prevent the gel from leaking into the petri dish. Two filter paper frames were 
placed within the mould to provide structural support for the gel. The frames were sized at 0.9 x 0.9cm. 
To solidify the gels, they were then placed in an incubator at 37°C, 5% CO2 for 2 hours. This process is 
detailed further in figure 2-3. These gels were made specifically for use in the atherosclerosis plaque 
model and RAW cells were seeded on top of the gel before solidification so that they were partially 







2.1.3.2 Electrospinning PLA nanofibers 
Aligned PLA nanofibers were used in the assembly of the TE constructs used here. Fibers were made 
by first dissolving Poly-L, D-lactic acid (96% L/4% D, inherent viscosity of 5.21 dL/g) (PLA) in chloroform 
for at least 8 hours, followed by addition of DMF for a further 8 hours of mixing to make a 2% PLA 
solution. Chloroform and DMF were mixed in a 7:3 ratio respectively. The operational parameters of 
nanofiber fabrication followed a previously established protocol (Yang, Wimpenny and Ahearne, 2011; 
Njoroge et al., 2021). Briefly, the 2% PLA solution was deposited on detachable metal collectors, 
consisting of two partially insulated steel blades (30 cm × 10 cm). The steel blades were connected to 
a permanent copper plate with a steel wire, and had a 5 cm gap between for fiber deposition. Fiber 
deposition involved connecting the permanent copper plate to a negative electrode, and a syringe 
3mm petri dish 
Metal mould 






50g metal weight 
Metal mould 







Figure 2-3: Collagen gel compression. Panel (a) shows the preparation of the moulds before collagen addition. (i) shows the 
solidified collagen in the moulds and (ii) the gel removed from the mould. To compress and extract the gels (b), the mould 
was turned upside down on a piece of nylon placed on layered sterilised tissue (iii). Once inverted, the glass cover slip is 
carefully removed to avoid breakage, after which the weight, designed to fit into the mould, is placed on the gel (iv). The 
weight is left on the gel for 5 minutes until the majority of the water content is removed. The filter paper frames are 




containing the 2% PLA solution was connected to a positive electrode. The PLA was extruded through 
an 18G needle and delivered at a rate of 0.025 mL/min. The electrodes were electrified with a power 
supply charged at ±6 kV (Spellman HV, Pulborough, 26 United Kingdom). Nanofibers were collected 
and attached onto pre-cut acetate frames. Before use in cell culture, aligned nanofibers were sterilized 
by UV irradiation thrice per side.  
 
2.1.3.3 TEML  
Representing the medial layer of a blood vessel, the tissue engineered medial layer (TEML) is made of 
HCASMCs embedded in a collagen type I hydrogel. The HCASMCs were seeded into the collagen gel at 
a density of 1 x 105 cells per hydrogel. 200µl of the cellular gel solution was pipetted into a hollow 
rectangle made of filter paper measuring 0.5cm x 2.4cm on the outside and 0.2cm x 2cm on the inside 
(figure 2-4). The dimensions of the filter paper were guided by the dimensions of the flow chamber 
and the gasket. The filter paper was placed on a piece of polytetrafluoroethylene (PTFE) to allow ease 
of transfer into a 6 well plate after gelation.  
 
The TEML was then placed in a humidified incubator set at 37°C and 5% CO2 for 30 minutes to permit 
it to set. After transfer to a 6 well plate, the TEML is cultured for at least 3-4 days in 3ml of smooth 
muscle supplemented media to allow the cells to elongate and proliferate. Media was changed every 





Figure 2-4: Filter paper frame. 200µl of collagen gel containing HCASMCs at a density of 1x105 cells was 
deposited into the hollow portion of the frame to create the medial layer of a blood vessel. After 10 days, 
the intimal layer is created on top of the medial layer of a blood vessel. After 10 days, the intimal layer is 






Representing the intimal layer, the tissue engineered intimal layer (TEIL) was fabricated by first making 
a collagen gel using the protocol and dimensions previously described in section 2.1.7.1. After the 
collagen gel has set, aligned PLA nanofibers coated in fibronectin were placed on the surface of the gel 
then the HUVECs are seeded on top to create a representation of the intimal layer. The HUVECs are 
seeded on the gel surface at a density of 4x104 cells per gel. The cells are allowed to attach onto the 
nanofibers for at least 40 minutes. This is followed by sealing the fibres and cells onto the construct 
using acellular collagen. The collagen is carefully pipetted onto the edges of the construct and allowed 
to set in an incubator set at 37°C and 5%CO2. The excess nanofibers are then cut off of the construct 
using a sterile blade. As with the TEML, the sample was then cultured in HUVEC media for at least 3-4 
days to allow attainment of normal cell morphology and surface area coverage. 
2.1.3.5 TEBV 
This model is a combination of the TEML and TEIL to make a tissue engineered blood vessel TEBV). 
Assembly was carried out as follows; after the HCASMCs have attained the desired spindle shaped 
morphology, HUVECs are seeded onto the fibronectin coated PLA nanofibers as described above. The 
fully assembled TEBV was then placed back into a new 6 well plate and topped up with both HCASMC 
and HUVEC supplemented media in a ratio of 7:3 respectively. The complete TEBV schematic is shown 




To ensure full coverage of the TE constructs, specifically the TEIL and TEBV, with endothelial cells, 
HUVECs were initially stained with Hoechst, seeded onto the TEML or acellular collagen gel, and 
imaged to confirm seeding was successful. Representative images can be seen in figure 2-6. 





Figure 2-6: Endothelial coverage post seeding on TE constructs. 
Hoechst-stained cells are visible as blue dots on the surface of 
the constructs represented here. This was done to verify success 
of endothelial seeding onto TEIL and TEBV.  
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Figure 2-5: Schematic of TEBV. This schema highlights the placement of cells and nanofibers in the assembly of the TEBV. 





2.1.3.6 3D Lesion Models 
2.1.3.6.1 FeCl3 
To mimic vascular injury, a FeCl3 lesion was created by dipping a 1mm2 (0.1cm2) square of filter paper 
in 10% FeCl3 and placing this onto the upper surface of the constructs for 1 minute. After this, the 
constructs were washed with PBS to eliminate excess FeCl3, then topped up with fresh media.    
2.1.3.6.2 Mechanical injury 
A 1mm2 piece of filter paper was placed on the surface of the tissue engineered (TE) constructs for 1 
minute then carefully peeled off the surface.   
2.1.4 Perfusion system 
2.1.4.1 Perfusion chamber 
To generate peristaltic flow and a range of shear stress values, a peristaltic pump (Watson-Marlow 505 
series, Fluid technology, UK) was used along with a commercially sourced parallel plate flow chamber 
(ProFlow Chamber, Warner Instruments, USA). The chamber was originally designed for 2D perfusion 
but was modified for our purposes. Details of the modifications are explained later in this section. The 
perfusate was contained in a 7ml reservoir connected to the pump and flow chamber using 
polyethylene (PE-90) tubing. The flow chamber inlet was connected to the reservoir and the outlet to 
the pump. The set-up of this system can be seen in figure 2-7.  
2.1.4.2 Perfusion gaskets 
To facilitate the perfusion of our 3D vascular models, specialised gaskets were created. The dimensions 
of the space within the gasket used were length 25mm (2.5cm), depth (thickness) 3mm (0.3cm), width 
5mm (0.5cm). The gasket was synthesised using PDMS. The PDMS was prepared by mixing Quantum 
Silicone (Qsil) polymer and cross-linker in a 10:1 ratio. 3ml of the solution is prepared in a small cell 
culture dish and left to set at room temperature overnight. Once the solution has set and the PDMS is 




30mm (3cm) is cut then a rectangular opening in the centre of the circle bearing the measurements 
described in figure 2-7 (PDMS gasket).   
 
 
Assembly was accomplished by first installing the cover slips into the designated view slots using 
silicone grease. Once in place, the sample was placed on the bottom plate and aligned with the inlet 
and outlet. The custom PDMS gasket was affixed to the top plate with silicone grease after ensuring 
alignment with the inlet and outlet. The two halves of the chamber, with the gasket and sample in 
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Figure 2-7: Perfusion chamber assembly. The sample is aligned along the flow path between the inlet and outlet on the 
bottom plate. The outlet, affixed with silicone grease to the top plate, is aligned in the same way and placed over the sample. 




place, were put together ensuring the sample was positioned entirely within the gasket. Once this was 
accomplished, the screws are inserted and tightened to ensure the system was sealed and water-tight. 
The inlet and outlet were then connected to the tubing, that was in turn connected to the pump and 
reservoir.   
2.1.4.3 Shear stress 
The assembled flow chamber was used to generate laminar flow as well as exerting shear stress on the 
intimal surface of the vascular models. The dimensions of the gasket used, which comprises and 
determines the dimensions of the flow chamber, were length: 25mm (2.5cm), width: 5mm (0.5cm) and 
depth/height: 3mm (0.3cm) when empty and 2.5mm (0.25cm) with TE constructs. The key dimensions 
that affect the shear stress profile are the depth and width of the chamber. The equation used to 




       
(Wong et al., 2016) 
This equation derived from Wong et. al., 2016, is intended for use in a parallel stationary-plate flow 
chamber, with τ being the shear experienced on the upper surface of the construct. With this equation, 
shear stress between stationary parallel plates is described as a function of volumetric fluid flow (Q) 
(Wong et al., 2016). The values required for the equation are the viscosity of the fluid being perfused 
(u), the flow rate (Q), the gasket width (b) and the gasket height with TE construct placed within (h). 
The flow rate used for the perfusion of the constructs was 0.07cm2/s. This value, using a viscosity value 
of 1.5 Cp (Jeevasankar et al., 2008), is used to determine that the shear stress exerted on the construct 
surfaces is 20.16 dyne/cm2. Aside from generating a useful range of shear stress values that range from 
1.44 dyne/cm2 to 172.8 dyne/cm2, the chamber was also able to consistently generate a laminar flow 
profile with the modified gasket design. 
2.1.4.4 See-saw Rocker  




on a standard see saw rocker set at 70 rpm for 1 hour at 7θ.  
2.1.4.5 Flow pattern characterisation 
To determine the nature of the flow pattern within the perfusion chamber, fluorescein was used in 
conjunction with PBS to visualise the flow pattern. The chamber and pump were assembled as in figure 
2-6. The reservoir was first filled with PBS, which was then pumped through the chamber. After this, 
the contents of the reservoir were removed and replaced with the fluorescent solution. As the solution 
flowed into the chamber, it was possible to visualise fluid movement as the two liquids mixed. Video 
footage was recorded and still images isolated.  
2.1.4.6 Perfusate cell labelling 
Cells were stained with CFSE, a live cell tracker. This membrane stain was used at a concentration of 
2µl in 1ml of cell suspension. The cells to be stained were passaged and counted and re-suspended in 
1m of fresh supplemented media. The stain was then added and the cells incubated for 15 minutes at 
37°C. The cell suspension was centrifuged for 3 minutes at 1200rpm and the pellet re-suspended in 
5ml of fresh supplemented media. The cell suspension was left to sit for the final esterification step for 
30 minutes at 37°C before use. Imaging was done using Leica inverted fluorescence microscope and a 
confocal microscope.  
2.1.5 Cytokine characterisation and quantification 
2.1.5.1 SDF-1 
The reagents for the mini ABTS ELISA kit were reconstituted according to manufacturer’s protocol. 
100μl of the capture antibody, diluted in PBS to a concentration of 2μg/ml, was added to the requisite 
number of wells, sealed and incubated overnight at room temperature. The wells were the aspirated 
and washed 4 times with 300μl of wash buffer per well. The wash buffer is comprised of 0.05% Tween 
20 in PBS.  Next, 300μl of 1% BSA in PBS (block buffer) was added to the wells and incubated for at 
least 1 hour at room temperature. The block buffer was then aspirated and the plate washed 4 times 
with the wash buffer. 100μl of sample solution (or standard) was added to each well and incubated at 




detection antibody, diluted in diluent (0.05% Tween 20 + 0.1% BSA) to a concentration of 0.5μg/ml. 
The plate was then incubated for at least 2 hours at room temperature. After this, the plate was again 
aspirated and washed 4 times. A 1:2000 dilution of Avidin-HRP conjugate was then added to the wells 
(100μl/well) and incubated for 30 minutes at room temperature. This was then followed by another 4 
washes, after which 100μl of ABTS liquid substrate was added per well. This was incubated at room 
temperature - with observation every 5 minutes for up to 1 hour - until colour development was 
observed. Once this was achieved, the plate was read using a plate reader set at 405nm.  
2.1.6 Atherosclerotic plaque model 
2.1.6.1 OxLDL synthesis 
200μl of LDL solution was mixed with 4ml PBS and 10μM CuSO4.5H2O to make a final solution of 
5mg/ml oxLDL. This solution was incubated for 24 hours at 37°C, 5% CO2. After oxidation, solution turns 
cloudy. To remove CuSO4 from the oxidised solution, thus preventing further oxidation, the solution 
was then transferred to a slide-a-lyzer dialysis cassette and dialysed in 550ml of 10μM EDTA in PBS for 
24 hours. Dialysis solution was changed every two hours for 8 hours then left to continue dialysis for 
the remainder of the duration. The dialysis solution was kept in motion using a magnetic stir bar. After 
dialysis was complete, solution was removed from the cassette, aliquoted and stored at -80°C. All 
procedures were carried out under sterile conditions.  
2.1.6.2 Foam cell formation 
To promote foam cell formation in RAW 264, cells were incubated with either oxLDL, oxLDL and LPS, 
oxLDL and IFN-γ or LPS, IFN-γ and oxLDL. LPS and IFN-γ were both used at a concentration of 100ng/ml, 
oxLDL at 100μg/ml. IFN-γ and oxLDL Incubation was done overnight. Cells were first incubated with 
IFN-γ, IFN-γ + LPS, or LPS overnight, after which the media was removed and replaced with LDL/oxLDL 
loaded media for a further overnight incubation. After incubation, media was replaced with normal 
cell media either with or without atorvastatin. For samples loaded with oxLDL, concentrations of oxLDL 
were maintained in the media used for experimentation. 




2.1.6.3 Co-culture with HUVEC: Nanofiber well inserts  
RAW 264 cells were cultured in conjunction with HUVECs. The two cell layers were separated using a 
customised nanofiber insert with the HUVEC layer seeded on the nanofibers and above the RAW cells. 
Assembly of this system is shown in figure 2-8. Aligned nanofibers were collected on acetate frames 
and were affixed to the customised rings using silicone glue. The   fibres were allowed to dry onto the 
ring for 2 hours in an oven set at 50°C. To facilitate media flow, a split rubber ring was affixed to the 
bottom of the assembled insert. Before use in cell culture, the inserts were sterilised by first incubating 






Figure 2-8: Nanofiber well insert assembly. The customised rings were fused together with the aligned 
nanofibers between. A split rubber ring was affixed to the bottom portion of the insert. After sterilisation, 
HUVECs are seeded onto the fibronectin coated nanofibers. The completed insert is placed inside a 24 well plate 





The sample was first incubated with 5% BSA for 1 hour at room temperature. Then the primary 
antibody was added at a 1:200 dilution and incubated for 2 hours at 37°C/5% CO2. The primary 
antibody is removed and the sample washed 2x with 0.05% Tween20 then 2x with PBS. The secondary 
antibody was then added and incubated with the sample for 1 hour at 37°C/5% CO2. After the 
incubation, the secondary antibody is removed and the sample washed again with 0.05% Tween20 (2x) 
then PBS (2x). After the washes, the sample is incubated with DAPI at 1μg/ml for 10 minutes after 
which the stain is removed and the sample washed with PBS before imaging. Negative control for 
secondary antibody was carried out by adding secondary antibody to PBS only wells. Specific 
antibodies used are detailed in the respective chapters.  
2.1.6.5 Nile Red Staining 
Nile red was obtained as a powder which was reconstituted by dissolving in isopropanol to make a 
1mg/ml stock solution that was diluted to 1μg/ml for active use. Staining was done on fixed samples. 
Samples were first washed twice with PBS, then 500μl Nile red working solution (1μl Nile red stock in 
1ml PBS) was added to samples. Samples were incubated with the dye for 20 minutes at room 
temperature, after which they were washed again with PBS. DAPI (10ng/ml) was added to samples for 
10 minutes for nuclear staining. DAPI was then removed and sample washed again with PBS, followed 
by imaging.  
2.1.6.6 Oil Red-O quantification  
Staining was done on fixed cells. Filtered oil red-o working solution was added to sample wells (500μl 
for 24 well plate) for 20 minutes at room temperature. After this, wells were gently washed with dH2O. 
This was followed by the addition of 500μl isopropanol per well. The well plate was then placed on an 
orbital shaker for 25 minutes. After this, 100μl of solution was collected in a 96 well plate and sample 
absorbance was read at 540nm. This would allow reverse determination of ox-LDL uptake.  
2.1.6.7 NO quantification 




mixed 1:1 (50μl:50μl) with gries buffer comprised of 1% sulphonamide, 2.5% phosphoric acid and 0.1% 
Naphthalene-diamine-hydrochloride. The mixture was read using a plate reader at 546nm. 
Quantification was done based on a standard curve created using a sodium nitrile dilution series.  
2.1.7 Statistics 
Statistical analysis was carried out where applicable with primary testing being one-way ANOVA, two-
way ANOVA and one sample T and Wilcoxon tests carried out. All analysis was carried out using 
GraphPad Prism 8 and specific details regarding tests carried out per data set are detailed further in 
upcoming chapters. All tests used a minimum of 3 repeats per group and the data is expressed as mean 



















3 Chapter 3:    
 Endothelial Progenitor 







Endothelial Progenitor cells (EPCs) is a broad reference to cells possessing the capability to differentiate 
into endothelial cells. These cells have been defined as circulating cells that express a variety of cell 
surface markers similar to those expressed by vascular endothelial cells, adhere to endothelium at sites 
of hypoxia/ischemia, and participate in neovascularisation (Luo et al., 2018); Yoder, 2012). Early work 
in the isolation and characterisation of this cell type identified that purified CD34+ hematopoietic 
progenitor cells from adults can differentiate ex vivo to an endothelial phenotype. (Poay Sian Sabrina 
Lee and Kian Keong, 2014) demonstrated that these EPCs showed expression of various endothelial 
markers and are incorporated into neo-vessels at sites of ischemia. Earlier studies suggested EPCs 
exhibited a CD34+/CD133+/VEGFR2+ phenotype. Later studies also considered the expression of CD45, 
CD105, CD106, CD117, CD144, acetylated low-density lipoprotein uptake, and aldehyde 
dehydrogenase activity (Chong, Ng and Chan, 2016). Other characteristics that can be used to define 
the EPC type are the capacity for tube formation and the formation of colonies.   
Tube formation in EPCs is commonly carried out by seeding cells in Matrigel and supplementing with 
angiogenic factors such as VEGF. This results in the formation of tube-like structures (Huang et al., 
2012; Zhao et al., 2018), an  observation also seen for cells cultured in collagen gels and has mainly 
been linked to colony forming EPCs (Peters, 2018).  
Colony formation, feature was first described by Asahara et., al. 1997, and was observed on plated 
CD34+ cells after 5 days of culture (Yoder, 2012b; Asahara et al., 1997). This was achieved by replating 
non-adherent cells after isolation from human? blood then quantifying the appearance of EPC derived 
colonies (Yoder, 2012b; Hill et al., 2003). Numerous follow-up studies have identified colony formation 
as a marker of an EPC phenotype, with colonies described as clusters of rounded cells surrounded by 
cells possessing an elongated spindle shape (Abou-Saleh et al., 2009).  
In this study, we intended to obtain EPC from commercial sources and to isolate this cell type from 
whole blood from healthy volunteers. This would be flowed by an evaluation of their capacity for 




would identify the cells as endothelial progenitors for subsequent chapter studies. Staining was done 




3.2 Materials and methods 
Materials used for this chapter are listed in chapter 2, section 2.1 under cell culture, EPC isolation and 
cell staining sections of table 1.  EPCs were obtained from whole blood collected from healthy, drug 
free volunteers.  
3.1.1 EPC culture 
Following the established isolation and culture protocols, EPC cultures were maintained by culturing 
cells as described in section 2.1.1.8. Briefly, following isolation using differential centrifugation, cells 
were cultured on either collagen or fibronectin coated plates and fed with medium 200 supplemented 
with 10% FBS and 1% AA. After separation from whole blood, cells were first plated in 2 wells of a 12 
well plate for the first day, followed by a transfer of unattached cells to a new well daily for 4 days, 
which allowed maximum trapping of unattached cells. Media was changed daily for the first 7 days 
then changed every 2 days for the duration of culture.  
3.1.2 EPC characterisation 
To aid in the identification of isolated cells, colony formation, surface marker expression and tube 
formation evaluations were done as described in section 2.1.2, and will be discussed further in this 
chapter.  
3.1.3 Immunostaining 
The expression of Flk-1 (KDR/VEGFR-2), CD45, CD31 (PECAM-1), CXCR4 and CD34 were used to 
characterise this cell type. Protocol for staining is as described in section 2.1.2.2. Primary (1°) 
antibodies were used at a dilution of 1:200 with PBS while secondary antibodies were used at a dilution 






3.1.4 Commercially available EPCs 
Initially, cells were sourced commercially from Biochain (amsbio), and were revived according to the 
supplier’s protocol. Unfortunately, there were unidentified particulates observed within the culture 
vessel that covered the base of the flask and prevented attachment of the EPCs. The number of EPCs 
observed in the flask were also very minimal, preventing attempts at proliferating these cells and 
establishing a cell line. The status of the cells after culture can be seen in figure 3-1.  
 
The bulk of the contents within the flask had irregular geometric shapes and appeared to be crystalline 
in nature. An assessment of the supplemented media ruled it out as the source of these structures. It 
is likely the anomalous structures observed in the culture vessel were crystals derived from the freezing 
medium. It was not possible to eliminate these structures which affected cell attachment and therefore 
proliferation as a result, alternative methods were employed to isolate and characterise EPCs. EPCs 
used for later experiments were isolated from whole blood, derived from healthy, drug free volunteers, 
as detailed in section 2.1.1.6.  
  
A B C 
Figure 3-1: EPC morphology. These images are of P0 EPCs taken at 10x (A) and 20x (B, C). Image C is of one of the structures 
identifiable as a cell within the flask and was taken after a media change. Image A and B Show the contents of the flask 1 




3.1.5 Morphology evaluation 
To determine the ideal substrate that will allow effective culture of peripheral blood EPCs, a comparative between collagen and fibronectin was made. 
Following isolation from whole blood, cells were seeded in two wells of a 12 well plate, on the first day. From day 2 till day 4, during the daily media change, 
old media was discarded and fresh media agitated and transferred to a new well to collect as many non-adhered adherent cells as possible. Representative 
images are shown in figure 3-2.   































Figure 3-2:  Endothelial progenitor cell culture on collagen vs. fibronectin coated plates. Representative images showing cell morphology over time on different 




The key difference between the different types of coating was that the cells grown on the collagen 
coated plates displayed mixed morphologies, with this heterogenicity being maintained throughout 
the culture process and managed to survive for slightly longer before cell density began to diminish 
around D10. Cells on the fibronectin coated plates were more homogenous in appearance, gradually 
adopting the spindle like shape of early EPCs, which was maintained for the duration of culture. 
Proliferation was not observed with the cultured cells but rather a gradual decline in cell population 
after 10 days of culture. Depending on volunteer, the average total density of isolated cells ranged 
between 2 x 105 and 4 x 105 cells. The density of cells within the wells started decreasing as can be 
seen between day 9 and 13 (Figure 3-2). At the end of culture, cell population was fully homogenous 
in appearance, following the well-to-well transfer in the first 4 days of culture.  
3.1.6  Colony formation 
Certain subsets of EPCs are characterised by their ability to form colonies in vitro.  representative 
images showing colony formation are shown in figure 3-3. Colonies were observed on cells cultured 










Colonies were observed fairly early in culture (between day 2 to day 6). For both types of coating, 
spindle like projections can be seen on the edges of the colony. These colonies gradually dissipated to 
Figure 3-3: Colony formation collagen vs. fibronectin coating. Representative images showing colony growth in isolated 





be replaced with exclusively spindle like cells on the fibronectin coated plates, as seen in figure 3-2, or 
a mix of rounded and elongated cells on the collagen coated plates, also represented in figure 3-2.  
3.1.7 Tube formation 
Another defining characteristic of EPCs is their ability to form tube-like structures. During culture, 
appearance of tube-like structures was seen in some of the wells, the collagen coated plates showed 
these structures after 20 days of culture while the fibronectin coated plates developed them after 13 
days. These structures appeared after 10 days in culture. As can be seen in figure 3-4, these tube-like 
structures appear to be formed from a number of cells linked end to end to form the tube.  
 
After about 10 days of culture some wells showed signs of tube formation, with approximately 2-3 
tubes appearing per well. On the fibronectin coated plates, the tubes appear to be cells aligning 
themselves in this orientation end to end forming a tube while the tube-like structures appearing on 
Figure 3-4: Tube formation. Representative images showing tube formation in EPC culture. 

































the collagen coated plates appear to be a continuous membrane, with no individual cells being 
obviously distinguishable as they are on the fibronectin coated plates.  
3.1.8 Immunostaining 
Immunostaining was done to determine the expression profile of the isolated cells. All staining was 
done on cells cultured on fibronectin. Cells used were between 14 and 20 days old. Staining was done 
by adding 1° antibody diluted 1:200 in PBS and 2° antibody diluted 1:400 in PBS. Secondary antibody 
negative controls were done at the same dilution in the absence of the 1° antibody, representative 
images are in figure 3-6. Staining was done for CD34, CD45, CD31, Flk-1 and CXCR4, representative 
images are in figure 3-5.   
 
Figure 3-5 shows the results of the antibody staining, with cells showing positivity for all the selected 
markers i.e., CD34, Flk-1, CD45, CD31 and CXCR4, strongly suggesting that these cells fit under the 
descriptor for EPC. Extent of staining is mostly ubiquitous for all the markers examined here, with CD31 















Figure 3-5: EPC markers. Images 
showing expression of (a) CD34, (b) 
Flk-1, (c) CD45, (d) CD31 and (e) 
CXCR4. The respective colours of the 
nuclear stain and receptor are 
indicated on each image. Images 





Figure 3-6: 2° Antibody negative 
controls. (a) Donkey anti-mouse IgG-
FITC conjugated (CD34 and CD45). (b) 
Donkey anti-rabbit IgG NL493 
conjugated (CXCR4). (c) mouse 
monoclonal IgG; Flk-1 Alexa Fluor® 594 
conjugated. (d) Donkey anti-mouse IgG 








The term endothelial progenitor cell was first used to define circulating cells that were able to display 
cell surface antigens similar to endothelial cells. As yet, there is no universal agreement on what 
specifications constitute an endothelial progenitor cell, primarily due to variations in isolation, culture 
and identification (Richardson and Yoder, 2011). In terms of what general characteristics are expected 
of the EPC, some agreement can be made on the expression of CD34, Flk-1 (VEGFR-2/KDR) and CD133 
being strongly suggestive of the EPC phenotype. Further to this, the additional expression of CD45 
would also support that these cells are of a haematopoietic lineage. Given the variety of identification 
characteristics, it becomes challenging to clearly identify isolated cells as EPCs. Recent works have 
attempted to narrow down the classification criteria for endothelial progenitors. As described by 
Huizer et. al., 2017, there are three categories of progenitor cells based on FACS sorting for specific 
surface markers. The three variants of progenitors are; haematopoietic progenitor cells (HPCs), 
circulating endothelial cells (CECs) and culture-generated outgrowth endothelial cells (OECs) (Huizer 
et al., 2017). They were also able to sub-divide HPCs into 4 sub-groups based on CD34, CD133 and c-
kit staining, namely CD133negc-kithigh, CD133lowc-kithigh, CD133highc-kithigh, and CD133highc-kitneg/low. They 
identified that expression of CD34 and CD45 was positively linked with CD133, and that expression of 
other endothelial markers, such as Flk-1, CD146 and CD105, were  indicative of small independent sub-
populations (Huizer et al., 2017). CECs were identified as expressors of CD34 and Flk-1 while negative 
for CD45, with additional expression of CD144 and CD146 (Huizer et al., 2017). OECs were plated 
without sorting, developing the typical spindle shaped morphology of early EPCs. These developed 
further after 1-3 weeks of culturing into OECs, which displayed characteristic cobblestone morphology, 
expression of VWF and formation of tube-like structures. These cells were found to express high levels 
of CD31, CD144, CD146 and CD105, while not expressing CD45 and CD133 (Huizer et al., 2017). From 
their findings, it is possible to extrapolate that the cells isolated here were at the very least of an 
endothelial progenitor phenotype.  




axis. CXCR4 is conspicuously expressed on haematopoietic stem cells and has been demonstrated to 
be important in their recruitment and homing (Sainz and Sata, 2007). The cells imaged here 
demonstrate strong expression of CXCR4, further suggesting that they are of a haematopoietic lineage.  
In regard to the morphological appearance of the cells cultured here, there is consistency with reports 
on classification of this cell type. Abou-Saleh et al. 2009 characterise their cells based on the 
appearance of cultured colonies. As is described in sources dealing with EPCs, the colonies have an 
appearance matching those seen in figure 3-2, where a central core of rounded cells is possessed of 
elongated sprouting cells at the periphery (Abou-Saleh et al., 2009). Here we have clear demonstration 
of this phenomenon which was observed fairly early in culture and later made way to homogenous 
cultures of the elongated cell phenotype. Further steps that could be taken to isolate a purer fraction 
of this cell type, or variants thereof, would be to conduct more functional assays such as acetylated 
LDL uptake as well as further characterisation of tube formation using standardised assays. This would 
also be done in conjunction with FACS analysis of a wider array of surface markers such as CD133. In 
regards to the intentions of this thesis, the characteristics described here were sufficient to allow 
subsequent experimentation with these cells.  
3.5 Conclusion 
Based on the key surface marker expression profiles demonstrated here, it is possible to say that the 
cells isolated can be defined as EPCs based on morphological and phenotypic characterisation. In the 
up-coming chapters, their responses to atorvastatin and interactions with endothelial cells and tissue 











4 Chapter 4:    
 Evaluating Atorvastatin’s 
Effect on Stem Cell Homing 







The maintenance of vascular integrity is vital to blood circulation and thus the health of organs and 
tissues in the body. There are a number of mechanisms in place to regulate the maintenance of 
vascular integrity. One of these is the recruitment of cells to sites of vascular injury. Cellular migration 
and integration is an essential aspect of numerous physiological processes, including 
neovascularization and angiogenesis, immunologic responses, wound healing, and organ repair (Dar, 
Kollet and Lapidot, 2006). A key player in ensuring vascular health is the endothelial cell. These cells 
are responsible for the regulation of vascular tone, vascular permeability, vessel wall inflammation, 
and thromboresistance  (Hirase and Node, 2012). Endothelial cells respond to and produce vasoactive 
substances that are able to regulate vascular permeability, smooth muscle cell functionality and 
recruitment of immune cells (Hirase and Node, 2012). In regards to their own migration, three 
mechanisms are involved in this process; chemotaxis which refers to directional migration in response 
to chemoattractants (chemokines), haptotaxis, which is the directional migration toward a gradient of 
immobilized ligands and mechanotaxis, which refers to the directional migration generated by 
mechanical forces (Lamalice, Le Boeuf and Huot, 2007). Another mechanism involved in vascular repair 
is the recruitment of circulating progenitor cells. Endothelial progenitor cells have received 
considerable interest since their discovery by Asahara et. al. in 1997 and are believed to contribute to 
the process of vascular repair (Sandhu, Mamas and Butler, 2017). These cells are believed to originate 
from the bone marrow and are mobilized into peripheral blood to participate in vasculogenesis and 
angiogenesis through the secretion of cytokines (Chong, Ng and Chan, 2016). These cells are a viable 
candidate for therapy due to the ease of their isolation and potent vasculo-and angiogenic effects 
(Chong, Ng and Chan, 2016). Other types of stem cells types have also proven to be useful tools for 
therapy. Mesenchymal stem cells (MSCs) are defined as multipotent cells capable of self-renewal and 
with the capacity to differentiate into a variety of mesenchymal cell types (Karp and Leng Teo, 2009). 
Introduction of MSCs to diseased hearts has been shown to improve cardiac function through 




they are introduced to. For example, adipose derived stem cells can produce large amounts of 
extracellular matrix along with immunomodulatory effects while bone marrow derived stem cells have 
a stronger proangiogenic and immunomodulatory effect (Bagno et al., 2018). As pertains to vascular 
repair, bone marrow MSCs have been shown to produce higher amounts of cell migration related 
chemokines, specifically stromal derived factor-1 (SDF-1) (Bagno et al., 2018). Chemokines are known 
to bind multiple receptors, with the same receptor being able to bind more than one chemokine. An 
exception to this rule is SDF-1, which exclusively binds to CXCR4 only (Kucia et al., 2005). For the 
homing of haematopoietic cells, the SDF-1/CXCR4 axis is crucial. Expression of SDF-1 is elevated in a 
majority of tissues following injury, and is vital in mobilization and migration of stem cells from the 
bone marrow to the site of tissue injury (Dimova et al., 2019; Mayorga et al., 2018). In studies utilising 
rodent systems, Mayorga et al., 2018, demonstrated that exogenous SDF-1, delivered through gene 
transfer or by infusion of MSCs, was enough to induce stem cell homing to injured myocardial tissue 
(Mayorga et al., 2018). The exclusivity of this chemokine-receptor pair suggests that they have a 
uniquely important biological role. SDF-1 can be expressed by stromal and endothelial cells including 
bone marrow, heart, skeletal muscle, liver, brain and kidney, and genetic knockouts of SDF-1 and CXCR4 
results in significant defects in the colonisation of embryonic and haematopoietic stem cells, as well 
as defects in the development of the heart, brain and large vessels (Ratajczak et al., 2006).   
The primary role of statins is to competitively inhibit HMG CoA, which induces the expression of LDL 
receptors in the liver, which in turn increases the catabolism of plasma LDL, resulting in the reduction 
of circulating LDL levels (Sandhu, Mamas and Butler, 2017). Atorvastatin has repeatedly been 
demonstrated as having effects outside of cholesterol lowering. These pleiotropic effects include 
actions such as attenuation of vascular inflammation, improved endothelial cell function, decreased 
vascular smooth muscle cell proliferation and migration, stabilization of atherosclerotic plaque, and 
inhibition of platelet aggregation (Sadowitz, Maier and Gahtan, 2010).  
Here we attempted to determine the effect atorvastatin has on HUVEC migration and wound closure. 




A scratch wound was selected due to the ease and speed of execution.  We further assess the influence 
of HUVECs co-cultured with rMSCs, hMSCs and EPCs with atorvastatin to evaluate if stem cells from 
different species have varying effects and whether MSCs and EPCs have different effects on cell 





4.2 Materials and methods 
4.1.1 Human umbilical vein endothelial cell (HUVEC) culture  
As described in section 2.1.1.2, HUVECS were cultured in medium 200 supplemented with 2% LSGS. 
Cells between P2 and P5 were used in the experiments detailed in this chapter.  
4.1.2 Rat mesenchymal stem cell (rMSC) culture 
As described in section 2.1.1.3 and 2.1.1.5, rMSCs were cultured in DMEM supplemented with 1% AA, 
1% LG and 10% FBS. Cells between P3 and P6 were used in experiments detailed in this chapter.  
4.1.3 Human mesenchymal stem cell (hMSC) culture 
As described in section 2.1.1.4 and 2.1.1.5, hMSCs were cultured in DMEM supplemented with 1% AA, 
1% LG, 1% NEAA and 10% FBS. Cells between P3 and P6 were used in experiments detailed in this 
chapter. 
4.1.4 Trilineage differentiation 
As described in section 2.1.1.6, a trilineage differentiation along osteogenic, chondrogenic and 
adipogenic lineages was carried out for rMSC and hMSCs to confirm their stemness. After 
differentiation, cells were stained with alizarin red and alcian blue for osteogenic and chondrogenic 
differentiation respectively, with oil red-O and Nile red staining done for the adipogenic lineage. 
Specific staining protocols are described in sections 2.1.1.6.1.1, 2.1.1.6.1.2, 2.1.1.6.1.3 and 2.1.14 
respectively.  
4.1.5 Atorvastatin dose effect 
As described in section 2.1.3, atorvastatin was dissolved in methanol and diluted to the following 
concentrations; 30μg/ml, 60μg/ml, 80μg/ml, 100μg/ml, 120μg/ml and 140μg/ml. During dilution with 
culture media, care was taken to ensure that methanol amounted to less than 1% of total media 
volume per sample. The assay to assess cell viability was CCK8. The assay was carried out after a 24-
hour incubation with or without atorvastatin, followed by the addition of the reagent as detailed in 




4.1.6 Scratch wound 
As described in section 2.1.6.2, a 10μl pipette tip was used to generate a scratch on a confluent layer 
of cells seeded in a 48 well plate. To aid in visualisation of cell migration and homing, HUVECs were 
stained with the nuclear dye Hoechst-33258, as described in section 2.1.6.1.1, while rMSCs, hMSCs 
and EPCs were stained with the membrane dye as described in section 2.1.6.1.2. Quantification of cells 
within the scratch wound was done using ImageJ.  
4.1.7 Immunostaining 
As described in section 2.1.13, samples were first incubated with 5% SA for 1 hour followed by addition 







4.1.8 Human umbilical vein endothelial cell (HUVEC) culture 
The cells achieved the expected cobblestone morphology and were successfully utilised in the 
proceeding series of experiments. Cell proliferation rates were consistent and sufficient to provide the 
necessary number of cells for all subsequent experiments. Cells used for experimentation were 
between passage 2 (P2) and passage 5 (P5). Images of the cell morphology can be seen in figure 4-1.  
4.1.9 Rat mesenchymal stem cell (rMSC) culture 
These cells adopted a flattened and spread-out morphology with spindle like projection as can be seen 
in figure 4-2. These also displayed rapid proliferation, doubling every 2 days. Cells used were not older 
than P6. To further evaluate the stemness of these cells, a tri-lineage differentiation was carried out 
as detailed in section 2.1.1.5. Images detailing progression of differentiation are shown in figure 4-3 
and 4-4. Cells used for differentiation were at P4, n=3.  
Figure 4-1: HUVEC morphology. Here we see typical HUVEC appearance in culture, 
with cobblestone morphology. HUVECs imaged are at P2. Scale bar = 100 μm   
Figure 4-2: rMSC morphology. These images show the cell morphology observed in 
these cells during monolayer culture. Cells imaged here are at P4 and 4x magnification. 





Figure 4-3: Trilineage differentiation timeline. This panel illustrates the morphological changes occurring over time during differentiation under osteogenic, chondrogenic and 








































Figure 4-4: rMSC trilineage differentiation. Cultured cells were exposed to either osteogenic, chondrogenic or Adipogenic media for 21 days. Morphological changes were observed 
between the control and treated samples and staining with alizarin red, alcian blue and oil red-o demonstrates differentiation of rMSCs along the osteogenic, chondrogenic and 




Looking at figure 4-3, the cells have a fairly similar phenotype at day 2, with the appearance of small 
lipid droplets visible in the adipogenic differentiation. These droplets get denser as the culture ages as 
seen at day 10 and eventually the droplets get larger as can be seen at day 20. Their completion of 
differentiation into adipocytes is confirmed in image 4-4 with distinct oil red-o (red) stained lipid 
droplets that are more easily distinguished at 20x. Osteogenically differentiated cells started to grow 
in clusters at day 10, with the clusters being more numerous at day 20. Staining with alizarin red is 
necessary to distinguish any further morphological and phenotypic changes to these cells. This is 
confirmed with the presence of mineral deposits stained red in figure 4-4. In figure 4-3, cells 
undergoing chondrogenic differentiation are extremely confluent at day 10 but density dramatically 
decreases at day 20. At day 20, typical chondrocyte morphology can be seen and their terminal 
differentiation is confirmed with the alcian blue staining seen in figure 4-4.  
4.1.10 Human mesenchymal stem cell (hMSC) culture 
These cells were successfully cultured and displayed an elongated phenotype as seen in figure 4-5. 
They were not highly proliferative cells, doubling approximately every 5 days. Cells used for 
experimentation were between P3 and P6.  
 
As with the rMSCs, tri-lineage differentiation was carried out to verify the stemness of these cells. 
Images detailing the differentiation are shown if figures 4-6 and 4-7. Cells used were at P4, n=3.  
Figure 4-5: hMSC morphology. This representative image shows the hMSC 
morphology typically observed during culture. Cells were imaged at 4x and at P4. 
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Figure 4-6: Trilineage differentiation morphological changes in hMSCs. This image details the morphological changes hMSCs underwent under osteogenic, chondrogenic and 



































Figure 4-7: Trilineage histological staining. The staining demonstrates that it was possible to differentiate these cells along the desired lineages, with noticeable mineral deposits in 





Across all lineages, as seen in figure 4-6, there are signs of differentiation as early as day 2, with cells 
starting to lose the elongated phenotype associated with hMSCs. At day 20, both osteogenic and 
chondrogenic lineages appear to have smaller cells than the control. Density of cells is also maintained 
in the chondrogenic lineage, unlike what is seen in the rMSCs between day 10 and 20. Histological 
staining (figure 4-7) for osteogenic and adipogenic differentiation of hMSCs shows clear mineral 
staining for the osteogenic and lipid staining for the adipogenic. The chondrogenic staining appears 
ambiguous with the control samples displaying stronger GAG staining, possibly due to the level of 









Figure 4-8: Nile red staining of adipogenic differentiation of rMSCs and hMSCs. Nile red staining was 
done using both FITC and Texas red emission to denote internalised lipid (gold) as well as the cell 
membrane (red). The gold colouration is a result of FITC and Texas red overlay. A larger density of lipid 
droplets is visible on the hMSCs compared to rMSCs. Blue staining is DAPI. Scale bar = 40 μm for 20x 




develop lipid droplets at day 2, which get denser and universally distributed by day 20 (figure 4-6). 
These droplets are larger and more ubiquitously distributed than those seen in the rMSCs, as seen in 
figure 4-8, which details adipogenic differentiated cells stained with Nile red. For both cell types, their 
multipotency was confirmed through successful differentiation into osteogenic, chondrogenic and 
adipogenic lineages.    
 
4.1.11 The effect of atorvastatin dose on cells’ metabolic activities 
To determine if atorvastatin has any detrimental effect on cell metabolism, a CCK8 assay was done 
comparing a control sample with various doses of atorvastatin i.e., 30μg/ml, 60mg/ml, 80mg/ml, 
100μg/ml, 120μg/ml and 140mg/ml. This assay functions by measuring metabolic activity through the 
conversion of tetrazolium salts (WTS-8) to formazan through NADPH. This evaluation was done for 
HUVECs, EPCs and rMSCs. CCK8 readings were taken after a 24-hour incubation with or without 
atorvastatin. HUVECs were seeded at a density of 2 x 104 cells per well of a 96 well plate, EPCs at 4 x 
103 cells per well and rMSCs at 1 x 104 cells per well. CCK8 readings were taken as described in section 
2.1.4. Effect of atorvastatin on proliferation of these cells is shown in figure 4-9. CCK8 control for the 
















































































































Figure 4-9: Atorvastatin effect on proliferation using CCK8. (A) atorvastatin effect on HUVEC proliferation. (B) atorvastatin 
effect on rMSC proliferation. (C) atorvastatin effect on EPC proliferation. (D) comparative of atorvastatin effect on cell 
proliferation for all cell types. From A to C, n= 3, 3 and 6 respectively. Statistical significance determined using one sample t- 
and Wilcoxon test for (A-C) p <0.0001****, and two-way ANOVA for (D) p = 0.0264*.  Analysis indicated significance between 
concentrations of atorvastatin.   
 
For the three cell types represented here, only the HUVECs appear to be positively impacted by higher 
concentrations of atorvastatin, with the highest reading being observed at 120μg/ml. EPCs 
demonstrate a rise in viability via metabolic markers only at 30μg/ml and 60μg/ml, while rMSCs are 
overall negatively affected by atorvastatin. The differences in OD readings between cell types is due to 
the different seeding densities used, as specified above. The data presented here suggests that 
atorvastatin’s effect is not only dose dependent but also cell type dependent, with 60μg/ml being the 






























Figure 4-10: Methanol effect on cell viability. A CCK8 evaluation was done to determine the potential effect of methanol, 
the delivery vehicle selected for atorvastatin, on viability of HUVECs. 2x104 HUVECs were seeded with plain media and the 
maximum usable volume of methanol (10μl/1%) was added, followed by a 24-hour incubation. N = 9. Statistical significance 
determined using two-way ANOVA, with significance identified between methanol and control (p <0.0001****) and also 
within each variable (p = 0.0443 *).  
 
The findings in figure 4-10 indicate that methanol does not have a negative effect on cell viability 
detected with CCK8, but rather appears to marginally promote metabolic activity compared to the 
control. Future experimentation involved the use of methanol at levels below 1% i.e., ≤ 5μl/ml of media 
used. 
4.1.12 The effect of atorvastatin and MSCs on cell distribution in a scratch wound model  
To assess the impact atorvastatin has on cell migration and wound closure, 4 x 104 HUVECs were 
seeded per well in a 48 well plate. Once confluent (figure 4-10 A), HUVECs were first stained with 
Hoechst as described in section 2.1.6.1.1. A scratch wound was then created using a 10μl pipette tip 
(figure 4-10 B). Denuded cells were aspirated and the well washed with PBS. This was followed by the 
addition of either rMSC, hMSCs or EPCs that had been stained with CFSE, as described in section 
2.1.6.1.2, at a density of 5 x 103. Atorvastatin was also added to the wells at this time; concentrations 
used were 30mg/ml, 60μg/ml, 80μg/ml, 100μg/ml, 120μg/ml and 140μg/ml. Fluorescent images of 




migrated cells was done using ImageJ. Appearance of HUVECs before and after lesioning are shown in 




Figure 4-11: HUVECs pre- and post- scratch wound. (A) shows HUVECs at 100 percent confluence in a 48 well plate 
before creation of the scratch wound. (B) scratch wound on confluent HUVEC layer, denoted by black dotted line. 




4.3.1.1 HUVECs and rMSCs 
Representative images of wound closure with HUVEC and rMSC co-culture under different doses of atorvastatin are shown in figure 4-11. Quantification based 
on image analysis is shown in figure 4-12.
Figure 4-12: Atorvastatin effect on rMSC and HUVEC wound closure. Higher concentrations of atorvastatin appear to have a concentration of cells within the scratch wound after 24 
hours. The rMSCs (green) are more clearly visible as clusters at 120mg/ml and more so at 140μg/ml. White dotted lines denote the denuded area. rMSC. HUVEC. Images taken at 4x. 
Scale bar = 100 μm.    






















The extent of the scratch wound has observably altered over 24 hours and there appears to be a 
correlation between drug dosage and distribution of cells within the lesion area. The cells present 
within the lesion area were counted and the comparative data is represented in figure 4-12.  
 































Figure 4-13: Distribution and number of HUVECs and rMSCs within scratch wound. Representation of cells located within 
the scratch wound created on confluent HUVECs, following a 24-hour incubation with rMSCs, and atorvastatin at different 
concentrations. Statistical significance between concentration of atorvastatin and number of cells present in scratch wound 
was determined using two-way ANOVA, p = 0.0218*. Significance was also found for differences in density of rMSC and 
HUVECs within the scratch wound, p = 0.0004 ***. N=9. 
 
Upon an evaluation of cell distribution, the behaviour observed appears to be more in line with cell 
migration towards the lesion site resulting in closure of the lesion versus homing of suspended rMSCs. 
This behaviour also appears to be dose dependent with the highest number of cells present within the 
lesion after 24 hours being at 120µg/ml (Figure 4-12).  A comparative with figure 4-11 shows that 
although there is a greater density of cells present at 120μg/ml, the cells appear smaller and are not 
evenly distributed throughout the scratch wounds but rather localised in the centre of the well. Across 
all the doses, HUVECs are more numerous than the rMSCs in denuded area. Two-way ANOVA was 
carried out, along with a one sample t and Wilcoxon test. Statistical significance was found between 




4.3.1.1 HUVECs and hMSCs 
Representative images of wound closure with HUVEC and hMSC co-culture under different doses of atorvastatin are shown in figure 4-13. Quantification based 
on image analysis is shown in figure 4-14. 
 
Figure 4-14: Atorvastatin effect on wound closure-HUVEC and hMSC co-culture. These representative images compare extent of infiltration into the scratch wound by HUVECs and 
hMSCs. Images show appearance of the scratch wound taken within 1-hour of endothelial layer disruption and after 24 hours in the presence of atorvastatin. hMSC. HUVEC. Images 
























Across various doses of atorvastatin, the densest coverage of the scratch wound is observed at 
60μg/ml and 80μg/ml. The closure seems to be predominantly as a result of hMSC (green) migration 
and distribution within the scratch area versus HUVECs (blue). Higher doses (100-140μg/ml) still have 
a clearly visible denuded area after 24 hours. 


































Figure 4-15: Distribution and number of HUVECs and hMSCs in scratch wound. Representation of cells located within the 
scratch wound created on confluent HUVECs, following a 24-hour incubation with hMSCs, and atorvastatin at different 
concentrations. Statistical significance between concentration of atorvastatin and number of cells present in scratch wound 
was determined using two-way ANOVA. Statistical significance denoted by P = 0.0382*. Significance was also found for 
differences in density of hMSC and HUVECs within the scratch wound, p < 0.0001. N=6. 
 
Contrary to the observations with the rMSCs, more cells were present within the wound region after 
24 hours at lower concentrations of atorvastatin (figure 4-13 and 4-14), specifically 30μg/ml, with 
HUVECs present in greater numbers than hMSCs across all the doses. Barring a small rise at 120μg/ml, 
the general trend reflects a negative effect of atorvastatin on wound closure. This data suggests there 
is some species variation in terms of responses to atorvastatin. Two-way AVOVA was carried out along 
with a one sample t and Wilcoxon test. Statistical significance was found between doses of atorvastatin 
as well as between cell types.  
4.1.12.1 HUVECs and EPCs 
Representative images of wound closure with HUVEC and hMSC co-culture under different doses of 

























Figure 4-16: Atorvastatin effect on wound closure-HUVEC and EPC co-culture. These representative images compare extent of infiltration into the scratch wound by HUVECs and 
EPCs. Images show appearance of the scratch wound taken within 1-hour of endothelial layer disruption and after 24 hours in the presence of atorvastatin. EPC. HUVEC. Images 





































Figure 4-17: Distribution and number of HUVECs and EPCs in scratch wound. Representation of cells located within the 
scratch wound created on confluent HUVECs, following a 24-hour incubation with hMSCs, and atorvastatin at different 
concentrations. Statistical significance between concentration of atorvastatin and number of cells present in scratch wound 
was determined using two-way ANOVA. Statistical significance denoted by P = 0.0024**. Significance was also found for 
differences in density of EPCs and HUVECs within the scratch wound, p < 0.0001 ****. N=3.   
 
The distribution profile of EPCs within the scratch wound at varying doses of atorvastatin follows that 
seen in HUVECs for this particular cell combination. EPCs seem to respond to atorvastatin better than 
the other human cell types, with peak attachment being achieved at 60μg/ml, versus 0μg/ml with the 
hMSCs, once again demonstrating that responses are dependent on cell type and combinations of 
cells. 60μg/ml also appears to be the ideal dose of atorvastatin for HUVECs when cultured with rMSCs 
and EPCs. Even though higher cell numbers are recorded at higher doses for the HUVEC-rMSC co-
culture, an assessment of figure 4-11 indicates that the cells are more in clusters at doses above 
100μg/ml, and there is incomplete closure of the scratch wound. It is believed the cluster of cells seen 
in figure 4-11 at 120μg/ml and 140μg/ml were not migratory but rather deposited by gravity in the 
centre of the well. Statistical significance was determined by carrying out a two-way ANOVA as well as 
a one sample t and Wilcoxon test. The two-way ANOVA showed significance in the interaction between 
atorvastatin dose and cell numbers within the scratch wound as well as significance between 
atorvastatin doses and extent of infiltration between cell types, suggesting that the dose and cell types 





4.1.13.1 CXCR4: hMSCs 
To determine if atorvastatin or the scratch wound has any effect on CXCR4 expression on hMSCs, a key receptor for vascular homing, a scratch wound was 
created on a confluent layer of hMSCs followed by the addition of atorvastatin at 30, 60 and 120μg/ml. The same doses were added to intact cells as a 












 Figure 4-18: Atorvastatin effect on CXCR4 expression on hMSCs.  These images show variations in CXCR4 expression between an intact and disrupted hMSC 




























From figure 4-18, it appears as though the absence of an injury and atorvastatin results in reduced 
expression of CXCR4 in hMSCs while the inclusion of atorvastatin appears to increase expression of 
this receptor, both with and without an injury, suggesting atorvastatin may stimulate expression of 
CXCR4, with the brightest staining, with large stained cytoplasm morphology, observed at 120μg/ml. 
Cells in the scratched wells appear to be more spread out while those in the intact wells appear smaller 
overall, possibly due to cell spreading as they migrate to cover the denuded area, resulting in staining 
that appears compacted around the nucleus. The doses selected reflect the concentrations where the 




4.1.13.2 CXCR4: HUVECs 
To determine if atorvastatin or the scratch wound has any effect on CXCR4 expression on HUVECs, a scratch wound was created on a confluent layer of HUVECs 
followed by the addition of atorvastatin at 30, 60 and 120μg/ml. The same doses were added to intact cells as a comparative. Representative images are 


























No Atorvastatin 30µg/ml 60µg/ml 120µg/ml 
Figure 4-19: Atorvastatin effect on CXCR4 expression on HUVECs.  These images show variations in CXCR4 expression between an intact and disrupted HUVEC 





An examination of figure 4-19 shows that expression of CXCR4 appears less on HUVECs when 
compared to hMSCs. There appear to be basal expression of CXCR4 as suggested by the drug free 
samples, either with or without a scratch wound. While expression appears consistent across the 
samples represented here, 120μg/ml atorvastatin appears to influence increased expression of CXCR4 
on HUVECs with a scratch wound, although cells here appear to have atypical morphology, adopting a 
“comma” like appearance compared to the mostly rounded appearance of cells at lower 
concentrations of atorvastatin. There also appears to be a moderate increase in expression at 60μg/ml 
on the scratched samples compared to the 30μg/ml and drug free samples. These images also suggest 
that atorvastatin has an effect on CXCR4 expression, but to a lesser extent in HUVECs than MSCs, 




Figure 4-20: Secondary antibody negative control: Mouse anti-
rabbit IgG-TR (Texas Red) Conjugated used as secondary antibody 





4.1.14 Cell distribution/migration towards wound closure 
The data here suggests that HUVEC migration is a larger contributor to wound closure compared to 
homing of either rMSCs, hMSCs and EPCs. The effect of atorvastatin has also been shown to be both 
dose dependent and cell type dependent with the murine cells responding better than the human cells 
(figure 4-12), and between human cells, the EPCs (figure 4-16) are more responsive to atorvastatin 
than the hMSCs (figure 4-14), demonstrating an increase in cells within the scratch wound in the 
presence of atorvastatin up to 60μg/ml. This suggests that the beneficial effects of atorvastatin, within 
the bounds of the experiments carried out here, are primarily on homing of EPCs to sites of vascular 
injury, an observation supported by findings which demonstrate that statins promote EPC mobilization 
and homing (Oikonomou et al., 2015). The effects seen with rMSCs could be explained by the cross 
reactivity of human and murine SDF-1, the primary chemokine responsible for the migration and 
homing of bone marrow derived cells. There is remarkable conservation of the amino acid sequence 
for SDF-1 during evolution in different species, with murine and human SDF-1 being cross reactive, 
suggesting an important biologic role (Dar, Kollet and Lapidot, 2006). This biological importance is 
supported by the observation that knockouts of SDF-1 and its receptor CXCR4 are lethal (Ratajczak et 
al., 2006).  
It was also possible to demonstrate the effect atorvastatin has on the production of CXCR4 (figure 4-
17 and 4-18). Findings from a murine model by Li et al., 2015 showed that atorvastatin increases the 
migration ability of MSCs and improves cardiac performance due to up-regulated expression of CXCR4 
(Li et al., 2015), which supports the observations seen here on human MSCs. Liu et. al., also 
demonstrated that increased surface expression of CXCR4 in mesenchymal stem cells resulted in 
enhanced migration (Liu et al., 2011), which is not what is seen here, suggesting that either the 
concentrations used here were not ideal for enhancing hMSC migration, some other conditions must 
be met to increase homing along with increasing CXCR4 expression, or that these observations do not 




et al., 2014; Bing et al., 2016), which could be supported by the observations in figure 4-12 which show 
that the best response was seen in HUVECs co-cultured with murine cells. Further evidence to support 
the suggestion that other mechanisms might be in play can be derived from Rüster et. al., 2006, who 
propose that the interaction of MSCs with  the endothelial layer is through shear, p-selectin and VCAM-
1 (Rüster et al., 2006). Additionally, the expression of CXCR4 in HUVECs was not greatly affected by the 
inclusion of atorvastatin, suggesting that some other mechanism may be involved in their migration 
into the scratch wound, or possibly the interplay between cell types could be a contributing factor.   
4.1.15 Atorvastatin dose effect 
The data represented here demonstrates that there is variation in viability due to atorvastatin based 
on cell type. Figure 4-9 (D) suggests that although there is an observable decrease in viability 
demonstrated by plots A-C, the compounded change when the plot are combines is not that large 
across the selected doses of atorvastatin. The assay used to determine cell viability relies on the 
activity of NADPH to convert tetrazolium salts to formazan, which gives the colour change used to 
quantify cell viability. Interference in the availability of NADPH would result in discrepancies in 
determining actual cell viability. Atorvastatin has been demonstrated to activate nitric oxide synthase 
(NOS), which mediated the survival of implanted MSCs in mini-swine (Song et al., 2013a). NADPH is 
required for the functioning of NOS, which is involved in the production of nitric oxide (Förstermann 
and Sessa, 2012). This finding is consistent with other reports that statins suppress NADH/NADPH 
oxidase23 or that a metabolite of atorvastatin has an antioxidant property (Sugiyama et al., 2005). 
These observations suggest that the availability of NADPH would be restricted in the presence of 
atorvastatin, which would in turn limit the conversion of the tetrazolium salts to the formazan end-
product, thus giving the impression of reduced cell viability. This supposition explains what is seen 
with the rMSCs and EPCs but not the HUVECs, which demonstrate increased viability on this assay at 






The data collected and presented here shows that atorvastatin has a positive impact on scratch wound 
closure, specifically in the context of HUVEC migration in the scratch wound versus migration of 
suspended cells to the scratch wound, and primarily with rMSC and HUVEC co-culture. rMSCs, in 
conjunction with HUVECs, demonstrated increased migration with increased atorvastatin 
concentration, attaining maximum infiltration at 120μg/ml. Contrastingly, hMSCs cultured together 
with HUVECs did not respond positively to atorvastatin. This observation is in line with published work 
and highlights the issue with using murine models to correlate responses with human tissue. In regards 
to the human cells used, it was determined that EPCs respond better to atorvastatin than MSCs, and 
the best response was at 60μg/ml, which highlights the potential importance of EPCs in vascular repair, 
especially in the presence of atorvastatin. The data here also sheds light on the interplays that happen 
between cells types, further demonstrating the need of the creation of biomimetic systems to 
generate clinically relevant data, and also to clarify the roles of individual cells as well as cellular co-
cultures. It is also important to consider a wider array of atorvastatin doses to accurately determine 
the ideal dose to obtain optimal results but this also needs to be done in a 3D context as the 
experimental set-up here is not an accurate representation of physiological conditions. The absence of 
shear, for example, could greatly alter the responses seen. The data here, however, manages to scratch 
the surface, demonstrating that atorvastatin stimulates expression of CXCR4 in hMSCs and it also 
promotes EPC infiltration into sites of endothelial damage in a dose dependent manner. It was also 
possible to show that different cell combinations give rise to varying responses to atorvastatin. The 
experiments conducted and conclusions drawn could be taken further to gain a better understanding 
















5 Chapter 5:    
 Evaluating Atorvastatin’s 
Effect on Stem Cell Homing 







Maintenance of vascular integrity is a vital process in ensuring vascular health. The endothelium plays 
a major role in repair mechanisms and maintaining homeostasis, primarily due to its location between 
circulating blood and the underlying tissue (Sima, Stancu and Simionescu, 2009). In the context of 
atherosclerosis, vascular inflammation promotes the development of atherosclerosis and the 
deterioration of atherosclerotic plaques (Peng et al., 2018). This process takes place over several years 
and involves activation of the endothelium, recruitment of immune cells, migration and proliferation 
of smooth muscle cells among other processes (Ramji and Davies, 2015). Aside from endothelial 
activation, another key contributor is shear stress, specifically regions exposed to low (less than 
15dyne/cm2) oscillatory or turbulent shear, have been shown to be the most vulnerable to the 
development of atherosclerotic plaques (Bentzon et al., 2014), while regions that are exposed to 
laminar flow with shear rates at or higher than 15dyne/cm2 are protected (Cheng et al., 2006). These 
regions of irregular shear stress can be found at arterial bifurcations or the inner curvature of the 
coronary artery (Cheng et al., 2006). Endothelial cells are particularly sensitive to shear stress and it 
regulates numerous functions such as inflammation, proliferation, and migration. Low shear 
contributes to the development of atherosclerosis by inducing endothelial expression of inflammatory 
molecules that coordinate the migration of leukocytes from the blood to the vascular wall (Mahmoud 
et al., 2016). Another contributor to endothelial dysfunction and activation is the accumulation of 
oxLDL in the intimal layer, which in turn leads to local inflammation where ROS are overproduced (Gao 
et al., 2020).  
Statins function as competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-
CoA), the rate regulating step in cholesterol synthesis (Stancu and Sima, 2001; Peng et al., 2018; L. Xu 
et al., 2019). Aside from reducing levels of circulating LDL through inhibition of cholesterol synthesis, 
statins have been shown to possess a variety of pleiotropic effects. One proposed effect of statin 
treatment is enhancing the recruitment of haematopoietic cells to damaged endothelium to promote 




well as reducing scar hypertrophy, and promote osteogenic differentiation of MSCs (Gorabi et al., 
2020). Of interest to this project is the effect that statins have on the recruitment of circulating/ bone 
marrow derived endothelial progenitor cells (EPCs). The characteristics of these cells have been 
discussed previously in chapter 3, but briefly, statins, specifically atorvastatin, have been shown to 
increase circulating levels of these cells as well as promote their mobilization, differentiation, and 
improve their survival (Walter, Dimmeler and Zeiher, 2004; Sandhu, Mamas and Butler, 2017). 
Concerning this effect on EPC mobilisation to sites of vascular injury, a proposed mechanism involves 
the stromal derived factor-1 (SDF-1/CXCL12)/CXCR4 axis. SDF-1 is the only ligand that CXCR4 interacts 
with, and their interactions have been the focus of a lot of research due to their importance in the 
mobilization of EPCs and other  progenitor cells (Hristov et al., 2007), and also the observation that 
knockouts of either the receptor or its ligand results in a significant defects of colonization of 
embryonic bone marrow by haematopoietic stem cells and in the development of the heart, brain and 
large blood vessels (Ratajczak et al., 2006). The CXCR/SDF-1 axis has also been associated with 
numerous downstream molecules that are involved in the physiological and pathological changes in 
diseases such as vasculopathy, local inflammation, cell migration and proliferation, and increased 
levels have been associated with dyslipidaemia (Gao, Yu and Tang, 2019). High doses of HMG-CoA 
inhibitors have been associated with decreasing circulating SDF-1 levels under hyperlipidaemic 
conditions (Camnitz et al., 2012; Gao, Yu and Tang, 2019). This trend, however, appears to be the 
opposite in the absence of elevated lipid levels, with low dose statin (10nM to 100nM) resulting in 
increased EPC mobilisation and angiogenesis when used in combination with SDF-1, or with increased 
local over expression of SDF-1 (Yu and Feng, 2008). It has also been suggested that vascular SDF-
1/CXCR4 limits atherosclerosis through the maintenance of vascular integrity, preservation of 
endothelial barrier function, and normal contractile phenotype in smooth muscle cells (Döring et al., 
2017). Many of the studies that have identified these effects of statins are based on the use of animal 
models which bring about its own issues, such as relatability due to species variation and the 




Sashindranath et al., 2019). More recent approaches are attempting to use tissue engineering to create 
biomimetic vessels (Papaioannou et al., 2019; Evans, Iruela-Arispe and Zhao, 2021) to study various 
aspects of cardiovascular disease, which eases the burden on the need for animal models as well as 
allowing for more flexibility of experimental design.  
Using principles of tissue engineering, this chapter will focus on evaluating the role atorvastatin plays 
on the homing of human mesenchymal stem cells (hMSCs) and, primarily, EPCs to sites of vascular 
injury on three blood vessel modes, i.e., intimal layer only (TEIL), medial layer only (TEML) and a 
composite model incorporating both layers (TEBV). Specifically, this effect will be evaluated under 
dynamic flow in a customised parallel plate flow chamber as well as in a see-saw rocker. The effect of 
type of injury on the number of homing cells and the production of SDF-1 will also be evaluated for all 
these models. The proposed effect of atorvastatin is detailed in figure 5-1. The complementary 









5.2 Materials and methods 
5.1.1 HCASMC culture 
As described in section 2.1.1.1, Human cardiac artery smooth muscle cells (HCASMCs) were used in 
the assembly of the tissue engineered blood vessel (TEBV) and tissue engineered medial layer (TEML). 
These cells were cultured in medium 231 and supplemented with smooth muscle growth supplement 
(SMGS) as per the supplier specifications. The cells used were between P3 and P5. 
5.1.2 HUVEC culture 
As described in section 2.1.1.2, Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in 
medium 200 supplemented with low serum growth supplement (LSGS) as per the supplier 
recommendations. The cells used were between P2 and P5 for the creation of TEBV and tissue 
engineered intimal layer (TEIL).  
5.1.3 hMSC culture 
As described in section 2.1.1.5, human mesenchymal stem cells (hMSC) were cultured in DMEM 
(4.5g/L glucose) supplemented with 10% FBS, 1% AA and 1% LG. Cells used were between passage 3 
and 6 (P3 and P6).  
5.1.4 EPC culture 
Following the isolation protocol described in section 2.1.1.8, EPCs were cultured in medium 200 
supplemented with 10% FBS and 1% AA on fibronectin (2.5μg/cm2) coated plates. Cells used were 
cultured for up to 20 days after primary isolation.  
5.1.5 Electrospinning PLA nanofibers 
Aligned PLA nanofibers were used in the assembly of the TE constructs used here. Fibers were made 
by first dissolving Poly-L, D-lactic acid (96% L/4% D, inherent viscosity of 5.21 dL/g) (PLA) in chloroform 
for at least 8 hours, followed by addition of dimethylformamide (DMF) for a further 8 hours of mixing 
to make a 2% PLA solution. Chloroform and DMF were mixed in a 7:3 ratio respectively. The operational 




Ahearne, 2011; Njoroge et al., 2021). Briefly, the 2% PLA solution was deposited on detachable metal 
collectors, consisting of two partially insulated steel blades (30 cm × 10 cm). The steel blades were 
connected to a permanent copper plate with a steel wire, and had a 5 cm gap between for fiber 
deposition. Fiber deposition involved connecting the permanent copper plate to a negative electrode, 
and a syringe containing the 2% PLA solution was connected to a positive electrode. The PLA was 
extruded through an 18G needle and delivered at a rate of 0.025 mL/min. The electrodes were 
electrified with a power supply charged at ±6 kV (Spellman HV, Pulborough, 26 United Kingdom). 
Nanofibers were collected and attached onto pre-cut acetate frames. Before use in cell culture, aligned 
nanofibers were sterilized by UV irradiation thrice per side.  
5.1.6 Dynamic flow TE constructs 
5.1.6.1 TEML 
As described in section 2.1.8.1, the TEML was made by embedding HCASMCs in a collagen type I 
hydrogel. The HCASMCs were seeded into the collagen gel at a density of 5 x 105 cells/ml. 200µl of the 
cellular gel solution was pipetted into a hollow rectangle made of filter paper measuring 0.5cm x 2.4cm 
on the outside and 0.2cm x 2cm on the inside (figure 5-1). The dimensions of the filter paper were 
determined by the dimensions of the flow chamber and the gasket. The filter paper was placed on a 








Figure 5-1: Filter paper frame. 200µl of collagen gel containing HCASMCs at a density of 5 x 105 cells/ml was 
deposited into the hollow portion of the frame to create the medial layer of a blood vessel. After 10 days, the intimal 




The TEML was then placed in a humidified incubator set at 37°C and 5% CO2 for 30 minutes to permit 
it to set. After transfer to a 6 well plate, the TEML is cultured for at least 3-4 days in 3ml of smooth 
muscle supplemented media to allow the cells to elongate and proliferate. Media was changed every 
2 days.   
5.1.6.2 TEIL 
As described in section 2.1.8.2, TEIL was fabricated by first making a collagen gel using the protocol 
and dimensions previously described in section 2.1.7.1. After the collagen gel set, aligned PLA 
nanofibers coated in fibronectin were placed on the surface of the gel, followed by HUVECs seeding 
(2x105 cells/ml) on top to create a representation of the intimal layer. The construct was then 
incubated for at least 40 minutes at 37°C/5% CO2 to allow firm cell attachment. This was followed by 
sealing the fibres and cells onto the construct using acellular collagen. After gelation, the excess 
nanofibers were cut off from the construct using a sterile blade. TEIL was cultured in HUVEC media for 





As described in section 2.1.8.3, the TEBV is a composite of the TEML and TEIL. Assembly was carried 
out in stages; first was creation of TEML and culturing until cells adopt spindle shaped morphology, 
followed by nanofiber placement and HUVEC seeding. The complete TEBV was placed back into a new 
6 well plate and topped up with both HCASMC and HUVEC whole media in a ratio of 7:3 respectively. 
The complete TEBV schematic is shown in figure -2.  
5.1.7 TE constructs for see-saw rocker experiments 
In regards to assembly of these constructs, the protocol followed was the same as that described in 
sections 5.2.5.1 to 5.2.5.3, the only change made was in the shape of the constructs i.e., from 
rectangular (figure 1) to square but with the same surface area, with the square gels measuring 1.09 
cm2 on the outer edge of the frame and 0.66 cm2 on the inner edge. This change allowed the use of 
the constructs in a 24 well plate.  
 




Figure 5-2: Schematic of TEBV. This schema highlights the placement of cells and nanofibers in the assembly of the 




5.1.8 FeCl3 injury of TE constructs 
To mimic vascular injury, a FeCl3 lesion was created by dipping a 1mm2 (0.1cm2) square of filter paper 
in 10% FeCl3 and placing this onto the upper surface of the constructs for 1 minute, generating a lesion 
approximately 1.5-2 mm in diameter. After this, the constructs were washed with PBS to eliminate 
excess FeCl3, then topped up with fresh media.    
5.1.9 Mechanical injury of TE constructs 
A 1mm2 piece of filter paper was placed on the surface of the constructs for 1 minute then carefully 
peeled off the surface, generating a lesion with the same dimensions as the filter paper square. After 
removal of the filter paper square, constructs were washed once with PBS. 
5.1.10 Experimental settings for shear stress generation on TE constructs 
5.1.10.1 Parallel plate flow chamber 
5.1.10.1.1 Perfusion chamber 
To generate peristaltic flow and a range of shear stress values, a peristaltic pump (Watson-Marlow 505 
series, Fluid technology, UK) was used along with a commercially sourced parallel plate flow chamber 
(ProFlow Chamber, Warner Instruments, USA) (figure 5-3). The system is comprised of a top and 
bottom plate with view slots included. The view slots were designed to accommodate coverslips; 
15mm in top plate, 25mm in bottom plate. The top and bottom plate are combined to form a complete 
chamber using screws as detailed in figure 5-3. The chamber was originally designed for 2D perfusion 
but was modified for our purposes, allowing the incorporation of 3D TE models. Details of the 
modifications are explained later in this section. The perfusate was contained in a 7ml reservoir 
connected to the pump and flow chamber using polyethylene (PE-90) tubing. The flow chamber inlet 
was connected to the reservoir and the outlet to the pump. The set-up of this system can be seen in 
figure 5-3.  
5.1.10.1.2 Perfusion gaskets 
To facilitate the perfusion of our 3D vascular models, specialised gaskets were created. The dimensions 




5mm (0.5cm). The gasket was synthesised using PDMS, which was prepared by mixing Quantum 
Silicone (Qsil) polymer and cross-linker in a 10:1 ratio. 3ml of the solution is prepared in a small cell 
culture dish and left to set at room temperature overnight. Once the solution has set and the PDMS is 
firm to touch, acetate templates are used to cut out the gasket. First a circular ring with a diameter of 
30mm (3cm) is cut then a rectangular opening in the centre of the circle bearing the measurements 
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Figure 5-3: Perfusion chamber assembly. The sample is aligned along the flow path between the inlet and outlet on 
the bottom plate. The outlet, affixed with silicone grease to the top plate, is aligned in the same way and placed 
over the sample. The assembled chamber is connected to a reservoir and a peristaltic flow pump. The chamber, 
reservoir and pump could then be moved for real time observation of cell attachment using an inverted fluorescence 
dissection microscope.  
Positioning for viewing and imaging 




Assembly was accomplished by first installing the cover slips into the designated view slots using 
silicone grease. Once in place, the sample was placed on the bottom plate and aligned with the inlet 
and outlet. The custom PDMS gasket was affixed to the top plate with silicone grease after ensuring 
alignment with the inlet and outlet. The two halves of the chamber, with the gasket and sample in 
place, were put together ensuring the sample was positioned entirely within the gasket. Once this was 
accomplished, the screws are inserted and tightened to ensure the system was sealed and water-tight. 
The inlet and outlet were then connected to the tubing, that was in turn connected to the pump and 
reservoir. The complete and connected system was then positioned under the fluorescence dissection 
microscope for live imaging and flow is initiated.  
5.1.10.1.3 Shear stress calculation 
The assembled flow chamber was used to generate laminar flow as well as exerting shear stress on the 
intimal surface of the vascular models. The dimensions of the gasket used, which comprises and 
determines the dimensions of the flow chamber, were length: 25 mm (2.5 cm), width: 5 mm (0.5 cm) 
and depth/height: 3 mm (0.3 cm) when empty and 2.5 mm (0.25 cm) with a TE construct. The key 
dimensions that affect the shear stress profile are the depth and width of the chamber. The equation 





(Wong et al., 2016) 
The values required for the equation are; (1) the viscosity of the fluid being perfused (u), (2) the flow 
rate (Q), (3) the gasket width (b) and (4) height between the TE construct and the top plate of the 
chamber (h). The flow rate used for the perfusion of the constructs was 0.07 cm2/s. This value, using a 
viscosity value of 1.5 Cp (Jeevasankar et al., 2008), derived from estimations based on supplemented 
media perfused with suspended cells, is used to determine that the shear stress exerted on the 
construct surfaces is 20.16 dyne/cm2. Aside from being capable of generating a useful range of shear 




consistently generate a laminar flow profile with the modified gasket design.  
5.1.10.1.4 Flow pattern characterisation 
To determine the nature of the flow pattern within the perfusion chamber, fluorescein isothiocyanate 
I to visualise the flow pattern. This solution was diluted 1:50 in PBS. The chamber and pump were 
assembled as in figure 5-3. The reservoir was first filled with PBS, which was then pumped through the 
chamber. After this, the contents of the reservoir were removed and replaced with fluorescein. As the 
solution flowed into the chamber, it was possible to visualise fluid movement as the two liquids mixed. 
Video footage was recorded and still images isolated.  
5.1.10.2 See-saw rocker model 
The TE constructs were placed in a 48 well plate and topped up with 600 μL of perfusate (CFSE labelled 
EPCs suspended in media), then placed on a standard see-saw rocker set at 70 rpm for 1 hour at 7θ, 
generating a maximum shear stress of 2.2 dyne/cm2 (Zhou et al., 2010).   
5.1.10.3 Perfusate cell labelling 
Cells were stained with CFSE, a live cell tracker. This membrane stain was used at a concentration of 5 
μM. The cells to be stained were passaged and counted and re-suspended in 1m of fresh supplemented 
media. The stain was then added, and the cells incubated for 15 minutes at 37°C. The cell suspension 
was centrifuged for 3 minutes at 1200 rpm and the pellet re-suspended in 5 ml of fresh supplemented 
media. The cell suspension was left to sit for the final esterification step for 30 minutes at 37°C before 
use. Imaging was done using Leica inverted fluorescence microscope. Stained cells were used for both 
dynamic perfusion (perfusion chamber) as well as in the rocker perfused models. Staining aided with 
both visualisation and subsequent quantification with ImageJ by counting attached cells on whole 
construct surface.  
5.1.11 Atorvastatin dose 
Atorvastatin calcium trihydrate, as detailed in section 2.1.3, was dissolved in methanol to create a stock 
solution of 20 mg/ml. This was diluted further in media to a final concentration of 60 μg/ml. 




incubated for 1, 3, 5, 7, and 9 hours.  
5.1.12 SDF-1 quantification 
The reagents for the mini ABTS ELISA kit were reconstituted according to the manufacturer’s protocol. 
100μl of the capture antibody, diluted in PBS to a concentration of 2μg/ml, was added to the requisite 
number of wells, sealed, and incubated overnight at room temperature. The wells were then aspirated 
and washed 4 times with 300μl of wash buffer per well. The wash buffer is comprised of 0.05% Tween 
20 in PBS.  Next, 300μl of 1% BSA in PBS (block buffer) was added to the wells and incubated for at 
least 1 hour at room temperature. The block buffer was then aspirated, and the plate washed 4 times 
with the wash buffer. 100μl of sample solution (or standard) was added to each well and incubated at 
room temperature for at least 2 hours. The plate is then aspirated and washed 4 times. Next, the 
detection antibody, diluted in diluent (0.05% Tween 20 + 0.1% BSA) to a concentration of 0.5μg/ml. 
The plate was then incubated for at least 2 hours at room temperature. After this, the plate was again 
aspirated and washed 4 times. A 1:2000 dilution of Avidin-HRP conjugate was then added to the wells 
(100μl/well) and incubated for 30 minutes at room temperature. This was then followed by another 4 
washes, after which 100μl of ABTS liquid substrate was added per well. This was incubated at room 
temperature - with observation every 5 minutes for up to 1 hour - until colour development was 
observed. Once this was achieved, the plate was read using a plate reader set at 405nm.  
5.1.13 Immunostaining 
Samples for immunostaining were first blocked with 5% BSA for 1 hour at room temperature then 
aspiration of BSA. This was followed by addition of 1° antibody diluted 1:200 with PBS. Samples were 
incubated with 1° antibody for 2 hours at 37°C/5% CO2. After this incubation, samples were washed 
once with 0.05 Tween20 and 3 times with PBS. 2° antibody was diluted 1:400 with PBS, added to the 
sample and incubated for 1 hour at 37°C/5% CO2. Following this incubation, samples were washed 
twice with 0.05% Tween20and twice with PBS. Samples were then incubated for 10 minutes with 
10ng/ml DAPI, followed by a final three washes with PBS, followed by imaging. Secondary antibody 




with a sample without primary antibody incubation.  
5.3 Results  
5.1.14 Cell culture 
5.1.14.1 HUVEC morphology 
Cultured cells achieved expected cobblestone morphology and were successfully seeded onto the TE 




Figure 5-4: HUVEC morphology: 
This set of images show HUVECs 
in 2D culture imaged at (A) 4x 
and (B) 10x and (C) HUVECs 2 
hours after seeding on aligned 





5.1.14.2 HCASMC morphology 
Cultured cells attained expected spindle shaped morphology in both 2D and 3D culture. Cell 




Figure 5-5: HCASMC morphology. 
This set of images shows typical 
HCASMC morphology (A) in 2D 
culture (10x), (B) 3D culture 4 hours 
after seeding (20x) and (C) 3 days in 




5.1.15 Flow characterisation 
To determine the nature of the liquid flow within the perfusion chamber, the set up defined in section 
5.1.10.1.2 (figure 5-3), and the methodology described in section 5.1.10.1.4 were carried out to 
characterise the nature of the flow pattern through the parallel plate flow chamber. Representative 
images describing the flow pattern can be seen in figure 5-6.  
The fluorescein solution gives a strong green glow seen in figure 5-6 (a). The initial turbulent flow seen 
in figure 5-6 (b) and (c) stabilised as the solution moved through the chamber, adopting a more laminar 
profile. Flow seems to fill at the edges of the chamber before the centre as seen between (b) and (e) 




Figure 5-6: Flow pattern characterisation. Still images isolated from video footage showing (a) perfusion chamber 




5.1.16 Atorvastatin effect on cell homing: Dynamic flow with hMSCs 
To evaluate the extent of attachment onto a lesioned TEBV, hMSCs were perfused over FeCl3 lesioned 
TEBVs that were incubated either with or without 60μg/ml atorvastatin for 3 and 5 hours. FeCl3 was 
applied onto the surface of the construct for 1 minute using a 1mm2 piece of sterilised filter paper. 
CFSE labelled hMSCs were perfused at a density of 6 x 103 cells/ml, and subjected to a shear stress of 
20.16 dyne/cm2 for 45 minutes, followed by a 10-minute PBS wash to remove any cells not fully 
adhered to the surface of the construct. Images were taken at the end of perfusion; representative 
images are in figure 5-7. Attached cells were quantified and this is represented in figure 5-8.  
 
As can be seen in figure 5-7, the cell attachment is densest at the inlet and outlet ends of the 
constructs. This pattern follows the flow pattern observed in figure 5-6, where we can see more 
turbulent flow at the inlet and outlet ends of the flow chamber, with a more laminar flow profile in 
the centre of the chamber, where the lesion was placed. Closer examination of the 5 hours with 
atorvastatin sample shows attachment in the central regions of the construct, but majority of 
attachment in this region is localised to the edges of the construct and primarily at the inlet and outlet 
A 
Figure 5-7: hMSC perfusion over FeCl3 lesioned TEBV. Panel (i) denotes a 3-hour comparative (A) with atorvastatin 
and (B) without atorvastatin. Panel (ii) is a 5-hour comparative with (A) TEBV with atorvastatin and (B) without 















ends. Even though there is turbulent flow at the inlet and outlet end, density of attached cells is still 
varied between samples, with those treated with atorvastatin showing denser cell attachment at both 
the inlet and outlet at both 3 and 5 hours, and those treated for 5 hours having a denser accumulation 
of cells than those incubated for 3 hours.  
 






















The presence of atorvastatin has a positive impact on the recruitment of cells onto the surface of a 
lesioned TEBV as shown in figure 5-8. Longer incubation periods also result in higher numbers of cells 
attached to the endothelial surface of the TEBV.  
 
5.1.17 Atorvastatin effect on cell homing: Dynamic flow with EPCs 
To determine the effect of the individual layers of the blood vessel model, the TEIL, TEML and TEBV 
were assembled as detailed in section 5.2.5.1 to 5.2.5.3. Constructs were lesioned with FeCl3 and 
incubated with 60μg/ml atorvastatin for 3 and 5 hours. The extent of cell attachment on each model, 
with and without atorvastatin and after 3 and 5-hour incubations, was evaluated under pulsatile flow 
at 20.16 dyne/cm2. As with the hMSCs in the previous heading, EPCs at a density of 6 x 103 cells/ml-
Figure 5-8: hMSC attachment on FeCl3 lesioned TEBV. Plot denotes cell attachment following a 45-minute 
perfusion with hMSCs, at 20.16 dyne/cm2, over FeCl3 lesioned TEBV, incubated for 3 and 5-hours with and without 
atorvastatin. Statistical analysis was done using two-way ANOVA and significance was identified between time 




were labelled with CFSE then perfused over the constructs for 45 minutes, followed by a 10-minute 
PBS wash. The constructs were then removed from the perfusion chamber and imaged. Extent of cell 
attachment is detailed below per TE model.  
5.1.17.1 TEIL 
This model is comprised solely of endothelial cells seeded atop aligned PLA nanofibers. Representative 
images showing cell attachment are shown in figure 5-9 and image quantification is shown in figure 5-
10.  
  
The density of cells adhered to the lesioned surface is not as dramatic as that seen with the hMSCs, 
primarily as EPCs are smaller in size than the hMSCs. Distribution does appear denser on the 3 hours 
with atorvastatin sample, with cells distributed across the majority of the construct from the inlet to 











Figure 5-9: EPC attachment on FeCl3 lesioned TEIL. Panel (i) shows the 3-hour comparative with (A) being with atorvastatin 
and (B) without. Panel (ii) shows the 5- hour comparative with (A) with atorvastatin and (B) without. Green dots are attached 




cell attachment appears denser for the atorvastatin treated samples which follows the expected trend 
observed with hMSC perfusion over lesioned TEBVs.  
 




















Figure 5-10: EPC attachment on FeCl3 lesioned TEIL. This plot details the differences in cell attachment, following a 45-minute 
perfusion with EPCs at 20.16 dyne/cm2, on a FeCl3 lesioned TEIL after 3 and 5-hour incubations with and without 60μg/ml 
atorvastatin. One sample t-and-Wilcoxon test was carried out with significance identified for samples treated with 
atorvastatin, p= 0.0178 *. N=3.  
 
As with the hMSC attachment on a lesioned TEBV, atorvastatin appears to positively influence numbers 
of attached cells for this model as well, with higher cell counts recorded for both the 3 and 5-hour time 
points. Unlike the hMSC perfusion over the TEBV, it appears that maximum attachment here is attained 
after 3 hours, with lower cell counts observed at 5 hours both with and without atorvastatin, implying 
a supporting role for the smooth muscle cell layer in enhancing cell recruitment signals.  
5.1.17.2 TEML 
As detailed previously, this model is comprised solely of smooth muscle cells (HCASMCs) embedded in 
a collagen gel. Constructs were also lesioned with FeCl3 prior to perfusion with CFSE labelled EPCs (also 
at 6 x 103 cells/ml). Representative images are shown in figure 5-11 and image quantification is shown 






Images represented in figure 5-11 show cell attachment on the surface of lesioned constructs with and 
without atorvastatin. Samples treated with atorvastatin appear to have denser accumulation of 
attached cells, especially after 3 hours. Quantitation is required to clearly distinguish differences in cell 










Figure 5-11: EPC attachment on FeCl3 lesioned TEML. Panel (i) is a 3-hour comparative; (A) with atorvastatin and 
(B) without atorvastatin. Panel (ii) shows the 5-hour comparative (A) with atorvastatin and (B) without 























Figure 5-12: EPC attachment on FeCl3 lesioned TEML. This plot compares extent of EPC attachment, following a 45-minute 
perfusion at 20.16 dyne/cm2, on a FeCl3 lesioned TEML incubated for 3 and 5-hours both with and without atorvastatin. 
Statistical analysis was done using one sample t-and Wilcoxon test, and significance was identified for samples without 
atorvastatin, p = 0.0044 **. N=3.   
 
Once again it appears that atorvastatin has an impact on extent of cell attachment on lesioned blood 
vessel models. A comparative of figure 5-12 and figure 5-8 shows there is a similar trend in that time 
affects extent of cell attachment i.e., longer incubations result in more cells attaching to the surface of 
the construct. Interestingly for the TEML (figure 5-12), the significance determined between time 
points without atorvastatin, suggests that time has no notable impact on cells attaching on the surface 
of the TEML, while the inclusion of atorvastatin results in more cells attaching at both the 3 and 5-hour 





This model is a composite of smooth muscle cells seeded in a collagen gel with endothelial cells seeded 
above on aligned PLA nanofibers. As with the previous two models, CFSE labelled EPCs were perfused 
at a density of 6x 103 cells/ml for 45 minutes, followed by a 10-minute PBS wash. Representative 




The attachment pattern here appears localised from the middle of the construct towards the outlet 
end. The density of cells at the 5-hour timepoint without atorvastatin appears to be the lowest of the 
set, with a faintly appearing cluster of cells near the outlet end. Quantification of attachment 


















Figure 5-13: EPC attachment on FeCl3 lesioned TEBV. Panel (i) compares the 3-hour time points, with (A) being the 
atorvastatin treated construct while (B) is untreated. Panel (ii) compares the 5-hour time point (A) with atorvastatin and (B) 
























Figure 5-14: EPC attachment on FeCl3 lesioned TEBV. This plot shows variations in cell attachment after 3 and 5-hour 
incubations with and without atorvastatin followed, by perfusion of EPCs at 20.16 dyne/cm2. Statistical analysis used was 
two-way ANOVA and statistical significance was identified for the interaction between time, i.e., 3 and 5-hours, and the 
presence or absence of atorvastatin, p = 0.0432 *. N=3.  
 
At the 3-hour time point, atorvastatin does not increase cell attachment compared to the control 
whereas the numbers are much higher at the 5-hour time point with atorvastatin than without. 
Interestingly, the number of attached cells is lower at 5 hours than 3 hours without atorvastatin which 
reflects the trend observed with the TEIL. This suggests that atorvastatin has more of an effect on the 
medial layer than the intimal layer as the FeCl3 lesion burns through both layers of the model, exposing 
the smooth muscle cells. The trend observed here appears to be a blend of that seen in Figure 5-10 
and Figure 5-12 in that without atorvastatin, there is a reduction in attached cells between 3 and 5 
hours while there is an increase between 3 and 5 hours when atorvastatin is included, suggesting a 
synergistic effect between endothelial (HUVEC) and smooth muscle cells (HCASMC). Two-way ANOVA 



























































































Figure 5-15: Comparative between models. Plots comparing differences in cell attachment on FeCl3 lesioned TEIL, TEML and 
TEBV, following 45-minute perfusions with EPCs at 20.16 dyne/cm2, and after 3 and 5-hour incubations either with or without 
atorvastatin. Two-way ANOVA was used for statistical analysis. (a) statistical significance was identified between time points 
(p = 0.0189 *, *, *), and between groups i.e., between TEBV, TEIL and TEML (p = 0.0016 **), and also between incubations 
with and without atorvastatin (p = 0.0189 *). (b) Statistical significance was identified between models i.e., TEIL, TEBV and 
TEML, p = 0.0204 *. (c) Statistical significance was identified between atorvastatin treated and drug free samples, p = 0.0017 
**. For all plots, n=3.  
 
Across all the models, atorvastatin has a positive impact on increasing numbers of attached EPCs on 
the lesioned models. In general, the longer the samples are incubated with atorvastatin, the higher 
the number of attached cells. The TEBVs record the lowest cells counts between the models both with 




present. Without atorvastatin, the numbers of attached cells on the TEML have very little variation 
between time points while the TEILs demonstrate the highest attachment at 3 hours with a decrease 
in attachment after 5 hours both with and without atorvastatin suggesting that the medial layer is 
involved in increasing/sustaining cell attachment in the presence of atorvastatin with longer 
incubations. The trend denoting atorvastatin’s impact on cell attachment is more stable/consistent 
across models at the 5-hour time point, further suggesting that duration of incubation is a contributor 
to increasing factors responsible for either, or both, cell attachment and recruitment. The statistical 
analysis showed differences between TE models as well as with and without atorvastatin, suggesting 
an impact of cell type and atorvastatin on the responses seen.  
5.1.18 Atorvastatin effect on cell homing using two injury models: Rocker flow with EPCs  
Following the experiments carried out with the perfusion chamber, in an effort to increase data 
throughput, the mode of perfusion was changed from the use of a flow chamber to a rocker. For the 
rocker experimentation, factors kept consistent were cell density as well as mode of quantification of 
cell attachment. Aside from the reduction in shear forces exerted on the constructs, the duration of 
perfusion was also altered, from 45 minutes to 1 hour at 37°C/5% CO2. Oscillating/ see-saw motion 
rocker are designed to generate low shear stresses i.e., up to 2.2 dyne/cm2 (Tucker et al., 2014). Two 
modes of injury creation were also employed i.e., FeCl3 and mechanical injury detailed in section 5.2.7 
and 5.2.8 respectively. With this perfusion model, it was also possible to evaluate cell attachment over 
a wider range of atorvastatin incubation time points i.e., 1, 3, 5, 7 and 9 hours. The same cell density 











Quantitative measurements of cell attachment for the TEIL after mechanical and FeCl3 injury 
represented in figure 5-16. 
 





































Figure 5-16: EPC attachment on TEIL with different injuries. These plots display cell attachment over various time points, 
for FeCl3 or mechanically injured TEIL, incubated both with and without atorvastatin, and perfused with EPCs for 1 hour 
under a shear stress of 2.2 dyne/cm2. One sample t-and-Wilcoxon test was carried out on the data sets, with significance 
identified between atorvastatin dosed and drug free samples for both mechanical (p = 0.0023 ** and 0.0011 ** for with and 
without atorvastatin respectively) and FeCl3 injury (p < 0.0001 **** and 0.0002 *** for with and without atorvastatin 
respectively). N=3.  
 
Figure 5-16 suggests the type of injury impacts the trend of cell attachment both with and without 
atorvastatin. With a mechanical injury, cell attachment with atorvastatin peaks sooner than without 
atorvastatin after which a decline is observed over time. Without atorvastatin, the peak is reached at 
5 hours versus 1 hour with. The number of attached cells, however, drops after this time point as is 
observed with atorvastatin. A comparative with the same model in figure 5-9 shows the same trend 
at the 3 and 5-hour time points i.e., a decrease in attached cells at 5 hours both with and without 
atorvastatin. The mode of injury appears to impact density of attached cells as well with FeCl3 injury 
having more cells counted on the construct surface than mechanical injury. This mode of injury also 
appears to trigger increasing cell attachment for a longer time frame before a decline is observed. 




of atorvastatin results in more cells attaching. For the mechanical injury, cell attachment peaks earlier 
(at the 1h time point), followed by a steady decline over time with atorvastatin, while the trend 
appears to be an interchange of increasing and decreasing cell attachment without atorvastatin, with 
peak attachment being observed after 5 hours. No statistical significance was found for these data.  
5.1.18.2 TEML 
Quantitative measurements of cell attachment for the TEML are represented in figure 5-17. 








































Figure 5-17: EPC attachment on TEML with different injuries. These plots display cell attachment over various time points, 
for FeCl3 or mechanically injured TEML, incubated both with and without atorvastatin, and perfused with EPCs for 1 hour 
under a shear stress of 2.2 dyne/cm2. One sample t-and-Wilcoxon test was carried out on the data sets, with significance 
identified between atorvastatin dosed and drug free samples for both mechanical (p = 0.0018 ** and 0.0001 ***, for with 
and without atorvastatin respectively) and FeCl3 injury (p = 0.0010 ** and 0.0002 ***, for with and without atorvastatin 
respectively). Two-way ANOVA was also carried out and significance was identified for the interaction of time, and presence 
or absence of atorvastatin for both the mechanically (p = 0.0106 *) and FeCl3 injured samples (p = 0.0354 *). N=3 
 
Here, the type of injury appears to have a significant effect on cell attachment with and without 
atorvastatin. With a mechanical injury, atorvastatin treated samples show higher cell attachment at 
the earliest time point with a steady decline until the 7-hour time point while untreated samples show 
a gradual rise to the same time point, followed by a drop in the number of attached cells. With FeCl3, 
both treated and untreated samples show the same trend i.e., a rise in attachment followed by a 
decline with the treated samples having higher cell counts. Inversely, the more severe injury (FeCl3) 
shows fewer cells attached overall than the mechanically injured one, an observation opposite to the 




increase in cell attachment between 3 and 5 hours, a similar trend to the atorvastatin free samples, 
whereas in the perfused samples, there was little difference between 3 and 5 hours for the drug free 
controls. This “steady state” between 3 and 5 hours is observed for the atorvastatin treated samples 
with a mechanical injury. As with previous data, the presence of atorvastatin, overall, has a positive 
impact on increasing numbers of attached cells. Two-way ANOVA was used for this data set with 
significance determined for the interaction of evaluated variables.  
5.1.18.3 TEBV 
Quantitative measurements of cell attachment for the TEML are represented in figure 5-18. 







































Figure 5-18: EPC attachment on TEBV with different injuries. These plots display cell attachment over various time points, 
for FeCl3 or mechanically injured TEBV, incubated both with and without atorvastatin, and perfused with EPCs for 1 hour 
under a shear stress of 2.2 dyne/cm2. One sample t-and-Wilcoxon test was carried out on the data sets, with significance 
identified between atorvastatin dosed and drug free samples for both mechanical (p = 0.0032 ** and < 0.0001 ****, for with 
and without atorvastatin respectively) and FeCl3 injury (p = 0.0018 ** and < 0.0001 ****, for with and without atorvastatin 
respectively). N=3.  
 
With the mechanical injury, the atorvastatin treated samples show peak cell attachment after 3 hours, 
after which there is a decline while the untreated samples appear to reach peak attachment after 1 
hour followed by a steady decline but overall, with higher numbers of attached cells than the 
atorvastatin treated samples from 5 to 9 hours. With the FeCl3 injury, the trend with atorvastatin 
treatment matches that observed for this model under dynamic flow i.e., peak attachment is reached 




cell count at 3 hours and a decline at 5 hours with atorvastatin and a higher count at 3 hours than 5 
hours without atorvastatin. However, at 7 hours, another rise is noted in the atorvastatin free samples, 
and appears to be maintained to the 9-hour time point whereas a sharp decline is observed at the 
same time points with the inclusion of atorvastatin. Regarding injury type, the trend here of overall 
cell attachment is the same as with the TEIL, in that the more aggressive injury (FeCl3) results in a 
higher density of attached cells.    
5.1.18.4 Comparative of rocker experimental conditions on cell homing 
To evaluate if there were significant or observable differences between injury types, a comparative 
was done to evaluate extent of EPC homing between TE construct types across time points, both with 

























































Figure 5-19: Model comparative. These plots compare EPC attachment on TEML, TEBV and TEIL, as well as comparing effect 
of atorvastatin on cell attachment, both compared across time points. These plots display cell attachment over various time 
points, for FeCl3 or mechanically injured TEML, TEBV and TEIL, incubated both with and without atorvastatin, and perfused 
with EPCs for 1 hour under a shear stress of 2.2 dyne/cm2. One sample t-and-Wilcoxon test was carried out on the data sets, 
with significance identified for each model, for both mechanical (p = 0.0018 **,   0.0001 ***, 0.0032 **, <0.0001 ****, 0.0023 
**, and 0.011 **) and FeCl3 injury (p = 0.0002 ***,   0.0010 **, 0.0018 **, <0.0001 ****, <0.0001 **, and 0.0002 **. Two-
way ANOVA was also carried out for these data sets, with significance found for the interaction between time and the 





Across the 3 different models, the biggest effect atorvastatin has on cell attachment appears to be 
regarding time taken to attain peak attachment. Samples treated with atorvastatin mainly attain peak 
attachment faster than untreated ones. A bigger effect is the type of injury on cellular responses. More 
aggressive injuries appear to affect the intimal layer response more than the medial layer where a 
stronger response was observed with the less aggressive injury.  With both the FeCl3 and mechanical 
injuries, the TEBV data appears to be a compounding of the TEML and TEIL responses, appearing as 
almost an average response between the two “half” models. With the FeCl3 injury, cell attachment 
appears to follow TEBV > TEIL > TEML, suggesting that endothelial cells are more sensitive to FeCl3 than 
the smooth muscle cells. On the other hand, a mechanical injury seems to favour attachment on the 
TEML, and very similar attachment profiles for the TEIL and TEBV, following the trend TEML > TEBV ≥ 
TEIL. The data shown in figure 5-19 also suggests that with a moderate injury, the absence of 
atorvastatin generally appears to generate a better homing response, whereas the more aggressive, 
oxidation based FeCl3 injury appears to favour the inclusion of atorvastatin to increase/improve cell 
homing. It also appears that the optimal time frame to achieve maximum cell attachment is between 
3 and 5 hours for both mechanical and FeCl3 injuries. Two-way ANOVA was used to analyse the data 
sets presented in figure 5-19, denoting significance in attachment between the TE models. 
5.1.18.5 Comparison of dynamic versus rocker flow on EPC homing 
To determine if there were significant differences between mode of perfusion, the common time 
points between dynamic perfusion and rocker perfusion, with FeCl3 injury, were compared. Results are 























































































































































Figure 5-20: Comparative of 3 and 5-hour time points with FeCl3 injury under perfused or see-saw rocker flow. These plots 
display cell attachment at 3 and 5-hours, following perfusion of EPC using either a parallel plate flow chamber, with shear 
stress of 20.16 dyne/cm2, or see-saw rocker with shear stress of 2.2 dyne/cm2 for 45-minutes and 1-hour respectively. Both 
types of perfusion were done over FeCl3 injured TEBV, incubated both with and without atorvastatin. One sample t-and-
Wilcoxon test was carried out on the data sets, with significance identified for each mode of perfusion (parallel plate versus 
see-saw rocker) per model, i.e., 20.16 dyne/cm2 (p = 0.0027 ** (TEIL), 0.0052 ** (TEML) and 0.0273 * (TEBV)) and 2.2 
dyne/cm2 (p <0.0001 **** (TEIL), = 0.0012 ** (TEML), and = 0.0008 *** (TEBV)). Additional significance was identified using 
two-way ANOVA for the TEBV comparative plot, with significance identified between time points, both with and without 
atorvastatin (p = 0.0310). N = 3.  
 
The plots in figure 5-20 show that the observed trend i.e., cell attachment is increased with longer 
incubation and in the presence of atorvastatin, is not altered with different modes of perfusion. At the 
common time points i.e., 3 and 5 hours, samples perfused in the parallel plate flow chamber and those 




the rocker flow samples generally have more cells attached on the construct surfaces than those under 
dynamic flow, with the largest variation in cell attachment observed in the TEBV samples where the 
rocker samples have significantly higher attachment. The data represented here suggests that 1) for 
the TEIL, the stronger contributor to cell attachment is the presence of atorvastatin, 2) for the TEML, 
incubation time and presence of atorvastatin both affect cell attachment and 3) for the TEBV, 
atorvastatin has a stronger effect with longer incubation, once again suggesting a synergistic interplay 
between the medial and intimal layers. No statistical significance was found between dynamic and 
rocker flow for any of the models. 
 
5.1.19 Atorvastatin effect on SDF-1 production 
To determine atorvastatin’s effect on the primary cytokine that’s associated with recruitment of cells 
to sites of vascular injuries, an evaluation of the production of SDF-1 was carried out. This was carried 
out for each of the models i.e., TEIL, TEML and TEBV and graphs are represented in figure 5-21 to figure 
5-23. Readings were taken for media collected at the following time points 10 minutes, 1 hour, 3 hours, 
5 hours, 7 hours, and 9 hours. Samples evaluated were lesioned with FeCl3 or mechanically, and with 

















































Figure 5-21: Effect of injury type and atorvastatin on SDF-1 production on TEIL. These plots display SDF-1 production over 
time on TEILs lesioned either mechanically or with FeCl3, and then incubated with or without atorvastatin for the stipulated 
time points. One sample t-and-Wilcoxon test was carried out on the data sets, with significance identified for samples with 
or without atorvastatin, for both injury types i.e., mechanical (p <0.0001 **** (With atorvastatin), and <0.0001 **** (without 
atorvastatin) and FeCl3 lesion (p = 0.0006 *** (with atorvastatin), and 0.0001 *** (without atorvastatin). Additional 
significance was identified using two-way ANOVA, with significance identified between time points, both with and without 
atorvastatin for Mechanical (p <0.0001 ****) and FeCl3 injury (p <0.0001****). N = 9.  
 
 
The most observable effect of injury type on SDF-1 production is the stability/consistency of its 
production, with the mechanical injury showing a more stable trend than the FeCl3 injury. Another 
difference is in the amounts of SDF-1 produced where the FeCl3 injury samples show much higher 
concentrations of SDF-1 across all time points. With both treated and untreated samples with FeCl3 
injury, initial peak production is followed by a gradual decline over time, with atorvastatin treated 
samples showing higher production. With mechanical lesion, the trend is the same for both treated 





















































Figure 5-22: Effect of injury and atorvastatin on SDF-1 production on TEML. These plots display SDF-1 production over time 
on TEMLs lesioned either mechanically or with FeCl3, and then incubated with or without atorvastatin for the stipulated time 
points. One sample t-and-Wilcoxon test was carried out on the data sets, with significance identified for samples with or 
without atorvastatin, for both injury types i.e., mechanical (p <0.0001 **** (With atorvastatin), and = 0.0001 *** (without 
atorvastatin) and FeCl3 lesion (p = 0.0015 ** (with atorvastatin), and 0.0208 * (without atorvastatin). Additional significance 
was identified using two-way ANOVA, with significance identified between time points, both with and without atorvastatin 
for Mechanical (p = 0.0087 **) and FeCl3 injury (p <0.0001 ****). N = 9. 
 
As with the TEIL, FeCl3 injury elicits an erratic response with fluctuations in production over time both 
with and without atorvastatin, and higher SDF-1 production over time. Samples without atorvastatin 
showed peak production after 10 minutes, generating the highest reading overall for FeCl3 injury, with 
another rise at 3 hours followed by a decline, while treated samples peaked at 1 hour with another 
rise at 5 hours. With the mechanical injury, the trend is, again, similar to that of the TEIL in its 
consistency, but varies in that after initial peak production, levels of SDF-1 dropped after an hour 
followed by semi stable/consistent production over time. Again, as with the TEIL, treated samples 
























































Figure 5-23: Effect of injury and atorvastatin on SDF-1 production on TEBV. These plots display SDF-1 production over time 
on TEBVs lesioned either mechanically or with FeCl3, and then incubated with or without atorvastatin for the stipulated time 
points. One sample t-and-Wilcoxon test was carried out on the data sets, with significance identified for samples with or 
without atorvastatin, for both injury types i.e., mechanical (p <0.0001 **** (With atorvastatin), and <0.0001 **** (without 
atorvastatin) and FeCl3 lesion (p = 0.0010 ** (with atorvastatin), and 0.0163 * (without atorvastatin). Additional significance 
was identified using two-way ANOVA, with significance identified between time points, both with and without atorvastatin 
for Mechanical (p <0.0001 ****) and FeCl3 injury (p <0.0001 ****). N = 9. 
 
For this model, the biggest effect of injury type is seen in atorvastatin free samples with FeCl3 injury. 
The highest production is seen after an hour followed by a sharp decline over time. The atorvastatin 
treated samples have peak production at the 5-hour time point, followed by a steep decline. As with 
the other models, the FeCl3 lesioned samples show higher production of SDF-1 compared to the 
mechanically injured samples. For this model, the trend observed with the FeCl3 lesion is consistent 
compared to the TEIL and TEML which showed peaks and drops across the time points. As with the 
other models, the presence of atorvastatin has a strong effect on the production of SDF-1, with 
consistently higher readings across most time points. Across all models, the mechanical injury triggers 
production of a roughly similar range of amounts of SDF-1, which are collectively lower than those 
with FeCl3 injury. The consistency of the trend with both mechanical and FeCl3 injury suggests that 
maintenance of SDF-1 is a concert effort between the medial and intimal layers, and that atorvastatin 






To determine if the primary receptor for SDF-1 is also affected by atorvastatin, immunostaining was 
done for CXCR4. 1° antibody was used at 1:200 dilution and 2° antibody at 1:400. Staining was done 
for TEBV, TEIL and TEML respectively, and representative images are shown in figure 5-24 to 5-26. E-
selectin expression was also evaluated for TEIL, TEBV and TEML lesioned with FeCl3. Images shown in 
figure 5-27. All images taken were only of the rocker perfused samples. Secondary antibody negative 



























1 Hour 9 Hours 
With Atorvastatin Without Atorvastatin With Atorvastatin 
Figure 5-24: TEBV CXCR4 staining. Images were taken for the 1 and 9-hour time points comparing different lesions and the presence of atorvastatin on the expression of CXCR4. Images 




The images shown in figure 5-24 suggest that atorvastatin reduces expression of CXCR4 with FeCl3 injury. A comparative of time points for this injury type 
shows a general reduction in expression over time both with and without atorvastatin, with even low expression observed after 9 hours with atorvastatin. 
Expression with mechanical injury appears to be the same at the 1-hour time point both with and without atorvastatin, however, at 9 hours the atorvastatin 
treated sample displays lower levels of CXCR4 expression.  
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Without Atorvastatin With Atorvastatin Without Atorvastatin With Atorvastatin 
Figure 5-25: TEIL CXCR4 staining. Images were taken for the 1 and 9-hour time points comparing different lesions and the presence of atorvastatin on the expression of CXCR4. Images taken 





Figure 5-25 suggests that atorvastatin inclusion, with FeCl3 lesion, results in more CXCR4 expression at both the 1 and 9-hour time points and as with the TEBV, 
expression appears to reduce at the 9-hour time point both with and without atorvastatin. For the mechanically lesioned samples, the trend is similar to that 
observed with the TEBV in that there is less expression of CXCR4 with atorvastatin at both time points.  
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For the TEML, expression of CXCR4 appears similar to both with and without atorvastatin at the 1-
hour time point in that there does not seem significant difference between the two groups. There 
does appear to be a reduction after 9 hours with the atorvastatin treated samples appearing to have 
slightly lower expression than the atorvastatin free sample.  
5.1.20.4 E-Selectin 
Expression of this receptor was evaluated only for FeCl3 lesioned samples treated with atorvastatin. 
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Figure 5-27: E-selectin expression in atorvastatin treated FeCl3 lesioned TEBV, TEIL and TEML. Images are taken at the 




The images shown here confirm the expression of E-selectin across the models, with fairly 
consistent expression across all time points imaged, and may contribute to the attachment of cells 
onto the TE surfaces.  
 
Figure 5-28 shows the negative antibody controls for the 1° antibodies used here. For E-selectin, as it 
is a fluorophore conjugated antibody, the antibody was added to cells that were known not to express 
E-selectin i.e., un-lesioned TEBVs not used for experimentation.   
(a) (b) 
Figure 5-28: secondary antibody negative control. (a) E-selectin Alexa Fluor® 488-conjugated negative control 





Maintenance of vascular integrity is a vital process in maintaining vascular health. When an injury 
occurs on the endothelial layer, either by mechanical removal of the endothelium or inflammatory 
activation of the endothelium, it induces a cascade of proinflammatory events which result in the 
infiltration of monocytic cells and the proliferation of smooth muscle cells (Dimmeler and Zeiher, 
2004). The proinflammatory events can lead to the development of atherosclerotic lesions, plaque 
rupture and cardiac infarctions. To reduce the likelihood of occurrence of these deleterious events, 
there are both endogenous i.e., resident endothelial cell based and exogenous i.e., circulating 
stem/progenitor cell based reparative mechanisms, which come together to reverse vascular damage 
and reinstate endothelial barrier function. They achieve this through regeneration of a functional 
endothelium and re-engagement of endothelial junctions (Evans, Iruela-Arispe and Zhao, 2021). 
Regarding the recruitment of circulating progenitor cells to sites of injury, the data presented here 
demonstrates that upon injury, the introduction of progenitor cells i.e., MSCs and EPCs, under 
physiologically relevant shear stress (20.16 dyne/cm2), results in their attachment onto the lesioned 
surface of the vessel constructs evaluated. Beginning with perfusion of human MSCs (hMSCs), this 
effect appears to be both time dependent as well as affected by atorvastatin. The hMSCs used here 
(figure 5-7 and 5-8), can be defined as such due to the demonstration of their capacity to differentiate 
into other cell types i.e., adipocytes, osteocytes, and chondrocytes, represented in the previous 
chapter (figure 4-7 to 4-9). Homing of MSCs is defined as the arrest of MSCs within the vasculature 
of a tissue followed by the transmigration across the endothelium (Karp and Leng Teo, 2009) or  as 
the ability of stem cells, either in circulation or exogenously introduced, to locate and enter an 
environmental niche (Liesveld, Sharma and Aljitawi, 2020). Here, it was possible to specifically 
demonstrate arrest and localisation of hMSCs to vascular injury. It was also possible to demonstrate 
an increase in the number of attached cells in the presence of atorvastatin. A number of studies have 
demonstrated the positive effect atorvastatin has on increasing survival of MSCs after transplantation 




et al., 2014). Simvastatin has also been shown to have a beneficial effect on MSC and CD133+/CD34+ 
endothelial precursor chemoattraction and migration to injured areas, specifically lung and spinal 
injury, suggesting its effectiveness in attracting cells from the bone marrow to injured areas. The 
increased migratory capacity was also demonstrated in trans-well and Matrigel based migration 
assays (Gorabi et al., 2020). It is also interesting to note that the effect of shear is that samples 
subjected to higher shear values showed lower cell attachment than those exposed to low shear 
stress (figure 5-20), an observation supported by previously published works (Truskey and Pirone, 
1990; Maan, Menon and Pullarkat, 2017; Jötten et al., 2019). The expression of E-selectin shown on 
the constructs used here (figure 5-27), shows that the TE constructs created were able to produce a 
receptor that aids in arrest of circulating lymphocytes and progenitor cells (Milstone et al., 2000; Liu 
et al., 2016). It was also possible to demonstrate E-selectin expression in smooth muscle cells, which 
has primarily only been reported in endothelial cells (Chen et al., 1997), suggesting atorvastatin may 
have an effect on smooth muscle E-selectin expression.  
The observation of increased attachment of hMSCs on the TEBV was also noted for EPCs and was 
consistent for all models in that, generally, more cells were counted with atorvastatin and with 
increased culture time. This same trend was noted when a different mode of perfusion was applied 
i.e., rocker motion (figure 5-16 to 5-20). For this set of figures, the other contributing factor is the 
type of injury used on the different models. The mechanical injury was less aggressive in that it 
involved the localised removal of a layer of cells, similar to the type of injury created by percutaneous 
transluminal coronary angioplasty (PTCA/balloon injury). FeCl3 is widely used in vascular thrombosis 
models to trigger platelet activation and aggregation, and it works by creating reactive oxygen species 
(ROS) that trigger endothelial damage (Li, Nieman and Sen Gupta, 2016). The data presented here 
(figure 5-19) suggests that the FeCl3 induced injury has more of an effect on the endothelial layer 
than the medial layer as the models that include an endothelial layer i.e., TEIL and TEBV, show higher 
density of attached cells with this mode of injury compared to mechanical injury. This figure also 




attachment profiles consistently appear to be a merge of the observations on the TEML and TEIL, and 
additionally implies that oxidative damage has more of an effect on endothelial cells than smooth 
muscle cells. Additionally, the production of SDF-1 is significantly increased following FeCl3 injury 
(figure 5-21 to 5-23) compared to mechanical injury. Oxidative stress is a key contributor to the 
development of cardiovascular disease (Sugiyama et al., 2005), and has been defined as the 
imbalance between the synthesis of ROS and their elimination by antioxidant defence systems (Costa 
et al., 2016). FeCl3 induced oxidation can be a result of the Fenton reaction, which leads to the 
generation of hydroxyl radicals and lipid peroxidation (Woollard et al., 2009). It can also oxidatively 
modify LDL, leading to vascular injury, and it can also form ferric oxide aggregates on the surface of 
the vascular lumen (Woollard et al., 2009). Given its mode of action, FeCl3 injury is more 
representative of the state of vasculature in atherosclerosis. A number of studies have highlighted 
the importance of ROS production in cellular signalling, e.g., in angiogenesis, in response to growth 
factors and other signals (Pi et al., 2014; Prieto-Bermejo et al., 2018). Low levels of ROS have been 
associated with contributing to maintaining pluripotency of adult stem cells while higher levels would 
commit them to a restricted lineage, a mechanism linked to the SDF-1/CXCR4 axis (Prieto-Bermejo et 
al., 2018). Wollard et. al., (2009) demonstrated that extent of oxidative damage with FeCl3 is reduced 
in the absence of blood (Woollard et al., 2009), which would support the theory that the extent of 
oxidative damage done on the vascular models here generated sufficient oxidation to promote SDF-
1 production, as was observed in figure 5-21 to 5-23, which was consistently and significantly higher 
in the FeCl3 lesioned samples compared to the mechanical injury samples. This increase in SDF-1 
could also potentially explain the higher attachment numbers observed with FeCl3 injured models. 
Atorvastatin has also been shown to positively impact the migration of adipocyte derived stem cells 
and this has been linked to increased SDF-1 production (Cai et al., 2013). Atorvastatin has also been 
associated with increasing mitochondrial ROS (Bouitbir et al., 2016), which would also contribute to 




Moving to the expression profiles observed for CXCR4, the primary receptor for SDF-1 (Ratajczak et 
al., 2006; Sainz and Sata, 2007; Dimova et al., 2019), its expression also appears to be affected by the 
mode of injury used, most notably with the TEBV (figure 5-24), in that the mechanically lesioned 
samples appear to have stronger expression of CXCR4 compared to the FeCl3 lesioned samples at the 
selected time points. The expression of this receptor is also affected by atorvastatin and it also 
appears to be time dependent as expression appears lower in the 9-hour samples compared to the 
1-hour samples, an observation that is reflected across all models (figure 5-24 to 5-26). This may not 
actively contribute to the homing of perfused EPCs as this was localised on the lesioned TE constructs, 
whereas CXCR4 on circulating EPCs would be more significant in recruiting them to the injured tissues 
(Ratajczak et al., 2006; Hristov et al., 2007; Dimova et al., 2019). The expression of E-selectin has also 
been reported to be affected by SDF-1 (Liu et al., 2016), so it is possible that the arrest of cells is due 
to this but further characterization is required to draw this conclusion. Because this receptor ligand 
pair are also associated with angiogenesis, it is possible that the expression on tissue locked cells 
serves to maintain vascular integrity, as noted by Döring et al. 2017, following injury and its 
expression reduces over time as cells are recruited to the lesioned surface of the constructs. 
Specifically, for the TEBV and TEIL, the less severe injury also displayed generally fewer cells attaching 
onto the surface, which might require more involvement of resident cells for repair function. Döring 
et al. 2017 also observed that endothelial CXCR4 deficiency resulted in arterial leakage and 
inflammatory leukocyte recruitment during atherogenesis (Döring et al., 2017). The restricted 
expression observed with FeCl3 could be associated with the levels of SDF-1 at the imaged time points 
in that higher levels of SDF-1 restrict expression of CXCR4  (Molino et al., 2000), possibly through 
triggering internalisation of CXCR4 as SDF-1 binding to CXCR4 results in internalisation of CXCR4 
(Förster et al., 1998; Hattermann et al., 2014), and possibly because expression of CXCR4 is 
heterogenous, with some endothelial cells expressing it and others not (Molino et al., 2000). The 
expression variation between time points supports this observation, and suggests that the initial 




reached an ideal that ends up binding all available CXCR4, resulting in reduced expression over time 
duue to maximum internalisation. Estimating from the graphs detailing SDF-1 production over time, 






Through the experiments carried out in this chapter, it was possible to demonstrate that atorvastatin 
has a positive effect on homing of circulating EPCs and hMSCs. It was interesting to note that this 
effect is both time and injury dependent, with generally higher numbers of attached cells recorded 
with longer incubations with atorvastatin, specifically more than 3 hours, and with the more 
aggressive FeCl3 injury. The possibility of generating partial and composite blood vessel models 
allowed the demonstration of a synergistic effect between the intimal and medial layers of the 
vasculature, with mode of injury, specifically FeCl3 induced oxidative damage, having a stronger effect 
on endothelial cells. This injury model also suggests that cellular responses to atorvastatin are 
improved in the context of oxidative damage. By adjusting the sizes of the TE constructs used, it was 
possible to increase throughput, and evaluate the effect of shear stress on cell homing to sites of 
vascular injury. With the two types of perfusion, it was possible to demonstrate the trends observed 
in terms of cell attachment between 3 and 5-hour incubations with the lesion were maintained, with 
the primary difference being the number of cells attached due to the variation in shear. The models 
used here not only allowed real time visualisation of cell rolling and attachment, but they also allowed 
relative quantification of this phenomenon on a time-point basis. It was also possible to further 
analyse the perfusate to categorise key cytokine production and track production over time. The 
production of SDF-1 and expression of CXCR4 were also shown to be affected by atorvastatin, 
incubation duration, and the mode of injury. These two factors complement each other, and this is 
more observable in the TEBV group. The FeCl3 injured group shows high SDF-1 production compared 
to the mechanical injury one, and both produce greater amounts of SDF-1 in the presence of 
atorvastatin than the drug free group (figure 5-23). Whilst CXCR4 expression is lower in FeCl3 lesioned 
group with atorvastatin, and with nearly zero expression at the 9-hour time point (Figure 5-24), this 
indicates that the CXCR4 receptors on the cells of TEBV are neutralized or internalized by the high 
concentrations of SDF-1 in their immediate surroundings, and with longer culture time, the more 




It should be possible to quantify a wider array of cytokines and thus characterise the biochemical 
interplay involved in the process of cell homing and vascular repair, and the impact of atorvastatin 
on these parameters. These models have also shown to be more versatile than the classic animal 
model, allowing the comparison and quantification of an array of variables. They have also shown 
their usefulness as a potential drug screening tool, with the possibility of evaluating a selection of 














6 Chapter 6:    








One of the main drivers of atherosclerosis is lipoprotein irregularities that result in plaque formation 
at vulnerable sites in the arterial tree. Plaque formation involves a variety of processes such as 
lipoprotein retention, inflammatory cell recruitment, foam cell formation, apoptosis, necrosis, SMC 
proliferation and matrix synthesis, calcification, angiogenesis, arterial remodelling and thrombosis 
(Bentzon et al., 2014).  One of the key cellular drivers of this process is the macrophage. In response 
to a steady accumulation of lipids and other inducers such as dysfunctional endothelial cells secreting 
cytokines and expressing adhesion molecules, monocytes are  recruited from circulation and 
surrounding tissue (Bentzon et al., 2014). The recruited monocytes infiltrate the sub-endothelial 
space, differentiating into macrophages and dendritic cell like phenotypes (H. Xu et al., 2019). One of 
the receptors that facilitate macrophage infiltration into the sub-endothelial space is CD146. 
Expression of CD146 is found on a wide variety of cells within the vascular tree such as endothelial 
and smooth muscle cells, and recent findings have identified CD146 transcripts and proteins in 
atherosclerotic plaque biopsies (Blin et al., 2019; Leroyer et al., 2019). Increased expression of this 
receptor has been associated with several inflammatory diseases associated with endothelial lesion, 
and it has also been associated with the early stages of lymphocyte rolling on the endothelium (Blin 
et al., 2019), as well as controlling the formation of foam cells (Luo et al., 2017). The presence of 
oxidised LDL (oxLDL) has been demonstrated to increase expression of CD146 and it has been 
suggested that CD146 traps/ encourages retention of macrophages within the arterial wall (Leroyer 
et al., 2019; Luo et al., 2017).  
Once the macrophages are exposed to atherogenic lipoproteins, they become foam cells. The primary 
contributing factor in foam cell formation is the excessive influx of modified LDL, such as oxLDL, and 
the accumulation of cholesterol esters within the macrophages. The foam cells then aggregate and 
proliferate leading to plaque progression by inducing a cascade of inflammatory responses that 
enhance lipoprotein retention, extracellular matrix modification and sustained chronic inflammation. 




cholesterol crystals and cell debris (Xu et al., 2019; Collot-Teixeira et al., 2007; Bobryshev, 2006). 
Cellular studies carried out to evaluate foam cell formation and behaviour will typically use stimulants 
to push macrophages to an inflammatory phenotype. Briefly, macrophages can have one of two 
defined phenotypes, namely M1 or pro-inflammatory and M2 or ani-inflammatory. Within this 
general definition, factors that affect their phenotype are dependent on recruiting signals and the 
macrophage location, resulting in a spectrum of activation between M1 and M2 (Murray et al., 2014; 
Bashir et al., 2016). Foam cells tend to fall under M1 macrophages as they both respond to and 
produce inflammatory cytokines such as IFN-γ, TNF-α and interleukin-6, 8 and 10 (Il-6, Il-8 and Il-10). 
Additional stimulants include bacterial fragments that interact with pattern recognition receptors 
(PRRs) and toll like receptors (TLRs), which would trigger a stronger inflammatory response, 
stimulating the production of more inflammatory cytokines as well as nitric oxide (NO) for pathogen 
destruction. Bacterial lipopolysaccharide (LPS) is the most common agent for this purpose, used 
primarily in conjunction with IFN-γ  (Bashir et al., 2016; Smith et al., 2018; Elyasi et al., 2020). The 
main animal models used are apolipoprotein deficient (apoE-/-) and LDL receptor deficient (Ldlr-/-) 
mice fed a “western” diet resulting in the development of atherosclerotic plaques in a manner similar 
to human pathology (von Scheidt et al., 2017). Of these cytokines listed here, IFN-γ is of particular 
interest as it has been found to induce the production of other cytokines, in addition to having 
multiple effects on all stages of atherogenesis (Elyasi et al., 2020). IFN-γ has been shown to activate 
a number of signalling pathways, including those that induce oxidative stress, promote foam cell 
formation and accumulation and smooth muscle proliferation and migration into the arterial intima 
(Elyasi et al., 2020). As pertains to cholesterol transport/homoeostasis, IFN-γ changes the expression 
of the forward and reverse cholesterol transport proteins in a manner that enhances foam cell 
transformation, and exposure of mature macrophages and smooth muscle cells to IFN-γ has been 
shown to increase expression of scavenger receptors, leading to increased uptake of cholesterol 
(Elyasi et al., 2020). Further to this, cholesterol metabolism has been identified as an important 




cholesterol lead to an accumulation of cholesterol ester, which in turn is stored as lipid droplets in 
the cytoplasm, triggering the formation of foam cells (Li et al., 2017). Scavenger receptors have been 
associated with this lipid uptake process, specifically type A scavenger receptors and CD36, a type B 
scavenger receptor (a.k.a. SR-B1). These have been identified as the primary markers for lesional 
macrophages that become foam cells (H. Xu et al., 2019). Macrophages are also able to remove 
intracellular free cholesterol via reverse cholesterol transport. This elimination, or efflux, of 
internalised lipid involves several membrane proteins, including ATP-binding cassette transporters A1 
(ABCA1)  and G1 (ABCG1) and type B scavenger receptors (Lin et al., 2016). Cholesterol efflux is 
dependent on extracellular lipid acceptors such as HDL and lipid poor apoproteins. Blocking or 
inhibition of scavenger receptor A and CD36 results in the blocking of foam cell formation in both 
human and murine models (Rahaman et al., 2006). CD36 has been identified as the most relevant 
HDL receptor and facilitates the selective uptake of cholesteryl ester from HDL into hepatocytes for 
disposal, and has been associated with the initiation of reverse cholesterol transport 
(RCT)/cholesterol efflux, with its overexpression resulting in enhanced cholesterol catabolism and 
excretion and slowing atherosclerosis progression (Kartz et al., 2014).  
The most commonly used drugs, for both the treatment and prevention of atherosclerosis, are 
statins. They function by lowering circulating LDL levels through inhibition of HMG-CoA (Cheng et al., 
2009). In addition to reducing circulating levels of LDL, statins have a number of pleiotropic effects 
that are still under investigation. In regards to foam cell formation, there is still some debate as to 
the effect statins, in this case atorvastatin, has on initiating cholesterol efflux/reverse cholesterol 
transport. Some studies report an inhibition of cholesterol efflux mechanisms (Qiu and Hill, 2008; 
Wang et al., 2013) while more recent studies suggest the opposite effect i.e. atorvastatin promoted 
cholesterol efflux and reduced cholesterol content in a dose dependent manner (Zheng et al., 2020; 
Peng et al., 2018).  
For this chapter, an investigation was carried out to determine if RAW264 cells, highly proliferative 




of either, IFN-γ, LPS or both in order to generate foam cells. These lipid-loaded foam cells would then 
be cultured with different doses of atorvastatin to examine the influence of atorvastatin on oxLDL 
uptake, retention and cholesterol efflux.  The experiences in Chapter 4 and 5 have been used to co-
culture a foam cell model with intact and lesioned human umbilical vein endothelial cells (HUVECs). 
The co-culture mimicked the cellular environment of atherosclerotic plaques, and associated 
cytokine secretion through a new experimental setting. Again, atorvastatin was included with these 
models, with the aim of observing cellular cross-talk, and the responses characterised through 
quantification of oxLDL uptake/retention. Uniquely, it was possible to evaluate nitric oxide (NO) 
production in both HUVECs and foam cells cultured together. Attempts were also made to culture 
RAW264 with human cardiac artery smooth muscle cells (HCASMCs). Formation of 3D atherosclerotic 
plaque through culturing foam cell within dense collagen gel, achieved through a plastic compression 
technique, has been undertaken. There were unexpected difficulties and underlying mechanisms 














6.2 Materials and methods 
6.1.1 RAW 264 Culture 
RAW264 cells were cultured in DMEM supplemented with 10%FBS, 1%LG and 1% AA. Cells were used 
between P3 and P14.  
6.1.2 HUVEC Culture 
HUVECs were cultured using Medium 200. P2-P5 cells were used for experimentation.  
6.1.3 OxLDL Synthesis 
OxLDL stock solution was prepared by sterile oxidation of LDL with copper sulphate (CuSO4), followed 
by dialysis in 10μM EDTA. Stock solution obtained was 5mg/ml in concentration. Differentiation 
between LDL and oxLDL was done by comparing absorbance values of 5mg/ml LDL and oxLDL at 350, 
400, 450, 500, 550 and 600nm. Absorbances were read using a plate reader. The characterisation 
protocol was adopted from Levitt, Chung and Suhling (2015) (Levitt, Chung and Suhling, 2015).  
6.1.4 Foam Cell Formation 
RAW264 cells were incubated with either LDL/oxLDL alone or LDL/oxLDL in combination with either 
LPS or IFN-γ. This was done in order to induce polarization of these cells into an M1 phenotype that 
would increase uptake of LDL/oxLDL and accelerate foam cell formation. LPS and IFN-γ were both 
used at a concentration of 100ng/ml, oxLDL and LDL at 100μg/ml.  
6.1.5 Statin dose  
Atorvastatin calcium trihydrate was dissolved in methanol to create stock solution of 20mg/ml. This 
was diluted in media to the following concentrations; 0.6μg/ml, 1.2μg/ml, 3μg/ml, 6μg/ml and 
60μg/ml. These concentrations were used to evaluate their effect on LDL/oxLDL uptake and identify 
the best concentration to observe this effect.  
6.1.6 Nile Red Staining 
Nile red working solution (1μg/ml) was added to cell containing wells, and incubated for 20 minutes 




fluorescence in water, with colour emission varying from deep red to strong yellow gold in 
hydrophobic environments (Rumin et al., 2015). Samples were washed twice with PBS them imaged 
using a confocal microscope. Imaging was done using either or both red and yellow-gold (red/green 
overlay) fluorescence. The red fluorescence (515-560nm excitation; >590 emission) primarily stains 
intracellular lipids while the yellow-gold (450-500nm excitation; >528 <590nm emission) can be used 
to view cytoplasmic lipid. Imaging is carried out with coupled wavelengths 488/565 to 585  (Rumin 
et al., 2015; Greenspan and Fowler, 1985).   
6.1.7 Oil Red-O Quantification 
A 0.5% solution of oil red-O in isopropanol was diluted 3:2 with deionised dH2O. Working solution 
was added to fixed cells and incubated for 20 minutes at room temperature. This was followed by a 
wash with dH2O, then the addition of isopropanol to elute the internalised stain. 100μl of this solution 
was then quantified using a plate reader set at 540nm.  
6.1.8 NO Quantification 
Media samples were collected and mixed with Griess buffer (1% sulphonamide, 2.5% phosphoric acid 
and 0.1% Naphthalene-diamine-hydrochloride) followed by quantification with a plate reader set at 
546nm. 50μl of media was added to 50μl of Griess buffer for quantification. Standard curve was 
created by measuring absorbance for a sodium nitrile dilution series.  
6.1.9 Co-culture model 
Co-culture was done with both HUVECs and HCASMCs together with RAW264. 4 x 104 HUVECs were 
seeded atop fibronectin coated nanofibers affixed to customised well inserts. The inserts were placed 
in wells seeded with 2.5 x 105 RAW264 cells.  HUVECs used in co-culture model were aged between 
P2 and P4. HUVECs were either left intact lesioned with FeCl3. FeCl3 lesioning was done by dipping a 
1mm2 (0.1cm2) square of filter paper in 10% FeCl3 and placing this onto the upper surface of the 
constructs for 1 minute, followed by a PBS wash. The design of the insert i.e., the nanofiber sheet, 




2 x 105 cells in collagen gel, along with RAW264 following the high-density collagen (plastic 
compression) protocol detailed below.  
6.1.10 3D Plaque Model 
6.1.10.1 Collagen gel solution 
Collagen gel was prepared at a concentration of 3 mg/ml. Following manufacturer’s protocol, stock 
collagen solution was mixed with 10x DMEM, 1M NaOH and sterile filtered dH2O. Depending on the 
desired final volume, the reagents are added one by one and to prevent premature gelation, the 
reagents were mixed in an ice bath with the collagen added last. Once the collagen is added, the 
solution is mixed by pipetting up and down several times until homogenous. Care is taken in the 
mixing to prevent formation of bubbles in the solution. 
6.1.10.2 Plastic compression 
6.1.10.2.1 RAW264 only 
RAW264 cells were seeded into a collagen gel, followed by plastic compression to increase collagen 
concentration and stiffness. The plastic compression carried out was based on a procedure modified 
from Brown et al., (2005). 1500μL of collagen solution, made as previously described, was poured 
into customised metal moulds placed in 9.6 cm² petri dishes under sterile conditions. A sterile cover 
slip (24 x 24mm) was placed at the bottom of the mould to create a sealed space and to prevent the 
gel from leaking into the petri dish. Two filter paper frames were placed within the mould to provide 
structural support for the gel. The frames were sized at 0.9 x 0.9cm. To solidify the gels, they were 
then placed in an incubator at 37°C, 5% CO2 for 2 hours. For cells seeded within the gel, cells were 
mixed with the collagen gel solution, which was then transferred to the compression moulds allowed 
to set and compressed for 5 minutes. Each mould was able to provide 2 compressed gels with 





6.1.10.2.2 RAW264-HCASMC co-culture 
For the HCASMC co-culture model, 1000μl HCASMC-containing collagen gel was first dispensed into 
the moulds, followed by careful distribution of 500μl RAW264-containing collagen gel. This ensured 
the RAW cells were only located on the upper surface of the gel, versus dispersed throughout the 
bulk. The collagen was allowed to set for 2 hours in an incubator at 37°C and 5% CO2, followed by the 





6.3 Results  
6.1.11 Foam cell formation model 
To study atherosclerotic plaque model, foam cells formation is an essential step. Foam cells are lipid-
laden macrophages, and typical in vitro practice involves culturing macrophage cell lines with low 
density lipoproteins. In this study, RAW264 murine macrophage cell line was used. 
6.1.11.1 RAW264 culture 
Cultured cells were highly proliferative, doubling population daily. They adopted a generally rounded 
morphology, with occasional fibroblast like cells appearing. Cells were semi-adherent and were able 
to grow in a sheet in 2D culture. How these cells appeared in culture is detailed in figure 6-1.  
 
 
6.1.11.2 Oxidation of LDL 
Following the oxidation process detailed in section 6.2.3, characterisation of LDL and oxidized LDL 
(oxLDL) were carried out to verify if oxidation was successful. Briefly, the absorbances at different 
wavelengths were recorded for the stock LDL solution and the oxidised LDL. Concentrations of both 
were 5mg/ml. The wavelengths used were 350, 400, 450, 500, 550 and 600nm. These readings are 
represented in figure 6-2. Further to this, effect on cell viability was evaluated to determine if there 
are functional differences between oxidised and native LDL. Data is represented in figure 6-3.  
Figure 6-1: RAW264 in 2D culture. RAW264 in 2D culture 
having primarily rounded morphology. Image taken at 


























Figure 6-2: Absorbance comparative between LDL and oxLDL. Absorbance readings at different wavelengths, evaluating 
spectral differences between stock LDL and oxLDL, both at 5mg/ml. Two-way ANOVA and one sample t-and Wilcoxon test 
were carried out to determine significance, significance was identified between wavelengths and between LDL and oxLDL 
(P<0.0001 ****, ****, ****. N=3.  
 
At the selected wavelengths, there is a difference in absorption intensity between LDL and oxLDL 
which suggests that there are structural, and thus spectral, differences between native LDL and the 
oxidised version-with oxLDL having a consistently higher absorption than LDL at all evaluated 
wavelengths-, showing that the oxidation protocol followed here was successful at generating an LDL 
variant. Two-way ANOVA was carried out and showed significance between LDL and oxLDL 
absorbance values. The data in figure 6-3 suggests there is also a functional difference between LDL 































Figure 6-3: Effect of LDL oxidation on cell viability. Cells were cultured for 24 hours with 100μg/ml LDL or oxLDL, after 
which viability was assessed using CCK8. Statistical analysis was done with one way t-and Wilcoxon test, and unpaired t-
test. Significance was identified for LDL and oxLDL absorbance values (p <0.0001 ****, ****), as well as between 
absorbance values for LDL and oxLDL (p = 0.0324 *). N=6.  
 
6.1.11.3 Effect of seeding density and oxLDL concentration on lipid uptake 
To determine the ideal or maximum lipid uptake in RAW264, two experiments were carried out. The 
first evaluated effect of cell seeding density. RAW264 cells were seeded at 125 x103, 250 x 103, 375 x 
103 and 500 x 103 cells in a 24 well plate, then incubated with a fixed concentration of oxLDL 
(100μg/ml) for 24 hours. The second experiment was evaluating the effect of oxLDL concentration on 
total uptake with a fixed cell number. 250 x 103 RAW264 cells were seeded and incubated with 
50μg/ml, 100μg/ml, 150μg/ml, 200μg/ml and 250μg/ml oxLDL. For both experiments, quantity of 
internalised oxLDL was determined using oil red-O. The results are represented in figure 6-4 and 6-5 























































































Figure 6-4: Seeding density effect on lipid uptake. 100μg/ml of oxLDL was used across all samples with an 
increasing density of seeded cells. Samples were incubated for 24 hours with oxLDL and internalised lipid was 
quantified using oil red-O. Statistical analysis was done using ordinary one-way ANOVA and two-way ANOVA, with 
significance identified between all cell densities (p <0.0001 ****), as well as one sample t-and Wilcoxon test, with 
significance identified for uptake for each cell density (p = 0.0003 ***, ***, ***, *** and p = 0.0005 ***). N=3.  
Figure 6-5: oxLDL concentration effect on total uptake. 250 x 103 cells were incubated with varying concentrations 
of oxLDL for 24 hours, followed by quantification of internalised lipid using oil red-O. Statistical analysis was carried 
out with one way ANOVA, with significance identified between the different oxLDL concentrations (p = 0.0421 * 
Bartlett test p = 0.0192 *). One sample t-test identified significance for all the concentrations of oxLDL (p <0.0001 





Cell density appears to have more of an effect on extent of oxLDL uptake than concentration of oxLDL 
added, which appears to have a maximum limit at 250 x 103, suggesting that lipid uptake by RAW264 
is dependent on lipid availability, i.e., more cells would require more lipid. The findings in figure 6-5 
support this in that as oxLDL concentration increased above 100μg/ml, the concentration within the 
cells increased, with a variation in absorbance of 0.01 between 100μg/ml and 200μg/ml. There does 
not appear to be much variation between 0 and 100μg/ml and between 150 and 250μg/ml. The final 
cell density settled on was 250 x 103 cells per well, to be incubated with 100μg/ml, as concentrations 
higher than this were demonstrated to trigger apoptosis in smooth muscle cells and are also toxic to 
macrophages and endothelial cells (Ding et al., 2012; Reid and Mitchinson, 1993; Han and Pak, 1999).  
6.1.11.4 RAW264 polarization and foam cell formation 
The normal/steady state of RAW264 cells is that of inactivated or M0 macrophages. In order to 
promote RAW264 uptake of oxLDL, stimulation with LPS and IFN-γ was carried out to push these cells 
to an M1 phenotype. Cells were incubated with LPS and/or IFN-γ, both at a concentration of 
100ng/ml, for 24 hours, followed by oxLDL or LDL incubation for a further 24 hours. Extent of lipid 
uptake was qualitatively evaluated using Nile red staining. The factors evaluated here include the shift 
of RAW264 from M0 to M1 based on stimulation protocols i.e., LPS vs. IFN-γ vs LPS + IFN-γ and effect 







The images in figure 6-6 show droplets appearing denser with LDL versus oxLDL, and cell density also 
appears to be lower post incubation in the LDL loaded samples, supporting the observation that LDL 
has a negative effect on cell viability shown in figure 6-3, compared to oxLDL treated group. Samples 
stimulated with LPS also appear to have a denser accumulation of droplets than those without as 
Figure 6-6: Stimulation of foam cell formation. To enhance the uptake of lipids, the RAW cells were 
treated with either LPS or IFN-γ or both, after which they were stained with Nile red. Untreated RAW264 




well as those with just IFN-γ stimulation. Co-stimulation with IFN-γ and LPS show the densest lipid 
uptake for both LDL and oxLDL. Given that LPS is in itself a lipid, samples incubated only with LPS had 
droplets present in amounts comparable to oxLDL or LDL only incubations. Samples treated with IFN-
γ and either oxLDL and LDL have stronger indications of lipid uptake than the IFN-γ only treated 
samples. A comparative of IFN-γ only samples with LPS and IFN-γ treated samples, in the absence of 
either LDL or oxLDL, further demonstrates that LPS addition results in internalised lipid within RAW 
cells that is unrelated to uptake of either oxLDL or LDL.  This resulted in the disqualification of LPS as 
a practical stimulant for foam cell formation, especially in light of the selected method of uptake 
quantification. Consequently, only IFN-γ stimulation was used in subsequent experiments to 
eliminate observed LPS influence.  
 
6.1.11.4.1 Stimulant effect on RAW264 NO production 
To characterise RAW264 NO production in response to various polarisation stimulants i.e., LPS, IFN-
γ, LDL and oxLDL, RAW264 cells were treated as follows; first 25 x 104 RAW264 cells were seeded into 
individual wells of a 24 well plate, followed by addition of the stimulants. NO readings were taken at 
the end of the incubations. Quantification was done using Griess buffer mixed 1:1 with media 
samples, followed by absorbance measurements on a plate reader set at 546nm. [NO] was 
determined using a previously established standard curve. IFN-γ and LPS were both used at 100ng/ml 
and both LDL and oxLDL at 100μg/ml for all samples. The results of the cell stimulations are shown 
































































Figure 6-7: NO production in stimulated RAW264 cells. Summary of all stimulants’ effect on NO production. All samples 
contained 250 x 103 cells, and were incubated with the stimulants for 24-hours before NO readings were taken. Statistical 
analysis was done using one-way ANOVA, and significance was identified between stimulants (P <0.0001 ***; Brown-
Forsythe test p = 0.0029 **; Bartlett test p <0.0001 ****). One sample t-and-Wilcoxon test was also carried out, and 
significance was identified for [NO] for each stimulant evaluated (p <0.0001 ****, ****, ****, ****, ****, ****, ****, **** 
and p = 0.0005 ***. N=5. One-way ANOVA used for analysis. Statistical significance denoted by *. P < 0.0001.  
 
The findings in figure 6-7 indicate that LPS is a far stronger stimulator, in respect to NO production, 
than the other stimulants, with the highest readings recorded in samples only treated with LPS. The 
findings here also suggest that IFN-γ has some limiting effect on NO production in that samples with 
IFN-γ inclusion, either with or without co-stimulation, generally have lower readings than those 





6.1.12 Atorvastatin dose effect on foam cell models  
To evaluate the effect atorvastatin has on RAW264 polarization, its effect on cell viability and NO 
production were evaluated as detailed below.  
6.1.12.1 LDL vs. oxLDL effect on cell viability under different doses of atorvastatin 
To determine if there were functional differences between LDL and oxLDL with the inclusion of 
atorvastatin, a CCK8 assay was carried out to determine effect on cell viability. Cells were incubated 
with either 100μg/ml LDL or 100μg/ml oxLDL, and different doses of atorvastatin for 24 hours before 
readings were taken. The findings are represented in figure 6-8.  
 































The overall trend regarding atorvastatin effect on cell viability is consistent for both LDL and oxLDL, 
with higher concentrations of atorvastatin consistently lowering cell viability. The reduction in cell 
viability observed at 0.6μg/ml atorvastatin was unexpected and a proper explanation for why this 
occurred has not been determined yet. LDL also appears to have a more negative effect on cell 
Figure 6-8: CCK8 cell viability assay. This plot compares both the effect of LDL oxidation state, and atorvastatin 
concentration on cell viability. 2.5 x 104 cells were first incubated with either LDL or oxLDL for 24 hours, followed by 
atorvastatin at the stipulated concentrations for 24 hours. Statistical analysis was done using two-way ANOVA, with 
significance identified between the concentrations of atorvastatin used (p = 0.0002 ***). Additional analysis was done 
with a one sample t-and Wilcoxon test, and significance was identified for each group i.e., oxLDL and LDL (p <0.0001 




viability than oxLDL, giving consistently lower absorbance readings across all doses of atorvastatin. 
This observation confirms that the oxidation process was successful. Two-way ANOVA was carried 
out on   these data sets, significance was set at a p value lower than 0.05. Significance was found 
between doses as well as between LDL and oxLDL treated samples. 
6.1.12.2 Atorvastatin effect on uptake of LDL vs. oxLDL 
An evaluation was done to determine what effect atorvastatin has on uptake and retention of lipid 
by foam cells, qualitative analysis using Nile red staining and quantification using oil red-O staining 
was carried out. Samples were first incubated with IFN-γ for 24 hours, followed by another 24-hour 
incubation with either LDL or oxLDL, then a 24-hour incubation with atorvastatin at the following 
doses; 0.6μg/ml, 1.2μg/ml, 3μg/ml, 6μg/ml and 60μg/ml. Representative images are shown in figure 






LDL LDL + 0.6µg/ml Ator LDL + 1.2µg/ml Ator 
LDL + 3µg/ml Ator LDL + 6µg/ml Ator LDL + 60µg/ml Ator 
Figure 6-9: Atorvastatin dose effect on lipid (LDL) uptake and retention. Samples were stained with Nile red for droplet visualisation. Atorvastatin was added after addition of the 


















oxLDL + 0µg/ml Ator oxLDL + 0.6µg/ml Ator oxLDL + 1.2µg/ml Ator 
oxLDL + 3µg/ml Ator oxLDL + 6µg/ml Ator oxLDL + 60µg/ml Ator 
Untreated cells 
Figure 6-10: Atorvastatin dose effect on lipid (oxLDL) uptake and retention. Samples were stained with Nile red for droplet visualisation. Atorvastatin was added after addition of 




Comparing both LDL and oxLDL uptake, atorvastatin appears to reduce the amount of internalised lipid 
at the highest dose, 60μg/ml after just 24 hours of culture. Red lipid droplets are far fewer at this dose 
than other concentrations of atorvastatin. There also appear to be fewer cells present in the wells for 
both LDL and oxLDL treated cells compared to the untreated controls, with generally fewer cells seen 
in the LDL treated wells than the oxLDL treated ones, again, as expected due to LDLs impact on cell 
viability, demonstrated in both figure 6-3 and 6-8. Cells also appear larger and denser for the oxLDL 
treated samples compared to LDL, with brighter droplet staining in the LDL treated samples.  
6.1.12.3 Atorvastatin effect on cholesterol efflux 
To determine whether the reduction in lipid droplets observed at 60μg/ml in both figure 6-8 and 6-9 
occurs at other concentrations of atorvastatin, the same treatment described in 6.3.1.5.2 was applied 
but the cells cultured for 24, 48 and 72 hours i.e., first IFN-γ (24h) then LDL/oxLDL (24h) and finally 
atorvastatin for 24, 48 or 72 hours. Media was changed daily and replenished with freshly made 
atorvastatin for the 48 and 72h samples. The drug free samples were replenished with untreated 
culture media. Representative images showing qualitative evaluation of lipid retention can be seen in 





















24h 48h 72h 24h 48h 72h 
Figure 6-11: Atorvastatin effect on LDL retention over time. Samples were 
incubated with 100μg/ml LDL for 24 hours, followed by the addition of 
atorvastatin, at the specified doses, for either 24, 48 or 72 hours. Images were 




















24h 48h 72h 24h 48h 72h 
Figure 6-12: Atorvastatin effect on oxLDL retention over time. Samples were 
incubated with 100μg/ml oxLDL for 24 hours, followed by the addition of 
atorvastatin, at the specified doses, for either 24, 48 or 72 hours. Images were 




For both LDL and oxLDL incubated samples, prolonged culture results in a reduction in cell density, 
both with and without the inclusion of atorvastatin. Density of lipid droplets appears densest at the 
48-hour mark, after which density of cells is markedly lower after 72 hours across all samples in both 
figure 6-11 and 6-12. Once again, density of lipid droplets is lower at the highest concentration of 
atorvastatin, 60μg/ml.  Other concentrations also have fewer accumulated droplets after 72 hours 
compared to 48 hours and the control samples. As reduction in cell density was seen across all samples, 
it is likely due to an overabundance of cells within the culture flask due to the highly proliferative nature 
of RAW264. This over confluence may have resulted in cell death due to limited availability of space 
and nutrients.  
6.1.12.3.1 Mode of stimulation effect on cholesterol efflux 
A quantitative analysis based on the images in figure 6-11 and 6-12 was carried out to verify that 
atorvastatin triggers the observed ejection, or efflux, of internalised lipid. For this experiment, only 
oxLDL loading was done to RAW264 cells. Culture conditions were as follows; one batch was treated 
first with 100ng/ml IFN-γ (24h), followed by 100μg/ml oxLDL (24h) then by atorvastatin (24, 48 and 
72h). The other batch was first treated with IFN-γ (24h), the atorvastatin (24h) then a combination of 
atorvastatin and oxLDL (24, 48 and 72h). After 24 hours, media was changed and replaced with fresh 
media containing only atorvastatin. After culture, samples were fixed with 4% PFA and internalised 
lipid content quantified using the previously described oil red-o method. Findings are represented in 






























































































































































































































































































































































































































































































































































































Figure 6-13: Effect of different doses of atorvastatin on OxLDL uptake over time: Extent of oxLDL uptake was evaluated using 
Oil Red-O staining. One set of samples was first incubated with IFN-γ, followed by oxLDL then atorvastatin (IFN-
γ→oxLDL→Ator). The other set was first incubated with IFN-γ, then atorvastatin, then a combination of atorvastatin and 
oxLDL (IFN-γ→Ator→Ator + oxLDL). Samples were then cultured for 24, 48 and 72 hours. Statistical analysis was done using 
one-sample t-and Wilcoxon test, significance was identified for each time point i.e., 24h, 48h, and 72h ((0μg/ml; p = 0.0205 
*, 0.0353 * and 0.0035 **), (0.6μg/ml; p = 0.0489 *, 0.0313 *, 0.0118 *) (1.2μg/ml; p = 0.0145 *, 0.0147 * and 0.0380 *) 
(3μg/ml; p = 0.0036 **, 0.0074 ** and 0.0133 *) (6μg/ml; p = 0.0048 **, 0.0024 **, and 0.0088 **) (60μg/ml; p = 0.0434 *, 
0.0238 *, and 0.0160 *). Additional significance was also identified using two-way ANOVA for the interaction between mode 






From the data represented in figure 6-13, the dose that provided the most consistent reduction in 
amount of internalised oxLDL over time is 6μg/ml, which had little variation between modes of 
stimulation i.e., there was no significant difference between whether atorvastatin or oxLDL was added 
first, compared to the drug free control and other doses. This dose also demonstrated progressive 
lowering over time, with the 72-hour incubation showing the greatest reduction for this dose.  
Statistical significance for this dose was found between time points, suggesting that mode of 
administration of atorvastatin was not a determining factor in reducing amount of internalised lipid 
but instead the selected dose. For the other doses tested, peak effectiveness appears to be after 48 
hours, with addition of atorvastatin after oxLDL proving the most effective at lowering internalised 
oxLDL.  
It should also be noted that pre-treatment with atorvastatin before addition of oxLDL showed a greater 
reduction in amounts of internalised oxLDL after 72 hours only in the higher doses of atorvastatin 
(6μg/ml and 60μg/ml), with 60μg/ml showing the largest variation between pre-treatment with 
atorvastatin versus treatment after oxLDL addition. 3μg/ml appears to have a similar trend to 6μg/ml, 
however, given the lack of statistical significance, subsequent experiments were carried out with 
6μg/ml.  
 
6.1.12.4 NO production 
The findings in figure 6-7 show the effect on the selected polarization stimulants on NO production, 
with LPS showing the greatest effect on NO production by RAW264. The effect of atorvastatin on NO 
production on stimulated RAW264 cells is detailed in figure 6-14. Stimulations were done as detailed 
in section 6.3.1.4.1 with atorvastatin being added either after the stimulations or at the same time as 
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Figure 6-14: Atorvastatin effect on NO production after LPS and IFN-γ stimulation. (s) denotes samples where atorvastatin 
was added at the same time as the stimulant. In all other cases, atorvastatin was added after addition of either LPS or IFN-γ, 
or LPS and IFN-γ, or oxLDL or LDL. Statistical analysis was done using one sample t-and Wilcoxon test, significance was 
identified per variable (IFN-γ + Ator, p = 0.0002 ***; Ator, p <0.0001 ****; oxLDL + Ator, p = 0.0002 ***; LDL + Ator, p <0.0001 
****; IFN-γ + Ator (s), p = 0.0001 ***; LDL, p <0.0001 ****; control, p <0.0001****; IFN-γ, p <0.0001****; oxLDL, p 
<0.0001****; IFN-γ + oxLDL,  p <0.0001****; LPS + Ator, p <0.0001****; IFN-γ + LPS + Ator, p = 0.0002 ***; LPS + IFN-γ + 
oxLDL, p = 0.0094 **; LPS + oxLDL, p <0.0001****; LPS + Ator (s), p <0.0001****; IFN-γ + LPS, p <0.0001****; LPS, p = 0.0005 
***).  Two-way ANOVA also identified significance between all the variables (p <0.0001). N=5.  
 
The data in figure 6-14 shows that atorvastatin has a negative effect on NO production by RAW264, 
especially when added after removal of the stimulants, suggesting a reversal of NO production 
triggered by LPS and IFN-γ either separately or in conjunction, thus implying that atorvastatin is a 
stronger inhibitor of NO production in inflammatory macrophages. This is also observed when only LDL 
or oxLDL are used as stimulants followed by the addition of atorvastatin. When atorvastatin is added 
simultaneously with either LPS or IFN-γ, there is also an observable reduction in [NO] but this is not as 




LPS also demonstrates the strongest capacity to stimulate NO production in RAW264, and also to limit 
the effect observed with atorvastatin.  
6.1.13 The effect of HUVEC co-culture on foam cell models 
After determining RAW264 responses to atorvastatin, the selected dose, 6μg/ml, was used in 
conjunction with HUVECs. In summation, RAW264 cells were either stimulated with 100ng/ml IFN-γ 
for 24 hours followed by a 24-hour incubation with oxLDL or just incubated with oxLDL for 24 hours. 
Following these stimulations, HUVECs seeded on nanofiber well inserts, at a density of 4 x 104 cells per 
insert, were placed atop the seeded RAW cells (figure 6-15). The nature of the insert allowed the use 
of individual cell media i.e., HUVECs were cultured with medium 200 supplemented with 2% LSGS 
while RAW264 were cultured with DMEM supplemented with 10% FBS, 1% LG and 1% AA. HUVECs 
were either lesioned with FeCl3 or left intact. Atorvastatin treatment was also included for both 
lesioned and intact HUVECs and for both IFN-γ stimulated and unstimulated RAW264 cells. The FeCl3 
lesion was created by adding 0.2μl the solution to a 1mm2 piece of filter paper, which was then placed 
on the HUVEC layer for 1 minute, followed by a PBS wash. The co-culture system was incubated at 
37°C/5%CO2 for 24 hours. Co-culture combinations are detailed in figure 6-16. NO readings were taken 
after final incubation and compared to control samples. Nile red imaging was done with both FITC and 
Texas red excitation on the confocal microscope. Oil red-O quantification was also carried out as 

























Top (well Insert) Bottom (well)  
Figure 6-15: Nanofiber well insert assembly. The customised rings were fused together with the aligned nanofibers between. 
A split rubber ring was affixed to the bottom portion of the insert. After sterilisation, HUVECs are seeded onto the fibronectin 
coated nanofibers. The completed insert is placed inside a 24 well plate well seeded with RAW 264. 
Figure 6-16: Flow chart of co-culture conditions. HUVECs were either lesioned or left intact and each group was cultured 
either with or without 6μg/ml atorvastatin. The HUVECs were then added to RAW264 either stimulated or unstimulated with 




6.1.13.1 HUVEC and Atorvastatin effect on oxLDL uptake 
Extent of oxLDL uptake is visualised in figure 6-17 and 6-18. Representative images are overlays of 
green (495nm) and red (604nm). Yellow-gold represents internalised lipid, red denotes primarily 
membrane staining. The use of co-excitation was selected here as it provides a clearer distinction 
between membrane lipids versus internalised lipid, allowing better elucidation of the effect HUVECs 
and/or atorvastatin have on cholesterol efflux.  
RAW264 + oxLDL + Lesioned HUVECs RAW264 + oxLDL + Intact HUVEC RAW264 + oxLDL  
Figure 6-17: Qualitative evaluation of oxLDL uptake with IFN-γ stimulation. Images are of RAW264 cells co-cultured with 
HUVECs either with or without a lesion and either with or without 6μg/ml atorvastatin. RAW264 were all stimulated with 





























RAW264 RAW264 + oxLDL + Lesioned HUVECs RAW264 + oxLDL + Intact HUVECs RAW264 + oxLDL  
Figure 6-18: Qualitative evaluation of oxLDL uptake without IFN-γ stimulation. Images are of RAW264 cells co-cultured with HUVECs either with or without a lesion and either with or 





























From both figure 6-17 and 6-18, internalised oxLDL generates a strong yellow-gold colouration, with 
only a faint yellow tinge on the membrane observed in the presence of atorvastatin. Samples without 
both oxLDL and atorvastatin display a redder colouration. The alteration of membrane colouration 
from a red to a yellow-red colour in the presence of atorvastatin could be a result of lipid content being 
transferred to the extracellular space (cholesterol efflux), resulting in a blending of the stronger red 
and yellow-gold.  This colour blending is more observable in the IFN-γ treated samples than the 
untreated ones. In figure 6-17, the RAW264 cells cultured with lesioned HUVECs and without 
atorvastatin have a redder membrane stain than the same group without IFN-γ, suggesting IFN-γ 
promotes retention of internalised lipid. A comparison of the same group without IFN-γ (figure 6-18) 
further shows the effect of IFN-γ on retention of internalised lipid i.e., blocking cholesterol efflux, as 
the cells imaged show far less yellow-gold staining, as well as less distinct red membrane staining, than 
the IFN-γ stimulated group. In the presence of IFN-γ, intact HUVECs appear to exert some protective 
effect on the maintenance of internalised lipid i.e., these samples appear to have fewer lipid droplets 
visible after 24 hours than those cultured with lesioned HUVECs. The presence of atorvastatin distinctly 
limits maintenance of internalised lipid as shown in both figure 6-17 and 6-18. The use of dual 
excitation/emission shows its value here, compared to earlier images that just show red, in that it’s far 
easier to distinguish internalised lipid from membrane lipid content as well as giving an impression of 
lipid localisation between the inner and outer sections of the cell.  
6.1.13.2 NO production 
Following the protocol described in section 2.1.16, the effect of atorvastatin, IFN-γ and oxLDL 
stimulation on NO production was determined, and results are detailed in figure 6-19. HUVECs were 
stimulated with 100ng/ml IFN-γ and readings were taken after 24 hours. RAW264 were stimulated with 
either IFN-γ or oxLDL for 24 hours then analysed, or first stimulated with IFN-γ (24h) followed by a 
further 24-hour incubation with oxLDL before readings were taken. Cells here were not used in the co-
















































































OxLDL has the strongest effect on RAW264 NO production, with IFN-γ stimulation also triggering an 
increase in NO production. IFN-γ had the opposite effect on HUVECs i.e., stimulation resulted in a 
reduction in NO production.  
 
6.1.13.2.1 Atorvastatin effect on NO production 
As detailed previously, RAW264 cells were stimulated with IFN-γ for 24 hours after which they were 
incubated with oxLDL for 24 hours, then co-cultured with either lesioned or intact HUVECs and either 
with or without atorvastatin as detailed in figure 6-16. Atorvastatin incubation was carried out for a 
further 24 hours, whereupon the media was collected and tested for NO. Media was collected from 
both the HUVEC insert and the RAW264 portion of the co-culture system (figure 6-15).  Data collected 
is represented in figure 6-20 and 6-21.  
 
Figure 6-19: IFN-γ effect on NO production. The data represented here shows the impact of IFN-γ on the production 
of NO in HUVECs and RAW264. IFN-γ does trigger NO production in both cell types, but oxLDL has a stronger effect on 
NO production than IFN-γ alone, or IFN-γ in combination with oxLDL. Statistical analysis was done using both one 
sample t-and Wilcoxon test, and two-way ANOVA, with significance identified both for, and between the variables (p 


















































































































































































Intact HUVECs + Ator










































































































































































































 Figure 6-20: NO production. These graphs provide a comparative of NO production between HUVECS and RAW264 as 
well as the effect of IFN-γ stimulation on NO production in both HUVECs and RAW264. (a) compares NO production in 
lesioned and intact HUVECs cultured with unstimulated RAW264; media collected from HUVEC well insert. (b) compares 
NO production for unstimulated RAW264 cultured with HUVECs from (a). (c) compares NO production in lesioned and 
intact HUVECs cultured with IFN-γ stimulated RAW264; media collected from HUVEC well insert. (d) compares NO 
production for IFN-γ stimulated RAW264 cultured with HUVECs from (c). (e) is a combination of (a) and (c) comparing 
effect of IFN-γ on NO production in HUVECs. (f) is a combination of (b) and (d) comparing effect of IFN-γ on NO production 
in RAW264. Statistical significance was determined through one sample t-and Wilcoxon test, and significance identified 
per variable i.e., lesioned and intact HUVECS, with and without atorvastatin ((a) p = 0.0009 ***, <0.0001 ****, 0.0005 
***, 0.0019 *; (b) p = 0.0002 ***, 0.0009 ***, 0.0005 ***; <0.0001 ****; (c) p = 0.0002 ***, 0.0159 *, 0.0005 ***, 
0.0013**; (d) p = 0.0002 ***, 0.0016 **, <0.0001 ****, 0.0003 ***; (e) p = 0.0002 ***, 0.0014 **; (f) p = 0.0003 ***, 
***). Additional significance was identified through two-way ANOVA, between IFN-γ stimulated vs. unstimulated 



































































































































































































































Figure 6-21: Cell comparative between IFN-γ stimulated and unstimulated HUVECs and RAW264. (a) compares NO 
production between HUVECs and RAW264, when RAW264 have been stimulated with IFN-γ. (b) compares NO production 
between HUVECs and RAW264 when RAW264 were not stimulated with IFN-γ. (c) is a comparative of (a) and (b). 
Statistical significance was determined using one sample t-and Wilcoxon test, with significance identified for HUVECs and 
RAW264, both with and without IFN-γ stimulation ((a) p = 0.0002 *** (HUVEC); p = 0.0003 *** (RAW264); (b) p = 0.0002 
*** (HUVEC); p = 0.0004 *** (RAW264); (c) p = 0.0002 *** (IFN-γ stimulated HUVEC); p = 0.0003 *** (IFN-γ stimulated 
RAW264); p = 0.0002 *** (unstimulated HUVEC); p = 0.0004 *** (unstimulated RAW264). Two-way ANOVA was carried 
out for all the data sets, no significance was identified for the data represented in (a), significance was identified for the 
interaction between HUVECs and RAW264 in (b) (p <0.0001). Three-way ANOVA was also carried out for the data 
represented in (c), with significance identified between IFN-γ stimulated HUVECs and RAW264 (p = 0.0014 **), 
Unstimulated HUVEC and RAW264 (p = 0.0014 **), IFN-γ stimulated and unstimulated RAW264 (p <0.0001 ****), IFN-γ 
stimulated and unstimulated HUVECs (p <0.0001 ****), and the interaction between IFN-γ stimulated versus 




An evaluation of figure 6-20 and 6-21 shows that the concentration of IFN-γ used here attenuates 
production of NO across both cell types, but more so in HUVECs, and to a lesser extent when 
atorvastatin is included in culture. RAW cells appear to produce more nitric oxide when cultured with 
lesioned HUVECs, especially in the absence of IFN-γ stimulation, and in the presence of atorvastatin 
(figure 6-21). As expected, intact HUVECs have a better NO production profile in general than lesioned 
HUVECs and atorvastatin appears to ameliorate the limiting effect of IFN-γ observed. The data in figure 
6-19 also support the observation that the selected concentration of IFN-γ used is not as effective a 
stimulator of NO production as oxLDL, especially on RAW264 cells and may not have fully pushed 
RAW264 cells to an M1 phenotype. Statistical significance for figure 6-21 (b) was found between 
RAW264 and HUVEC NO production but not between the lesioned and intact groups, either with or 
without atorvastatin. In figure 6-21 (c) significance was found between IFN-γ stimulated and 
unstimulated cells and again not between the lesioned and intact groups, either with or without 
atorvastatin. These analyses suggest that the more significant contributor to these differences 
observed is the inclusion of IFN-γ, rather than lesioning HUVECs or the inclusion of atorvastatin.  
6.1.14 Cholesterol efflux 
As described previously, oil red-O was used to quantify extent of lipid uptake with and without 
atorvastatin and IFN-γ stimulation. This method was used exclusively on RAW264. These cells were 
those used in co-culture with HUVECs as described in section 6.2.9 and 6.3.1.6 and figure 6-16. Briefly, 
fixed cells were first stained with oil red-O, after which the excess dye was removed, followed by 
extraction of bound oil red-O from the cells using isopropanol. The absorbance was read at 540nm and 




























































































































































































































































































Figure 6-22: Co-culture oxLDL quantification. (a) oxLDL uptake in IFN-γ stimulated RAW264. (b) oxLDL uptake in unstimulated 
RAW264. (c) comparative between IFN-γ stimulation and no stimulation on oxLDL uptake in RAW264 cultured with lesioned 
and intact HUVECs and either with or without atorvastatin. One-way and two-way ANOVA, as well as one sample t-and 
Wilcoxon tests were carried out and they all showed significance for each variable, as well as between variables, and all having 
p <0.0001 ****. N=12. 
  
The findings in figure 6-22 demonstrate that atorvastatin inclusion results in a reduction of internalised 
lipids i.e., atorvastatin triggers cholesterol efflux. Both with and without IFN-γ stimulation, RAW264 




RAW264 controls were not incubated with any oxLDL, and their absorbance readings suggest there is 
a baseline amount of internalised lipid, likely obtained from FBS content in culture media. This lipid 
content is also affected by the presence of atorvastatin, given that samples not treated with oxLDL, 
followed by treatment with atorvastatin, showed lower absorbance values than the control. These 
findings also suggest that lesioned HUVECs are also able to marginally promote cholesterol efflux, both 
with and without atorvastatin, as the absorbance values are consistently lower than with intact 
HUVECs, especially in the presence of IFN-γ. Statistical analysis identified significance between the 
inclusion or exclusion of IFN-γ (figure 6-22 (c)), lesioned and intact HUVECs (figure 6-22 (a, b)), as well 
as the presence of atorvastatin (figure 6-22 (a, b and c)), suggesting an interaction of these factors in 
the uptake/efflux of oxLDL in RAW264, with each factor contributing in one way or another.  
 
6.1.15 Immunostaining   
Immunostaining was carried out to track the expression of CD36 and CD146. Briefly, the primary 
antibody was added to the samples following a 1-hour incubation with 5% BSA. 1° antibody was 
incubated with the sample for 2-hours at 37°C/5% CO2. After 1° incubation, samples were washed 
twice each with 0.05% Tween20 and PBS. This was followed by a 1-hour incubation with the 2° antibody 
also at 37°C/5% CO2. Two 0.05% Tween20 and two PBS washes followed. DAPI was then added to the 
samples and incubated for 10 minutes, followed by three PBS washes. Negative control samples were 
only incubated with the secondary antibody and DAPI for the same duration and without the BSA 
blocking stage. Representative images of staining, taken with a confocal microscope, are shown in 






Figure 6-23: Unstimulated RAW264 CD36 staining. Samples used were RAW264 cells co-cultured with lesioned or intact HUVECs, either with or without atorvastatin. Images taken 
at 20x magnification. DAPI; CD36 
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Figure 6-24: IFN-γ stimulated RAW264 CD36 staining. Samples used were RAW264 cells co-cultured with lesioned or intact HUVECs, either with or without atorvastatin. All images 
taken at 20x. DAPI; CD36 
RAW264 + oxLDL + 6ug/ml Ator.  
RAW264 + oxLDL + Lesioned HUVEC 
RAW264 + oxLDL + Lesioned HUVEC + 6ug/ml Ator 
RAW264 + oxLDL + Intact HUVEC 
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RAW264 





Figure 6-25: Unstimulated RAW264 CD146 staining. Samples used were RAW264 cells co-cultured with lesioned or intact HUVECs, either with or without atorvastatin. All images 
taken at 20x. DAPI; CD146. 
RAW264 + 6ug/ml Ator RAW264 + oxLDL + Intact HUVEC + 6ug/ml Ator 
RAW264 + oxLDL + Intact HUVEC 
RAW264 + oxLDL + Lesioned HUVEC + 6ug/ml Ator 
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Figure 6-26: IFN-γ stimulated RAW264 CD146 staining. Samples used were RAW264 cells co-cultured with lesioned or intact HUVECs, either with or without atorvastatin. All images 
taken at 20x. DAPI; CD146.  
RAW264 + oxLDL + 6ug/ml Ator. 
RAW264 + oxLDL + Lesioned HUVEC 
RAW264 + oxLDL + Lesioned HUVEC + 6ug/ml Ator. 
RAW264 + oxLDL + Intact HUVEC 
RAW264 + oxLDL + Intact HUVEC + 6ug/ml Ator. 
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Looking at figure 6-23, the expression of CD36 is triggered by the presence of oxLDL, and appears to 
be enhanced with atorvastatin, with no visually obvious difference between IFN-γ stimulated (figure 6-
24) or unstimulated (figure 6-23) RAW264 cells. Lesioned HUVECs also appear to have a positive impact 
on CD36 expression when compared to intact HUVECs without atorvastatin. For the IFN-γ stimulated 
cells, CD36 expression seems elevated in samples co-cultured with lesioned HUVECs, with a slight 
reduction in the atorvastatin treated lesioned HUVEC co-culture. CD146 on the other hand, seems to 
be influenced by IFN-γ stimulation in that unstimulated samples (figure 6-25) showed an apparent 
reduction in extent of CD146 expression when atorvastatin was added, while those stimulated with 
IFN-γ (figure 6-26) show the opposite i.e., a stronger expression of CD146. Given the absence of a 
positive signal in samples not exposed to oxLDL, this suggests that the staining protocol was successful 
and only specific for the targeted receptors, which are selectively expressed on macrophages exposed 
to oxLDL. 
6.1.16 3D atherosclerosis plaque model: Foam cells in plastically compressed collagen 
After evaluating RAW264 behaviour in a 2D environment, the same was attempted for 3D culture. The 
selected density of cells i.e., 2.5 x 105, were seeded either individually or together with HCASMCs as 
described in section 6.2.10. Compressed gels were selected for culturing RAW264 due to the increased 
stiffness afforded by a compressed gel. Compression protocol is detailed further in figure 6-27. Image 
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Figure 6-28: RAW264 in 3D culture. (A) RAW264 after compression (within an hour). (B) RAW264 
after 48 hours in compressed collagen. All images taken at 10x.  
Figure 6-27: Collagen gel compression. (a) shows the preparation of the moulds before collagen addition. (i) shows the 
solidified collagen in the moulds and (ii) the gel removed from the mould. To compress and extract the gels (b), the mould 
was turned upside down on a piece of nylon placed on layered sterilised tissue (iii). Once inverted, the glass cover slip is 
carefully removed to avoid breakage, after which the weight, designed to fit into the mould, is placed on the gel (iv). The 
weight is left on the gel for 5 minutes until the majority of the water content is removed. The filter paper frames are 





The brightfield images shown in figure 6-28, showing 3D culture of RAW264 at different time points, 
and the fluorescent ones in figure 6-29 highlight the differences in appearance of cells in different 
environments. Compared to 2D culture, RAW264 adopted a more clustered growth pattern when 
cultured in 3D for at least 48 hours. After initial seeding and compression (figure 6-28 A), cells appear 
individual and diffused throughout the entire gel. After 48 hours (figure 6-28 B; figure 6-29 (right)), 
cells appear to have clustered together and the diffusion through the gel seen in panel A of figure 6-
28 appears to have reversed and be replaced with larger clusters of cells that are not as densely 
distributed as they were immediately post seeding. The Nile red staining clearly denotes the 
differences in membranes between individuated and clustered cells while showing no uptake of lipid.  
The polarization stimulations done for 2D RAW264 culture were also done for 3D culture as shown in 
figure 6-30. RAW264 cells were able to demonstrate oxLDL uptake, although extent of uptake is 




Figure 6-29: Comparison of 2D RAW264 culture and 3D RAW264 culture in compressed collagen hydrogel. RAW264 
appearance in 2D (left) versus 3D culture (right). Samples stained with Nile red. For 3D culture, cells were seeded at 5 x 
105 cells in 1500μl collagen (3mg/ml) before compression and separation into two gels. Compressed gels were cultured 
















































As evidenced by figure 6-28, 6-29 and 6-30, the clustered growth of RAW264 adds complexity to the 
evaluation of extent of oxLDL uptake with either LPS or IFN-γ or both and also in the presence of 
atorvastatin. Atorvastatin does seem to have an effect on accumulation of lipid droplets and their 
retention within cells i.e., there appear to be fewer droplets in the drug treated samples and for the 
IFN-γ treated samples, the lipid droplets do not seem associated with an intact cell body but rather a 
ruptured cell. The clusters observed as a regular feature of 3D culture also appear to have dissociated 
into individual cells in the presence of IFN-γ and oxLDL (figure 6-30). This appears to be an effect unique 
to IFN-γ or oxLDL inclusion as this “clump dissociation” is more apparent in IFN-γ, and to a lesser extent 
oxLDL, treated samples. The same is observed in the live dead staining below (figure 6-31), in that the 
size of green bodies in the image are distinctly smaller and fewer in the IFN-γ and oxLDL treated 
samples, especially in the absence of atorvastatin. The Image of the untreated sample was taken 





The live/dead images in figure 6-31 suggest that atorvastatin has a positive impact on cell viability/proliferation, with treated samples showing large and 
numerous cell clusters, which indicate higher density of RAW264 cells.  The images appear to indicate there more live cells in the presence of atorvastatin 























Figure 6-31: Live/dead viability evaluation: A live/dead (green/red) evaluation was carried out across 3D RAW264 culture samples. The RAW264 untreated sample was cultured in 




than without. Given the density of clusters i.e., larger sized green stained bodies observed in the 
presence of atorvastatin, it can be suggested that atorvastatin has a positive impact on proliferation 

























































Figure 6-32: RAW264 in 3D - CCK8 cell viability. This plot compares cell viability of RAW264 embedded in a compressed 
collagen hydrogel. Samples were cultured for 24 hours before analysis with CCK8. Statistical analysis was done using one 
sample t-test as well as two-way ANOVA, with significance identified for each variable and between variables. For all 
analyses, the generated p value was <0.0001 ****. N=4.  
 
The data represented in figure 6-32 shows that atorvastatin, in the presence of oxLDL, appears to result 
in a reduction in cell viability. With 6μg/ml atorvastatin, compared to the control sample, appearing to 




6.1.16.1 Effect of HCASMC co-culture on foam cell models  
Attempts were made to culture both RAW264 and HCASMCs to create a lipid and macrophage rich 
“plaque”. To accomplish this, different seeding techniques were applied. The first follows the 
protocol described for seeding RAW 264 cells in compressed gels. For the co-culture model, the 
acellular gel first dispensed into the compression moulds was replaced with a collagen-HCASMC 
mix, with HCASMCs seeded at 1 x 105 cells/gel. RAW264 cells suspended in collagen were then 
added to the mould and allowed to set, followed by compression. The main problem presented by 
this seeding method was that the thickness of the compressed gel does not permit visualisation of 
both cell types simultaneously (figure 6-33).  
 
 
As was observed in figure 6-30, there also appears to be some evidence of “clump dissociation” in the 
oxLDL treated samples (figure 6-33). This may be a feature specific to partially activated/polarized 
RAW264 cells, and may be reversed by the inclusion of atorvastatin. Given the challenge in 
visualisation of these gels, an alternative method was attempted to seed RAW264 cells on smaller un-
compressed collagen gels seeded with HCASMCs. These alternative co-culture gels were made by first 
RAW + HCASMC + oxLDL 
 
RAW + HCASMC 
 
Figure 6-33: HCASMC-RAW264 co-culture. Nile red staining of RAW264 co-cultured with HCASMC in a compressed 
collagen gel. Samples here were not treated with any stimulants aside from oxLDL. Images taken at 40x. Nile red, 
DAPI.  
 
Figure 6-34: HCASMC-RAW264 co-culture. Nile red staining of RAW264 co-cultured with HCASMC in a compressed 
collagen gel. Samples here were not treated with any stimulants aside from oxLDL. Images taken at 40x. Nile red, 
DAPI.  
 
Figure 6-353: HCASMC-RAW264 co-culture. Nile red staining of RAW264 co-cultured with HCASMC in a compressed 
collagen gel. Samples here were not treated with any stimulants aside from oxLDL. Images taken at 40x. Nile red, 
DAPI.  
 
F gure 6-36: HCASMC-RAW264 co-culture. Nil  red staining of RAW264 co-cultured with HCASMC in a co pressed 
collagen gel. Samples here were not treated with any stimulants aside from oxLDL. Images taken at 40x. Nile red, 
DAPI.  
 
Figure 6-373: HCASMC-RAW264 co-culture. Nile red staining of RAW264 co-cultured with HCASMC in a compressed 
collagen gel. Samples here were not treated with any stimulants aside from oxLDL. Images taken at 40x. Nile red, 
DAPI.  
 




dispensing 200μl HCASMCs suspended in collagen gel onto 1 x 1cm2 filter paper frames to form a TEML. 
This primary gel was allowed to set for 20 minutes at 37°C/5% CO2. This was followed by injecting 
RAW264 cells suspended in collagen into the centre of the TEML. The resultant hydrogel would, ideally, 
have a zone enriched with RAW264 cells that was separate from the HCASMCs while having a gel that 
can be examined microscopically. Versions of this alternative co-culture seeding method are 
































Figure 6-34: RAW264 and HCASMC co-culture. These images represent different attempts at injecting RAW264 into TEMLs. 
Version one involved the syringe being angled perpendicular to the TEML then injecting the RAW264 cells. Version two and 
three, the syringe was angled approximately 45 degrees to the TEML surface before injecting RAW264. White dotted circle 




Of the three attempts at an alternative seeding method represented in figure 6-34, version one gave 
the best expected result but with unwanted tearing of the TEML during injection. The resultant gel has 
distinct separation of the RAW264 and HCASMCs, and RAW264 cells permeated the depth of the gel 
versus only surface infiltration in versions 2 and 3, with version 3 having more scattered distribution 






6.1.17 IFN-γ is a weak inducer of macrophage polarization 
Macrophages are involved in a number of regulatory functions in many organ systems such as innate 
and adaptive immunity, haematopoiesis, vasculogenesis and systemic metabolism. These numerous 
functions are also associated with varying cellular phenotypes with general classification under either 
M1 or M2. M1 or classically activated macrophages are associated with pro-inflammatory processes 
while M2, or alternatively activated macrophages, are associated with anti-inflammatory processes 
and tissue remodelling (Liu et al., 2014). One of the objectives of this chapter was to switch RAW264 
cells into an M1 phenotype which would result in increased uptake of oxLDL. This was attempted with 
both IFN-γ and LPS, but using only IFN-γ as a stimulant was the preferred method due to the 
quantification method being applied here. While we have observed uptake of both LDL and oxLDL 
here, quantification data suggests that the influence of IFN-γ does not trigger vastly stronger uptake 
of oxLDL. This could be explained by findings that state IFN-γ treatment can actually lower circulating 
amounts of cholesterol (Whitman et al., 2000) as well as the lipid content within cells, resulting in the 
decrease of foam cell numbers in atherosclerotic plaques rich in T-cells secreting lesional IFN-γ (Young, 
Libby and Schönbeck, 2002). These variations in IFN-γ effect on foam cell formation could be a result 
of differing environmental signals that shift polarization along the M1/M2 spectrum. Macrophages are 
able to change their activation state in response to growth factors, cytokines and additional external 
cues such as any entity capable of being recognised by macrophages (Murray et al., 2014). Here, the 
inclusion of HUVECs and/or atorvastatin appears to limit the expected effect IFN-γ has on oxLDL 
uptake/retention in that the quantification done shows lower oxLDL concentrations on the IFN-γ 
treated samples than the unstimulated ones, especially in lesioned HUVECs in the presence of 
atorvastatin (figure 6-22).  
6.1.18 NO is a useful biomarker for foam cell models 




production in both HUVECs and RAW264, however they also indicate that IFN-γ stimulation results in 
lower NO production compared to unstimulated cells, and that oxLDL is a stronger stimulus for NO 
production than IFN-γ (figure 6-19 and figure 6-21). Figure 6-20 (e, f) shows that in regards to NO 
production, addition of IFN-γ appears to limit NO production in HUVECs and, to a lesser extent, in 
RAW264. The co-culture model shows expected responses in terms of NO production, with intact 
HUVECs consistently demonstrating higher NO levels than lesioned HUVECs. The highest NO readings 
were seen for cells cultured without IFN-γ stimulation and in the presence of 6μg/ml atorvastatin. 
Produced by endothelial cells, NO is a key regulator of vascular health and reduction in its production 
is related to oxidative stress, lipid infiltration, alteration of vascular tone and the expression of 
inflammatory factors (Chen et al., 2018). In macrophages, production of NO is associated with their 
activation, along with the production of inflammatory mediators such as interleukin, tumour necrosis 
factor (TNF) and reactive oxygen species (ROS). This increase in production is to aid in destruction of 
internalised pathogens (Guo et al., 2020). IFN-γ has been associated with triggering NO production in 
macrophages, through inducible nitric oxide synthase (iNOS), as part of native immunity (Hoeksema 
et al., 2015). The data presented in figure 6-16 suggest that atorvastatin negatively affects NO 
production in RAW264 stimulated with IFN-γ, while the opposite effect is seen on IFN-γ stimulated 
HUVECs where the inclusion of atorvastatin promotes NO production, albeit in a somewhat lesser 
extent than without IFN-γ. This suggests that atorvastatin exerts some protective effect on maintaining 
vascular health in that it promotes the beneficial production of NO in endothelial cells, while limiting 
deleterious RAW264 NO production. This observation can be supported by findings that suggest that 
atorvastatin exerts some immunomodulatory effects and can promote a shift from a pro- to and anti-
inflammatory profile.  
6.1.19 oxLDL contributes to foam cell formation and macrophage polarization 
oxLDL has also been associated with an increase in NO production in macrophages. Specifically, the 
increased production on iNOS which facilitates extended production of NO (Huang et al., 2014). A key 




this is done with IFN-γ (for an M1 phenotype) in conjunction with toll like receptor (TLR) activation 
with immunological substrates such as LPS for further activation (Hoeksema et al., 2015; Guo et al., 
2020). oxLDL has been demonstrated as being able to stimulate toll like receptors (Chávez-Sánchez et 
al., 2014), which would potentially explain the increased NO production seen when IFN-γ was used in 
conjunction with oxLDL (figure 6-19), versus just IFN-γ stimulation alone. These observations are 
corroborated by the data in figure 6-7, where LPS demonstrates a very strong effect on NO production 
on its own, and to a lesser extent with the inclusion of oxLDL.  
6.1.20 Atorvastatin has a strong impact on cholesterol efflux 
The experiments conducted here also demonstrate that atorvastatin has an effect on cholesterol 
efflux/reverse cholesterol transport. Nile red imaging and oil red-O quantification show the inclusion 
of atorvastatin results in fewer lipid droplets observed within samples (figure 6-9 to figure 6-12) and 
lower concentrations of quantified lipid content (Figure 6-13 and figure 6-22). There is a general lack 
of consensus on whether atorvastatin has an effect on cholesterol efflux, but it has been suggested as 
a strong possibility. The regulation of the scavenger receptor ATP-binding cassette transporter G1 
(ABCG1) expression on macrophages has been linked to atorvastatin related cholesterol efflux (L. Xu 
et al., 2019). The work by Xu et. al., 2019, related to advanced glycation end products (AGEs) in 
diabetes, showed that atorvastatin increased expression of ABCG1, a receptor that is associated with 
cholesterol efflux and maintaining cholesterol homeostasis, reversing the inhibition of this receptor 
done by AGEs. Counter to these findings, earlier work by Qui and Hill, 2008, suggested that atorvastatin 
inhibits expression of another variant of scavenger receptor, ATP-binding cassette transporter A1 
(ABCA1), and thus cholesterol efflux. Their work, however, found this inhibition only on non-
cholesterol loaded macrophages and this effect was compromised after acetylated LDL loading, 
suggesting that atorvastatin’s efflux effect may be dependent on cells actually having internalised lipid 
in the first place (Qiu and Hill, 2008). The findings in this chapter also suggest that the efflux effect of 
atorvastatin is stronger in IFN-γ stimulated samples than unstimulated samples. This may be explained 




anti-inflammatory profile. Cheng et. al., 2009 observed that levels of IFN-γ and the ratio of IFN-γ: Il-4 
were significantly decreased with atorvastatin in patients suffering from chronic heart failure (Cheng 
et al., 2009).  
6.1.21 HUVEC integrity affects foam cell formation and cholesterol efflux 
Lesioned HUVECs also appear to limit the efflux effect, suggesting that the cytokine 
profile/environmental cues associated with lesioned HUVECs, along with IFN-γ stimulation especially, 
also contribute to cholesterol efflux. HUVECs triggered into dysfunction produce a variety of pro-
inflammatory mediators, adhesion molecules and pro-thrombotic factors. Some of these pro-
inflammatory mediators include IFN-γ, tumour necrosis factor-alpha (TNF-α), tumour growth factor-
beta (TGF-β) and macrophage colony stimulating factor (M-CSF) (Ramji and Davies, 2015). Findings 
from chapter 5 demonstrate that atorvastatin has an effect on increasing and sustaining SDF-1 
production in both endothelial and smooth muscle cells. Li. et. al., 2020 identified SDF-1 (CXCL12) 
production by macrophages (THP-1 cells) as a promoter of atherosclerosis development. Cells were 
first stimulated with poly-methyl acrylate (PMA) then oxLDL to promote foam cell formation. oxLDL 
loaded cells were cultured with vascular smooth muscle cells (VSMC) and they found that the foam 
cells produced SDF-1, which in turn promoted VSMC uptake of oxLDL, resulting in their proliferation 
and their becoming foam cells (Li et al., 2020).  As stated previously, pro-inflammatory cytokines like 
IFN-γ and TNF-α are associated with driving foam cell formation in atherosclerosis, as such, it is likely 
that the lesioned HUVECs are producing these pro-inflammatory cytokines that are affecting 
cholesterol efflux. 
6.1.22 Scavenger receptor (CD36) expression is affected by oxLDL and atorvastatin 
CD36 is a scavenger receptor able to bind to a number of ligands, such as modified phospholipid, long 
chain fatty acids, oxLDL, oxidized and negatively charged phospholipids, collagen and apoptotic cells,  
and is found on the surface of a number of cell types such as platelets, endothelial cells, smooth muscle 
cells and macrophages (Collot-Teixeira et al., 2007; Choromañska et al., 2017). Binding of oxLDL to 




CD36 expression (Collot-Teixeira et al., 2007). Animal studies have demonstrated that deletion of CD36 
prevented the development of atherosclerosis despite a lipid rich diet and human studies based on 
autopsies of obese subjects have demonstrated increased expression of CD36 on plaque localised 
macrophages (Choromañska et al., 2017; Lara-Guzmán et al., 2018). The data presented here (figure 
6-23), supports these observations in that the inclusion of oxLDL to RAW264 culture results in 
increased expression of CD36, compared to the absence of this receptor in untreated samples. The 
data here also suggests that atorvastatin may upregulate the expression of CD36, in that the staining 
shown in figure 6-23 and figure 6-24 appears marginally stronger than in the atorvastatin free samples. 
These observations are supported by Ruiz-Velasco et. al., 2004, who found that statins (lovastatin, 
Fluvastatin and atorvastatin) increased CD36 expression in THP-1 cells in a time and dose dependent 
manner. The doses used were between 2-10μM, which fits with the selected concentration used here 
(6μg/ml = 4.96μM) (Ruiz-Velasco, Domínguez and Vega, 2004). In regard to IFN-γ effect on expression 
of CD36, the comparative between lesioned and un-lesioned HUVEC co-culture, both with and without 
atorvastatin, for samples treated with or free of IFN-γ, there does not appear to be any significant 
effect of IFN-γ on the expression of CD36. Some works have suggested that IFN-γ decreases expression 
of CD36 (Geng and Hansson, 1992; Nakagawa et al., 1998), but more recent works demonstrating the 
positive effect of IFN-γ on foam cell formation, rather than an inhibitory effect, suggest that this may 
not be the case (McLaren and Ramji, 2009) and also that IFN-γ may have a stronger effect on other 
scavenger receptors, triggering foam cell formation in a CD36 independent manner (Reiss et al., 2004; 
Yu et al., 2015). Intracellular levels of cholesterol do not regulate CD36 mediated uptake of cholesterol, 
leading to continuous uptake of oxLDL and the differentiation of macrophages into foam cells (Rios, 
Gidlund and Jancar, 2011). This observation may partially explain reduction in circulating LDL levels 
observed with administration of atorvastatin and in light of the data shown here suggesting that 





6.1.23 CD146 expression is affected by atorvastatin and IFN-γ 
CD146 has been associated with the development of a number of non-resolving inflammatory diseases 
such as rheumatoid arthritis, inflammatory bowel disease and inflammatory diseases associated with 
endothelial damage (Blin et al., 2019), and has been found on activated inflammatory cells, suggesting 
it confers a pro-inflammatory profile on immune cells (Luo et al., 2017). Its expression has been 
identified on infiltrated macrophages in atherosclerotic plaques and has been associated with plaque 
vulnerability. Its expression on macrophagic foam cells is upregulated by oxLDL, and mediates CD36 
internalisation during lipid uptake (Luo et al., 2017; Blin et al., 2019). The data here supports 
observations that oxLDL promotes CD146 expression and suggests IFN-γ may promote expression of 
CD146 (figure 6-26) when compared to unstimulated cells (figure 6-25). The images in figure 6-25, 
specifically those of RAW264 cultured with lesioned HUVECs, indicate atorvastatin restricts expression 
of CD146, while having little to no effect on CD146 expression in intact HUVECs. There is not a lot of 
literature available discussing the role of CD146 in the context of atherosclerosis and in relation to 
atorvastatin, with only the work done by Luo et. al., 2017 being the most significant, but the effect 
seen here suggests that the increase in CD36 expression observed in the unstimulated RAW264 cells 
co-cultured with lesioned HUVECs is possibly a result of the decreased CD146 expression seen for the 
same variable combination. Further characterization of CD146 and its role in foam cell formation is 
required.  
To truly verify the effect atorvastatin has on cholesterol efflux, further evaluation needs to be done 
here; for example, visualisation and quantification of additional scavenger receptor expression. 
Further characterization of the impact of individual variables, and these same variables in conjunction, 
would be ideal. A number of atorvastatin doses also need to be applied to determine conclusively the 
doses at which this effect on CD146 and CD36 is observed. Here we visualised efflux at 6μg and 
60μg/ml atorvastatin, with stronger indications of efflux, possibly tied to reduced cell numbers, 
observed at 60μg/ml. It has been observed that a CD146 deficiency results in neutrophilia and the 




receptor. This did not impact LDL uptake but did result in an increase in atherosclerotic plaque size 
(Blin et al., 2019). The work by Blin et. al., 2019 highlights a possible correlation between CD146 
expression and RANTES (CCL5) expression and further emphasises the need for further work on the 
role of CD146 in atherosclerosis.  
6.1.24 3D models demonstrate variations in foam cell behaviour compared to 2D culture 
For the 3D culture of RAW264 cells, the primary challenge was in optimising conditions to allow clearer 
visualisation of foam cells and physiologically relevant inclusion of smooth muscle cells. It was possible 
to generate higher concentration collagen gels with RAW264 embedded within the gel but these cells 
displayed different growth profiles than 2D culture. Images in figure 6-28 to figure 6-31 show what 
appear to be cell clusters as these cells proliferated. This phenomenon has been described as fusion, 
which occurs when macrophages are implanted in a 3D environment, resulting in the formation of 
multinuclear cells called “foreign body giant cells”, which are commonly occurring in the  foreign body 
reaction against implanted biomaterials (Fang, Yang and Han, 2020). Fang et. al., 2020 demonstrated 
that at different concentrations of collagen, affecting material stiffness, implanted RAW264 slowed 
their proliferation with increasing concentration (and thus stiffness) of collagen. These observations 
align with the CCK8 data represented here (figure 6-32), where readings for cells seeded at the same 
density in 2D and 3D were markedly different, with the 3D cultured cells having much lower readings 
which correlate with reduced proliferation. The live dead images (figure 6-31) indicate that seeding 
into collagen followed by compression did not negatively affect cell health and also provides evidence 







The data collected in this chapter have been successful at demonstrating RAW264 induction to 
promote LDL/oxLDL uptake as well as the effects of atorvastatin in reversing this effect in a time and 
dose dependent manner. It was also revealed that the production of NO is affected by numerous 
factors, most notable being LPS, and that atorvastatin was able to restrict production of NO by 
macrophages in an inflammatory state. The experiments caried out also demonstrated the positive 
effect of atorvastatin on cholesterol efflux, likely due to manipulation of scavenger receptor 
expression. It was also possible to demonstrate the effect atorvastatin has on scavenger receptor 
expression. It was possible to create an alternative co-culture model with HUVECs and RAW264, 
demonstrating a synergistic effect in regards to NO production and oxLDL retention in the presence of 
atorvastatin. The attempts at incorporating RAW264 into a 3D matrix showed that cell behaviour is 
affected by environmental cues and this work can be taken further through experimentation with 
material stiffness and incorporation of different cell types. With the possibility of combining various 
variables, it should be possible to characterise the contributions of other pro-inflammatory cytokines 
as well as cell types using this foam cell model to generate a clearer picture of foam cell formation and 































7.1 Background review 
Cardiovascular disease is recognised as the leading cause of morbidity and mortality globally and 
atherosclerosis has been identified as the underlying cause for cardiovascular diseases, such as heart 
attacks and strokes (Gareus et al., 2008). This has resulted in a lot of research into the pathophysiology 
of atherosclerosis to better understand the mechanisms involved in its initiation and progression, and 
thus provide better insights into better preventative and curative measures. Currently, it is accepted 
that atherosclerosis is associated with both metabolic disorder and chronic inflammation in the arterial 
wall, a process initiated by the deposition of apolipoprotein B-containing lipoproteins in the sub 
endothelial space (H. Xu et al., 2019). The primary lipoprotein associated with atherosclerosis is LDL, 
which can trigger endothelial activation/dysfunction as well as being prone to oxidation (Badimon, 
Padró and Vilahur, 2012; Moriya, 2019). These oxidised LDLs, combined with an endothelial 
inflammatory response, result in the recruitment of immune cells, primarily macrophages/monocytes, 
neutrophils, T-and B-lymphocytes, which contribute further to disease progression (Moriya, 2019).  
For a number of years, the primary prescribed treatment for atherosclerosis has been statins. Studies 
have demonstrated that patients prescribed statins show statistically significant and clinically 
important reductions in risk of cardiovascular disease manifestation (Hennekens, Schuttenberg and 
Pfeffer, 2019). Their primary application is in the regulation of cholesterol levels and they have 
demonstrated very good effects on lowering the incidence of cardiovascular events in patients, with 
atorvastatin being the main statin used for this kind of treatment (Peng et al., 2018). Aside from the 
lipid lowering effect, this drug has demonstrated a capacity to affect the inflammatory process, with 
evidence showing treatment with atorvastatin significantly ameliorates the secretion of pro-
inflammatory cytokines such as tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), as well as 
levels of C-reactive protein (CRP) which is a common inflammation marker (Sugiyama et al., 2005; 
Sadowitz, Maier and Gahtan, 2010; Peng et al., 2018). Of particular interest in recent years is the effect 
statins have on endothelial progenitor cells (EPCs). A number of studies have reported beneficial 




Butler, 2017), enhancing homing/recruitment of EPCs to sites of vascular injury (Oikonomou et al., 
2015)(Walter, Dimmeler and Zeiher, 2004) and improving EPC attachment/adhesion and 
differentiation (Liu et al., 2012).   
As pertains to the obtainment of the observations on factors contributing to the pathogenesis of 
atherosclerosis, and additional effects of statins, a significant number of studies rely on animal models 
to generate data. The obvious limitations of this, primarily cost, ethical considerations, species 
variability and the inhibitory effect of anaesthetic agents on platelet aggregation (Atkinson, Taylor and 
Chetty, 1985; Nakagawa et al., 2002), which potentially limit reproducibility and relatability of results, 
highlight a need for an alternative mode of data collection. In vitro models have also played an 
important role in determining contributing factors and elucidating mechanisms of action, but in 
addition to being carried out in a two-dimensional context, they also lack a key component involved in 
the pathophysiology of atherosclerosis, which is shear stress. Flow based models that can incorporate 
functional three-dimensional models for cellular responses in drug screening studies would have 
tremendous value in providing insight for future development of ideal strategies against 
atherosclerosis (Khodabandehlou et al., 2017).  
The work carried out in this thesis aimed to develop and apply 3D tissue engineered vascular models 
to investigate the pleiotropic effects of statins. First, the work here attempted to define the differences 
in stem cells and progenitor cells’ responses in homing towards a lesion, using cells from different 
species. The second objective was to highlight the differences observed in stem and progenitor cells’ 
responses in 2D and 3D physiologically relevant environments i.e., with an injury and under shear 
stress. The third objective was to demonstrate the applicability and ease of use of the 3D blood vessel 
model to create complex systems such as the atherosclerosis model. For all the objectives listed, the 





7.2 Key findings  
Through the experiments conducted within this thesis, it was possible to demonstrate the value of 
having 3D tissue models to study disease pathology, and these models were able to highlight the 
contributions of the intimal and medial layers, separately and in concert, to the recruitment of 
circulating cells and in response to different activation stimuli. The use of nanofiber inserts to create a 
novel HUVEC-RAW264 co-culture system provided a convenient, and rapid system to study 
atorvastatin’s effect on cholesterol efflux, while evaluating the impact of intact or lesioned intimal layer 
on this process. These models were also useful in characterising cellular responses to atorvastatin, 
demonstrating both a time and dose dependent effect in regards to wound closure, EPC homing (under 
high and low shear stress), SDF-1 production, cholesterol efflux, inhibition of inflammatory effects of 
IFN-γ, and regulation of NO production. These models also manage to highlight the differences in 
relatability of responses between animal and human cells.   
7.3 EPCs demonstrate different features of stemness compared to MSCs. 
Characterisation of EPCs is a challenging task as since their discovery in 1997 by Asahara et.al., there 
has been a general lack of consensus regarding defining the characteristics that are used to identify 
this cell type (Chopra et al., 2018c). Because of this lack of consensus, a general definition of EPCs can 
be used which identifies them as cells formed in either nonhematopoietic tissues or the bone marrow, 
and conceptually can be considered a heterogeneous group of cells, which can characteristically be 
detected at different phases of endothelial differentiation in the peripheral blood (Poay Sian Sabrina 
Lee and Kian Keong, 2014). Over the years, EPCs have been sourced either from umbilical cord blood, 
adult peripheral blood or bone marrow (Ii, 2010; Yoder, 2012; Chen et al., 2021). As relates to their 
origin, one theory states that EPCs are derived from haemangioblasts, a precursor of both 
haematopoietic and endothelial cells (Chopra et al., 2018c). Upon first discovery, these cells were 
initially identified through expression of CD34, a marker indicating haematopoietic lineage, and Flk-1 
(KDR/VEGFR-2) which is an endothelial lineage marker and co expression of CD34 and Flk-1 have been 




2012). To aid with increasing specificity for EPCs, inclusion of CD133 as a marker was done as it denotes 
a more immature haematopoietic cell (Urbich and Dimmeler, 2004). Another marker of interest is 
CXCR4 and its association with SDF-1, which contributes to the mobilisation and homing of bone 
marrow derived cells. Studies have indicated an importance of the SDF-1/CXCR4 axis in promoting the 
mobilisation and homing of EPCs, with disruption to the SDF-1/CXCR4 interaction resulting in impaired 
incorporation of EPCs into ischaemic sites (Yu and Feng, 2008). Cells that express CD34 have been 
shown to express low levels of CD45, and detection of this receptor has been suggested as an 
additional method of characterising EPCs (Fadini, Losordo and Dimmeler, 2012). CD31 has also been 
proposed, and used, as a potential marker for these cells even though it can also be expressed on 
mature endothelial cells (Poay Sian Sabrina Lee and Kian Keong, 2014; Melchiorri et al., 2016).  
For our purposes, the markers selected to verify the nature of the cultured cell type were CXCR4, CD34, 
Flk-1, CD45 and CD31, which proved sufficient to define these cells as endothelial progenitors. Further 
to surface marker expression, tube formation is an additional assay used to define cells as endothelial 
progenitors. This involves the seeding of isolated cells in Matrigel supplemented with factors such as 
vascular endothelial growth factor (VEGF), which stimulates vessel formation (Huang et al., 2012; Zhao 
et al., 2018). In our 2D aspect of this study, it was possible to observe spontaneous formation of tube-
like structures, with cells joining end to end to form a closed loop structure, observed in both 
fibronectin and collagen coated plates, which provided additional evidence that the cells isolated from 
whole blood were progenitors. Additionally, it has been demonstrated that cells capable of colony 
formation would also result in the formation of tubes (Peters, 2018). The cells cultured in this study 
always formed colonies within the first 3-4 days of culture, further suggesting that they were the 
desired cell type given the subsequent spontaneous formation of the tube-like structures as well as 
the expression of a number of surface receptors that correlate with EPCs.  
Aside from the characterisations done on the EPCs on their own, their responses to atorvastatin and 
interactions with the TE constructs is in line with published work (Petit, Jin and Rafii, 2007; Yu and 




perfused cells on atorvastatin treated and lesioned constructs, at both low and high shear stress in 
chapter 5. 
7.4  Murine cells have different responses to atorvastatin compared to human cells 
As relates to the beneficial effects of atorvastatin, the data collected here has demonstrated that 
murine cells had higher migration rates into a scratch wound compared to human derived MSCs 
(hMSCs) and EPCs, and more cells were present with increasing concentrations of atorvastatin, with 
peak infiltration observed at 120μg/ml. The methods applied here were a simple scratch wound which 
allowed rapid collection of data as well as providing a starting point for evaluating cellular responses 
to atorvastatin. In comparison, hMSCs showed reduced numbers of cells at all doses of atorvastatin 
compared to the drug free control. This model was also useful in showing that depending on cell 
combinations, the HUVEC response was also varied in that when co-cultured with rMSCs, HUVEC 
migration into the scratch wound followed the same trend, with increasing cell numbers with higher 
concentrations of atorvastatin, with peak cell numbers also achieved at 120μg/ml. When HUVECs were 
cultured with hMSCs, peak attachment was observed at the lowest concentration of atorvastatin 
applies, 30μg/ml. This was followed by a reduction in cells within the scratch wound, with a second 
smaller peak observed at 120μg/ml.  As for the EPCs, they showed a positive response to atorvastatin 
up to 60μg/ml, however HUVECs were fewer in number with atorvastatin compared to the drug free 
control. They did demonstrate a small peak at the same point as the EPCs (60μg/ml), further 
highlighting that there are cellular interplays that influence the behaviour of surrounding cells.  
Exploration of a wider range of atorvastatin concentrations would have allowed clarification of the 
interaction between the endothelial cells used here and hMSCs, as numerous studies have explored 
the possibility of using MSCs from various locations as therapies and have shown promising results in 
regards to atorvastatin enhancing the migration and differentiation of MSCs, and improving 
incorporation of MSCs to injury sites and improving endothelial health (Song et al., 2013b; Zhang et 
al., 2014; Bing et al., 2016). The variations observed between the work carried out here and the studies 




2013b) or rats (Cai et al., 2014) could affect outcomes as well as differences in experimental design in 
that other pathways and cellular stimulations/activations were investigated (Zhang et al., 2014).    
To further explore these differences observed by using different cell types in culture, more work would 
be needed to clearly characterise the inter-relationship between endothelial cells and MSCs as the 
data here suggests that even between human cells, the cell types have different interactions with each 
other as is demonstrated by the EPC responses to atorvastatin versus the hMSC responses to the same, 
in conjunction with HUVECs. As previously mentioned, it is likely that the concentration of atorvastatin 
that would be ideal to enhance MSC homing is different to that observed with EPCs, with different 
studies reporting varying ranges of concentrations with similar results, for example Yu and Feng, 2008 
reported that EPC migration was enhanced at low concentrations of atorvastatin i.e., 10 nM-100 nM, 
whereas the beneficail effect observed was significantly inhibited at concentrations higher that 1000 
nM (Yu and Feng, 2008). It should be noted that these findings were based on a mouse model of 
ischaemia (Yu and Feng, 2008), so again, species variation may also be a contributing factor. Other 
works report the concentration in terms of weight (Song et al., 2013b; Cai et al., 2014; Zhang et al., 
2014), which makes it difficult to compare without the weights of the animals used or resorting to 
using animal models. It would also be interesting to compare adhesion molecule expression between 
these cell types i.e., other than the commonly expressed CXCR4, and determine if there are specific 
conditions that are not met by the parameters set out in this experiment, and also possibly determine 
if there is a concentration of atorvastatin that works equally for both cell types, improving the 
functionality of these cells together with endothelial cells.  
7.5 Multiple factors affected 3D culture and perfusion outcomes. 
Advancing from the established 3D tissue engineering blood vessel (TEBV) studies  in which single and 
multi-cellular layers and extracellular matrix (ECM) can be included into TEBV models (Musa, Harper 
and Yang, 2016), the work in this study, has incorporated multiple factors to assess TEBV responses 
under physiologically relevant conditions. Under static culture, these models have been 




Ca2+ signalling (Musa, Harper and Yang, 2016). Their anti-platelet and pro-platelet activation features 
have been confirmed when the intimal layer is intact and absent respectively, replicating the anti- and 
pro-aggregatory properties of native arteries. Furthermore, it is evident that the neo-collagen 
formation in medial layer was pro-aggregatory, whilst collagen gel from rat tail used as the scaffold for 
medium layer didn’t. To the end of replication of physiological relevant environment, multiple factors 
have been investigated including perfusion modes via commercially-available parallel-plate flow 
chamber versus rocker; different statin dose and incubation duration; lesion modes and TEBV models.  
7.1.1 The effect of mode of perfusion 
The data collected in chapter 4 suggested that hMSCs are not responsive to atorvastatin at the selected 
doses, possibly because additional factors such as shear are required to facilitate this (Rüster et al., 
2006). When shear was introduced using a parallel plate flow chamber in chapter 5, perfused hMSCs 
showed increased attachment over the TEBVs incubated with atorvastatin versus those without. The 
parallel plate flow chamber provided a defined flow pattern and enabled variable shear stress through 
changing the flow rate or the dimensions of the gasket which holds the sample. Using the attached 
cells as the readout, consistent observations across hMSC and EPC perfusion with FeCl3 as the lesion 
model have been obtained. Contrastingly, even though the rocker model did show some difference 
between atorvastatin treated and drug free samples, the differences were not as significant as those 
seen under physiologic shear stress, although it was possible to evaluate cell attachment over a wider 
range of time points. These two modes of perfusion showed that peak attachment is generally attained 
at the 5-hour time point across models, with some variation between 5 and 7-hours, with the most 
noticeable difference being the number of attached cells on the surface of the constructs i.e., lower 
shear stresses resulted in higher numbers of attached cells, while maintaining the same trend denoting 
the impact of atorvastatin and duration of incubation on the same. The advantage of the parallel plate 
flow chamber is that the shear stress is physiologically relevant and adjustable, and the flow 
unidirectional and continuous, whereas with the rocker, the flow alters the directionality of shear 




that it limits the test sample number, while the rocker is ideal for high throughput testing (Zhou et al., 
2010). 
7.1.2 The effect of statin incubation duration 
To simulate a clinical scenario, the injured TE constructs were incubated with atorvastatin for different 
durations before perfusion of hMSCs and EPCs. Oral intake of atorvastatin would require time to 
circulate to the lesion site and enhance cytokine production for cell homing. Injured tissues themselves 
would have a time frame during which peak cytokine production would naturally be reached. What 
we were able to determine from the 3D models is that atorvastatin was able to increase density of 
attached cells on the surfaces of lesioned TE constructs. This effect was also seen to be time dependent 
as consistently across the TEIL, TEML and TEBV, longer incubations resulted in an increased density of 
attached cells, with the optimal time frame being around 5-hours post lesioning and incubation with 
atorvastatin. This effect was observed under different modes of perfusion i.e., dynamic flow within a 
parallel plate flow chamber and with a see-saw rocker, which were able to provide high (20.16 
dyne/cm2) and low (up to 2.2 dyne/cm2) shear stress respectively.  
In addition to the influence atorvastatin had on cell attachment onto the lesioned TEBV, the duration 
of incubation also contributed to an increase in the number of attached cells, with the 5-hour 
incubation having more cells attached onto the surface compared to the 3-hour incubation. The 
difference here could be because of shear or it could also be because the hMSCs were not also 
incubated with atorvastatin at the same dose or for the same duration, but rather only inoculated with 
atorvastatin immediately before perfusion. For further clarification, it would have been ideal to have 
a comparative of hMSCs also incubated with atorvastatin for 3 and 5-hours before perfusion.  
Relative to the static incubation with hMSCs, despite a longer incubation period (24 hours versus 3 and 
5-hours), and with the same density of cells used for both conditions i.e., 6 x 103 cells/ml, the samples 
subjected to shear showed overall higher numbers of cells attaching on the surface of the TEBV 
compared to the numbers of cells recorded within the scratch wound. This again highlights the 




stress, it was also possible to incorporate smooth muscle cells, which would have their own separate 
effect on stimulating cell attachment. Another difference is the surface area for evaluation. The scratch 
wound provides a smaller surface area than the TEBV and does not accurately represent the conditions 
of the vasculature that the perfusion system does i.e., hMSCs would be in motion through the 
vasculature versus being suspended over the endothelial layer as happened in the scratch wound 
model. It was evidenced that the incubation duration of atorvastatin and the host blood vessel cells 
was an essential factor in triggering EPC or MSC homing, while the inclusion of hear stress and other 
cell types e.g., smooth muscle cells, were more a more important factor in affecting EPC migration 
than the atorvastatin incubation time.  
 
7.1.3 The effect injury type 
We were also able to examine the effect of injury type on cell responses and it was possible to 
determine that this too has an impact on observations. The injury types evaluated here were 
mechanical-representing mild denudation as can be seen with percutaneous transluminal coronary 
angioplasty (PTCA/balloon injury)- and FeCl3 induced oxidative injury, which is more representative of 
the oxidative damage seen in atherosclerosis (Varghese, Patel and Yadav, 2017). The mechanical injury 
provided an opportunity to regulate the extent of injury, causing only a disruption in physical integrity 
and provides useful insight into vascular responses in a non-oxidation-based injury, and allowed the 
investigation of whether the potential damage caused by balloon injuries would need pharmaceutical 
intervention to aid in repair and trigger mild/moderate cellular responses. The data obtained with 
these injury models suggested that atorvastatin’s beneficial effects are linked to oxidative stress, and 
thus FeCl3 provides a more biomimetic model to represent native injury. The mechanical injury model 
did not generate consistent observations of cell migration. To take this a step further, characterizing 
NO and endothelial nitric oxide synthase (eNOS) production, along with other markers of oxidative 





These observations again demonstrate the value of a 3D tissue model as it is fairly simple to simulate 
oxidative damage on the constructs, and regulate the extent of damage by adjusting parameters such 
as filter paper size and volume of FeCl3 used, creating a zone with oxidative damage surrounded by 
healthy tissue.  
7.1.4 The effect of TEBV models 
In addition to facilitating the inclusion of shear stress, the various TE models also allowed the 
exploration of the roles of the intimal and medial layers separately and in concert on EPC and MSC 
homing. With this, it was possible to identify differences in extent of observed responses between the 
individual layers and the composite model, further supporting the observation that observations in 
monoculture are different from those in co-culture, underlining the value of 3D tissue models. As the 
TEBV is a composite model, it also appears as though the responses seen with the TEBV are also a 
composite of the responses seen in the TEIL and TEML.  
From the data collected, especially the results obtained in chapter 5, it was determined ha the TEBV is 
a more appropriate blood vessel model to study the cellular interactions, as well as atorvastatin’s 
enhancing effect between the blood vessel and the perfused EPCs. With 5-hour incubation with 
atorvastatin (figure 5-15-EPC and figure 5-5-hMSC), attached cells, both hMSC and EPCs, demonstrate 
a more than 50% increase compared to the drug free controls.  
 
7.6 Atorvastatin promotes production of SDF-1 and expression of CXCR4 
The data collected in chapter 4 showed that atorvastatin had an effect on expression of CXCR4, with 
an increase in expression on hMSCs noted with an increased concentration of atorvastatin, both with 
and without ECM disruption with the scratch wound. This observation, however, was not reflected in 
HUVECs, which showed an almost steady state expression of this receptor with a seeming increase at 
120μg/ml atorvastatin in the presence of a scratch wound. CXCR4 has been identified as the primary 
receptor for the cytokine SDF-1, and they both are associated with migration and homing of stem cells 




development (Hattermann et al., 2014; Döring et al., 2017). In chapter 5, the expression of CXCR4 
appears to fluctuate over time and is also affected by mode of lesioning, with mechanically lesioned 
samples generally showing more expression of this receptor, and with sustained expression between 
the 1 and 9-hour time points evaluated. Given the observation that CXCR4 gets internalised upon 
binding to SDF-1 (Förster et al., 1998; Hattermann et al., 2014), it is likely that the reduced expression 
observed with FeCl3 injury is as a result of this mode of injury triggering secretion of higher levels of 
SDF-1, which would in turn result in more internalisation of its receptor (Yu and Feng, 2008), and also 
because SDF-1 has been shown to reduce expression of CXCR4, likely through receptor consumption 
(Molino et al., 2000; Hattermann et al., 2014). These observations are suppoted by the exxpression of 
CXCR4 seen in chapter 5 where staining appeared higher at the 1-hour time point compared to the 9-
hour time point in the presence of atorvastatin, and more so with FeCl3 injury.  
Recently, attention has fallen on CXCR7 which has been identified as another receptor for SDF-1 (Hao 
et al., 2017) but its role in the context of atherosclerosis and cardiovascular disease has yet to be fully 
elucidated and it would be interesting to observe it’s behaviour in the context of our models. The 
models used here have proven useful in providing a tool that allows tracking of SDF-1 production over 
time, and demonstrating the effect statins have on this. These models could be used to characterise 
an array of cytokines that are associated with inflammation and oxidative damage and aid the 
provision of more insight into the complex interplay of factors involved in these processes.  
7.7 Atorvastatin promoted cholesterol efflux and restricted macrophage NO production 
Because atherosclerosis and cardiovascular disease were the primary motivators for the contents of 
this thesis, an evaluation of foam cell formation and the generation of a plaque model were a natural 
follow-up to the other experiments carried out for this thesis. Metabolic syndrome, a collective term 
referring to hyperglycaemia, dyslipidaemia and hyperinsulinemia-the primary risk factors for the 
development of atherosclerosis-, has been shown to aid in the instigation of a hypoxic environment 
along with oxidative stress leading to the generation of reactive oxygen species, which in turn lead to 




dysfunction, foam cell formation and smooth muscle cell proliferation and migration (Varghese, Patel 
and Yadav, 2017).  The data in chapter 6 showed that atorvastatin contributes to reversal of foam cell 
formation through cholesterol efflux. RAW264 cells dosed with either LDL or oxLDL, then treated with 
atorvastatin, consistently displayed reduced amounts of cholesterol compared to drug free controls, 
showing up to a 13% reduction in amount of internalised cholesterol. We determined that the ideal 
dose that this can be observed within 24 hours was 6μg/ml and the dose used in previous chapters, 
60μg/ml, also showed efficacy in this aspect but was accompanied by a significant reduction in cell 
numbers following the stipulated culture period. This aspect of cell death could be beneficial in terms 
of reducing plaque size and general uptake of LDL/oxLDL. On the other hand, atorvastatin, and statins 
in general, are primarily prescribed to lower circulating levels of LDL through inhibition of the 
cholesterol synthesis pathway, so in that context, concurrent reduction/death of lipid loaded 
macrophages i.e., foam cells may not have this potential detrimental effect.  
One other effect noted with atorvastatin in chapter 6 is that it had an effect on reducing NO production 
in macrophages, which is associated with a non-inflammatory macrophage phenotype and, in this 
context, be beneficial in reducing inflammation associated with atherosclerotic plaques, thus easing 
the strain on the vasculature in dealing with inflammation. With the model created here incorporating 
HUVECs cultured together with RAW264 cells, it was possible to see, to an extent, the interplay 
between activated macrophages and endothelial cells. HUVECs were shown to have the ability to affect 
foam cell formation and behaviour depending on the presence or absence of oxidative damage 
induced by FeCl3. Specifically, RAW264 foam cells cultured with lesioned HUVECs had lower levels of 
internalised cholesterol, and this reduction was more apparent in IFN-γ induced RAW264 cells, and 
even more so in the presence of atorvastatin. It was also interesting to note that atorvastatin limits 
the effects of IFN-γ on RAW264 lipid uptake (figure 6-22). As to what components are produced by 
lesioned HUVECs to cause this observation, further work needs to be done to define these parameters 
in terms of the cytokine profile present in the HUVEC-RAW264 co-culture model. As was previously 




may not be truly representative of a 3D environment, providing insight but not conclusive evidence. 
This was further highlighted by the observation that RAW264 behave differently in 2D and 3D i.e., 
shifting from a monolayer sheet to cluster formation when incorporated into a 3D collagen matrix. As 
was discussed in chapter 6, material stiffness has been shown to impact macrophage behaviour (Fang, 
Yang and Han, 2020) so it would have been interesting to see if altering collagen stiffness from that 
generated by compressing collagen to that used in making the other TE constructs would have given 
us a model that was easier to visually characterise. Attempts were made to make such a model i.e., 
attempting to create a plaque zone within a collagen gel which could have smooth muscle and 
endothelial cells added to it but time and the current global situation were not on our side. The value 
of including both cell types here is shown by observations recorded in chapter 5 where it was noted 
that oxidative damage has differing effects on endothelial and smooth muscle cells, with more of an 
effect, in terms of cellular responses to the damage as well as the functioning of atorvastatin, being 
observed on endothelial cells.  
Through the experiments carried out in chapter 6, it was possible to also see the effect atorvastatin 
and oxLDL have on expression of the scavenger receptor CD36. This identified the need to look at other 
scavenger receptors as it was not possible to definitively declare that atorvastatin has a strong effect 
on CD36 expression, even though atorvastatin did visibly and quantifiably result in reduced oxLDL 
within RAW264, suggesting that CD36 may not directly contribute to cholesterol efflux. Other 
published works point out the role of other scavenger receptors i.e., ABCA1 in contributing to 
cholesterol efflux, so it would be useful to determine the effect atorvastatin has on these receptors in 
the context of our model. The data collected here also highlighted a deficiency of information 
regarding the role of CD146 in atherosclerosis, with available information, two papers by Luo et.al, and 
Blin et. al., suggesting a role in retention of macrophage in atherosclerotic plaques as well as 
contributing to CD36 internalisation during cholesterol uptake (Luo et al., 2017; Blin et al., 2019). We 
have managed to show that atorvastatin has an effect on the expression of CD146 i.e., without IFN-γ, 




may contribute to reduced uptake of cholesterol by CD36 given the role of CD146 in promoting CD36 
internalisation (Luo et al., 2017; Shu et al., 2020). In the presence of IFN-γ, atorvastatin appears to 
have less of an influence on expression of CD146. This is interesting as Blin et.al., 2019 demonstrated 
that CD146 deficiency promoted plaque formation in a mouse model of atherosclerosis through 
promotion of RANTES production and resultant increased inflammatory responses (Blin et al., 2019). 
This suggests that under the influence of inflammatory mediators such as IFN-γ, which is possibly 
stronger than that of lesioned HUVECs, the downstream effects of atorvastatin are altered, possibly 
due to the observation that IFN-γ increases ROS production (Voloshyna, Littlefield and Reiss, 2014) and 
as we have seen in other chapters, atorvastatin functions better/triggers cellular responses in an 
oxidative environment.  
The data collected here, and supported by experiments done in chapter 4 and 5, also highlights the 
importance of evaluating experimental components individually and in concert. For this chapter, this 
was in evaluating the impact of foam cell stimulants IFN-γ and LPS. It was observed that in regards to 
NO production and quantification of oxLDL uptake, LPS is a far stronger promoter of NO production 
than IFN-γ due to its nature as a bacterial cell wall component, and can influence visual and 
quantitative evaluations of foam cell formation due to its being a lipid-based compound, again as it is 
a bacterial cell wall component.  
7.8 Conclusions 
What we have determined through the experiments carried out here is that atorvastatin has several 
effects aside form lowering cholesterol. Through the two modes of perfusion applied on the 3D 
constructs, atorvastatin was able to increase density of attached cells on lesioned TE constructs. This 
effect was observed to be time dependent as consistently across the TEIL, TEML and TEBV, longer 
incubations resulted in an increased density of attached cells, with optimal attachment being reached 
5-hours post lesioning and incubation with atorvastatin. The parallel plate flow chamber was more 
physiologically relevant, and with adjustable parameters allowing the generation of unidirectional and 




linked to oxidative stress, demonstrating that FeCl3 is a more biomimetic injury model.  
Atorvastatin has shown a capacity to increase secretion of SDF-1 and affect expression of CXCR4, likely 
through modulation of SDF-1 secretion. The models used to evaluate SDF-1 production highlight the 
concert effect of both smooth muscle cells and endothelial cells in terms of stabilising production over 
time. This concert effect is also demonstrated when evaluating cell recruitment to the surface of the 
injured TE constructs, with the TEBV showing responses that were a midway point between the intimal 
and medial layer constructs. It was also possible to observe differences in responses based on species 
of cells used, with murine cells showing better responses with higher doses of atorvastatin compared 
to human cells. There was also variation observed between human cells, suggesting that EPCs are more 
adapted to vascular repair than MSCs. Atorvastatin was also shown to positively influence recruitment 
of perfused cells at both high and low shear stress.  
The EPC and MSC homing phenomenon have been studied by evaluating the SDF-1 CXCR4 axis. It was 
confirmed in both 2D and 3D that the extent of damage caused by both the mechanical means and 
oxidative damage were sufficient to trigger production of SDF-1, with the FeCl3 induced oxidative 
damage resulting in higher SDF-1 levels than the mechanical injury. In the 3D TE models, production 
of SDF-1 increased with longer incubation duration with optimal expression once again being around 
5 hours post lesioning and incubation with 60μg/ml atorvastatin. In the 2D model, CXCR4 expression 
increased in both hMSC and HUVEC with a scratch wound and increasing atorvastatin. In the 3D model, 
all TE models showed reduced CXCR4 expression after 9 hours incubation compared to the 1-hour 
incubation counterpart. The reduction in expression was more noticeable in the atorvastatin treated 
group, implying that the atorvastatin induced SDF-1 production resulted in complete binding and 
internalisation of available CXCR4, leading to reduced expression over time due to maximum 
internalisation. The expression pattern of SDF-1/CXCR4 axis potentially explains the higher attachment 
numbers observed with FeCl3 injured models.  
It was also possible to show that atorvastatin affects efflux of internalised cholesterol from foam cells, 




stimuli such as IFN-γ and LPS both individually and in concert, showing that LPS is a far stronger 
stimulator of NO production and as such is not an ideal tool to use in generating foam cells as the 
effects are more indicative of an infection versus an inflammatory disorder. The foam cell model, made 
with RAW264 cells dosed with either LDL or oxLDL, demonstrated that treatment with atorvastatin 
resulted in consistently reduced amounts of internalised cholesterol compared to the drug free 
controls, showing up to a 13% reduction in the amount of internalised cholesterol. The ideal dose at 
which this can be observed is 6μg/ml.  
The use of a new prototype incorporating nanofibers into a well insert revealed the interplay between 
activated macrophages and endothelial cells. HUVECs were shown to have the ability to affect foam 
cell formation and behaviour, depending on the presence or absence of oxidative damage induced by 
FeCl3. Specifically, IFN-γ stimulated RAW264 foam cells, cultured with lesioned HUVECs, showed higher 
efficacy at cholesterol efflux in the presence of atorvastatin. It was also interesting to note that 
atorvastatin was not as effective at stimulating efflux when IFN-γ was not used to induce RAW264 lipid 
uptake. The nanofiber well inserts also allowed the investigation of the role of endothelial cells in the 
expression of CD36 and CD146. Without IFN-γ induction, CD36 expression was higher in RAW264 cells 
cultured with lesioned HUVECs, and the presence of statin showed no change of CD36 expression. 
With IFN-γ stimulated RAW264 cells, there was no difference in CD36 expression between lesioned or 
intact HUVECs or with atorvastatin, indicating that IFN-γ is a strong trigger for CD36 expression. It was 
also possible to highlight the deficiency in information regarding the role of CD146 in atherosclerosis, 
generating data that suggests atorvastatin has an effect on expression of this receptor and that IFN-γ 
appears to negate this effect i.e., atorvastatin reduces expression of CD146 in oxLDL loaded RAW264 
foam cells in the absence of IFN-γ.  The versatility of these models was that they can be adjusted to 
different dimensions and could be used to evaluate different types of injury and gauge cellular 
responses both to the injury as well as the effects of atorvastatin in these contexts. Through this, it 
was possible to demonstrate that atorvastatin is more effective in a cellular environment affected by 





7.9 Future perspectives 
As with any body of work, addressing research problems sheds light on additional avenues of 
investigation based on outputs generated and experimental parameters. For the experiments carried 
out here, we have evaluated directions this work could take to make some things clearer and address 
new questions raised through experimentation.  
To further improve the relatability of chapter 6, switching to human cells i.e., human macrophages 
such as THP-1 cells would help in seeing of the observations recorded for RAW264 cells could be 
applied to human cells, the importance of this not only being the relatability to humans but also to 
confirm accuracy of observations as data collected in chapter 4 and the discussion earlier 
demonstrates the variability of responses between human and murine cells. It would also be 
interesting to investigate the effects of material stiffness on macrophage behaviour due to 
observations of differing behaviour in 2D versus 3D culture. As pertains to foam cell formation and 
cholesterol efflux, we identified an area lacking sufficient research, i.e., the specific role of CD146 in 
atherosclerosis. It was possible to identify an impact of both IFN-γ and atorvastatin on expression of 
this receptor, but the effect of a variety of other inflammatory mediators/cytokines on expression of 
this and other receptors associated with foam cell formation and potentially cholesterol efflux are still 
to be determined. The models used here were able to both quantify and track expression of SDF-1, as 
such it should be more than possible to quantify and track expression of others related to inflammation 
and atherosclerosis such as IFN-γ, the interleukin family of cytokines and TNF-α and compare the 
extent of expression both with and without atorvastatin, thus gaining a clearer picture of the 
interactions at play during atherosclerosis associated inflammation. This would also be ideal in 
determining redundancies between cytokines and their related receptors.  
Further characterization of EPCs would also be beneficial as there is still disagreement in regards to 
specific characteristics that define this cell type. We used the receptors CXCR4, CD34, Flk-1, CD45 and 




was supported further by observations that reflected previously published work. It would also be 
interesting to see if different isolation protocols, such as the use of antibody coated magnetic 
beads/magnetic activated cell sorting (MACS), flow cytometry and modified culture conditions could 
be applied to extract a purer fraction of cells with a more homogenous surface receptor profile (Urbich 
and Dimmeler, 2004; Yoder, 2012; Chong, Ng and Chan, 2016; Chopra et al., 2018c). It would also be 
interesting to compare behaviour of a purer fraction with a more heterogenous cell mixture and 
possibly including platelets which have been shown to be able to transfer receptors such as Flk-1 and 
CD133 to other cells when cultured together (Medina et al., 2010; Fadini, Losordo and Dimmeler, 2012; 
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